[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 690
1. Kimple RJ, Grabowski S, Papez M, Collichio F, Ewend MG, Morris DE: Concurrent temozolomide and radiation, a reasonable option for elderly patients with glioblastoma multiforme? Am J Clin Oncol; 2010 Jun;33(3):265-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent temozolomide and radiation, a reasonable option for elderly patients with glioblastoma multiforme?
  • OBJECTIVES: There is no accepted standard of care for patients over age 70 with glioblastoma (GBM).
  • METHODS: We reviewed the records of all patients aged 70 or older who were diagnosed with glioblastoma since 2002 at the University of North Carolina to determine age at diagnosis, performance status, neurologic status, recursive partitioning analysis class, treatment received, and toxicity.
  • Grade 1/2 toxicity was seen in 20% of patients, whereas only 1 patient had grade 3 toxicity.
  • CONCLUSIONS: Concomitant daily temozolomide and radiation followed by adjuvant temozolomide is a tolerable and reasonable treatment option and has a good performance status for elderly patients diagnosed with glioblastoma.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Dacarbazine / analogs & derivatives. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Palliative Care / methods. Radiotherapy, Conformal
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19823072.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


2. Liau CT, Wei KC, Tseng CK, Jung SM: Combination chemotherapy with carmustine and cisplatin followed by procarbazine, lomustine, and vincristine for adult high-grade astrocytoma. Chang Gung Med J; 2005 Jan;28(1):16-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination chemotherapy with carmustine and cisplatin followed by procarbazine, lomustine, and vincristine for adult high-grade astrocytoma.
  • BACKGROUND: We have reported that carmustine (BCNU) and cisplatin administered before, during, and after radiotherapy did not improve the survival of patients with high-grade astrocytomas and were associated with more serious toxicities than radiotherapy plus BCNU.
  • Of these, 20 had glioblastoma multiforme and 22 had anaplastic astrocytoma.
  • The median time to tumor progression was 7.2 months (range, 0-88.7 months) and median survival time was 13.3 months (range, 1.7-88.7 months).
  • This combined modality treatment program was associated with reversible grade 3 to 4 hematological toxicity in 10 patients, with grade 3 ototoxicity in one patient and grade 2 neurotoxicity in one patient.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Glioblastoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Carmustine / administration & dosage. Cisplatin / administration & dosage. Female. Humans. Lomustine / administration & dosage. Male. Middle Aged. Procarbazine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15804144.001).
  • [ISSN] 2072-0939
  • [Journal-full-title] Chang Gung medical journal
  • [ISO-abbreviation] Chang Gung Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; Q20Q21Q62J / Cisplatin; U68WG3173Y / Carmustine
  •  go-up   go-down


3. Sridhar T, Gore A, Boiangiu I, Machin D, Symonds RP: Concomitant (without adjuvant) temozolomide and radiation to treat glioblastoma: a retrospective study. Clin Oncol (R Coll Radiol); 2009 Feb;21(1):19-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concomitant (without adjuvant) temozolomide and radiation to treat glioblastoma: a retrospective study.
  • Twelve patients had very large or multicentric glioblastoma multiforme with a poor performance status and received TMZ plus radiation doses of 45-50.4 Gy.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / radiotherapy. Dacarbazine / analogs & derivatives. Glioblastoma / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Radiotherapy Dosage. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18838255.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


Advertisement
4. Balossier A, Dörner L, Emery E, Heese O, Mehdorn HM, Menei P, Singh J: Incorporating BCNU wafers into malignant glioma treatment: European case studies. Clin Drug Investig; 2010;30(3):195-204
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Four patients are described in whom BCNU wafers were implanted during the course of treatment for glioblastoma multiforme, the most severe and common type of malignant glioma.
  • [MeSH-major] Brain Neoplasms / drug therapy. Carmustine / administration & dosage. Drug Implants / administration & dosage. Glioma / drug therapy
  • [MeSH-minor] Adult. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Alkylating / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Europe. Female. Humans. Male. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / radiotherapy. Treatment Outcome

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. Carmustine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet Oncol. 2009 May;10 (5):459-66 [19269895.001]
  • [Cites] Pharm Res. 1996 May;13(5):683-91 [8860422.001]
  • [Cites] J Neurosurg. 2002 May;96(5):941-5 [12005403.001]
  • [Cites] N Engl J Med. 1980 Dec 4;303(23):1323-9 [7001230.001]
  • [Cites] Curr Med Res Opin. 2009 Jan;25(1):149-60 [19210148.001]
  • [Cites] J Clin Oncol. 2008 Sep 1;26(25):4189-99 [18757334.001]
  • [Cites] Cancer Treat Rep. 1983 Feb;67(2):121-32 [6337710.001]
  • [Cites] Neurosurg Focus. 2006 Apr 15;20(4):E3 [16709034.001]
  • [Cites] J Neurooncol. 2008 Jul;88(3):353-7 [18389176.001]
  • [Cites] CNS Drugs. 2007;21(9):775-87 [17696576.001]
  • [Cites] Curr Med Res Opin. 2008 Nov;24(11):3239-57 [18940042.001]
  • [Cites] N Engl J Med. 2000 Nov 9;343(19):1350-4 [11070098.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6307-10 [11103789.001]
  • [Cites] Surg Neurol. 2000 Mar;53(3):220-4 [10773252.001]
  • [Cites] Eur J Neurol. 2005 Jun;12 Suppl 1:45-9 [15877778.001]
  • [Cites] Neuro Oncol. 2003 Apr;5(2):79-88 [12672279.001]
  • [Cites] Cancer Control. 1998 Mar;5(2):130-137 [10761024.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89 [15977639.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):672-84 [9485020.001]
  • [Cites] Neurology. 1980 Sep;30(9):907-11 [6252514.001]
  • [Cites] Br J Cancer. 2008 Sep 23;99 Suppl 1:S98-101 [18813276.001]
  • [Cites] Cell Mol Neurobiol. 2000 Apr;20(2):217-30 [10696511.001]
  • [Cites] Cancer Res. 1990 Oct 1;50(19):6119-29 [2205376.001]
  • [Cites] J Neurooncol. 1994;20(2):155-63 [7807192.001]
  • [Cites] Clin Pharmacokinet. 2002;41(6):403-19 [12074689.001]
  • [Cites] J Natl Cancer Inst. 2007 Nov 7;99(21):1583-93 [17971532.001]
  • [Cites] Expert Rev Anticancer Ther. 2008 Mar;8(3):343-59 [18366283.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2388-99 [11981013.001]
  • [Cites] J Neurooncol. 2007 Sep;84(2):189-99 [17431547.001]
  • [Cites] J Neurosurg. 1992 Apr;76(4):640-7 [1545259.001]
  • [Cites] Neuro Oncol. 2001 Oct;3(4):246-50 [11584894.001]
  • [Cites] Radiother Oncol. 2000 Nov;57(2):131-6 [11054516.001]
  • [Cites] Acta Neurochir (Wien). 2006 Mar;148(3):269-75; discussion 275 [16482400.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14 ):3793-9 [8033099.001]
  • [Cites] J Neurosurg. 2009 Mar;110(3):583-8 [19046047.001]
  • [Cites] J Clin Nurs. 2003 Jan;12(1):77-84 [12519253.001]
  • [Cites] Crit Rev Neurosurg. 1999 Sep 24;9(5):295-302 [10525848.001]
  • [Cites] Acta Neuropathol. 2005 Jan;109(1):93-108 [15685439.001]
  • [Cites] Ann Oncol. 2008 May;19 Suppl 2:ii83-5 [18456781.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;44(2):173-6 [10412954.001]
  • [Cites] Cancer Chemother Pharmacol. 1993;32(1):59-63 [8462125.001]
  • [Cites] J Neurooncol. 1992 Jan;12 (1):33-46 [1541977.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • [Cites] Ann Oncol. 2003;14 Suppl 5:v61-118 [14684501.001]
  • [Cites] Lancet. 1995 Apr 22;345(8956):1008-12 [7723496.001]
  • (PMID = 20155992.001).
  • [ISSN] 1173-2563
  • [Journal-full-title] Clinical drug investigation
  • [ISO-abbreviation] Clin Drug Investig
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Drug Implants; U68WG3173Y / Carmustine
  •  go-up   go-down


5. Obeid M, Ulane C, Rosenfeld S: Pearls & Oy-sters: Large vessel ischemic stroke secondary to glioblastoma multiforme. Neurology; 2010 Mar 30;74(13):e50-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pearls & Oy-sters: Large vessel ischemic stroke secondary to glioblastoma multiforme.
  • [MeSH-major] Brain Ischemia / therapy. Brain Neoplasms / therapy. Glioblastoma / therapy. Stroke / therapy
  • [MeSH-minor] Adult. Brain / blood supply. Brain / pathology. Cerebral Angiography. Humans. Magnetic Resonance Angiography. Magnetic Resonance Imaging. Male


6. Zhen L, Yufeng C, Zhenyu S, Lei X: Multiple extracranial metastases from secondary glioblastoma multiforme: a case report and review of the literature. J Neurooncol; 2010 May;97(3):451-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple extracranial metastases from secondary glioblastoma multiforme: a case report and review of the literature.
  • Extracranial metastasis of glioblastoma multiforme (GBM) is very rare, in spite of very aggressive tumor behavior and being documented in only a few patients.
  • In this article we present a 25-year-old man with secondary glioblastoma associated with extracranial progression and distant metastasis.
  • Histology revealed a diffuse astrocytoma (grade II).
  • The tumor recurred 1 year later and the patient received a second craniotomy.
  • The cytomorphological features supported a diagnosis of metastatic glioblastoma multiforme.
  • The neck dissection was made and histology confirmed the fine needle aspiration diagnosis of glioblastoma multiforme.
  • [MeSH-major] Brain Neoplasms / pathology. Glioblastoma / pathology. Neoplasms, Second Primary / secondary
  • [MeSH-minor] Adult. Craniotomy / methods. Humans. Magnetic Resonance Imaging. Male. Receptor, Epidermal Growth Factor / metabolism. S100 Proteins / metabolism. Tomography, X-Ray Computed / methods. Tumor Suppressor Protein p53 / metabolism

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1990 Jul 1;66(1):180-4 [2162242.001]
  • [Cites] Cancer. 1978 Dec;42(6):2854-64 [215298.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89 [15977639.001]
  • [Cites] Cancer. 1976 Mar;37(3):1577-83 [177171.001]
  • [Cites] Acta Cytol. 1993 Nov-Dec;37(6):938-42 [8249517.001]
  • [Cites] Brain Pathol. 1996 Jul;6(3):217-23; discussion 23-4 [8864278.001]
  • [Cites] Brain Pathol. 2001 Apr;11(2):159-68 [11303791.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6892-9 [15466178.001]
  • [Cites] Clin Exp Neurol. 1987;23:111-7 [2822301.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1992 Jul;118(7):755-6 [1320896.001]
  • [Cites] Cancer. 1980 Jan 1;45(1):112-25 [6985826.001]
  • [Cites] J Neurosurg. 1969 Jul;31(1):50-8 [4307543.001]
  • [Cites] J Neurosurg. 1970 Jul;33(1):88-94 [4316740.001]
  • [Cites] J Korean Med Sci. 2001 Aug;16(4):481-8 [11511795.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Nov-Dec;17 (10 ):1929-31 [8933881.001]
  • [Cites] Cancer Treat Rev. 1984 Mar;11(1):1-26 [6203642.001]
  • [Cites] J Neurosurg. 1985 Jun;62(6):918-21 [2987441.001]
  • [Cites] Ann Neurol. 1980 Dec;8(6):605-8 [6260012.001]
  • (PMID = 19898745.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / S100 Proteins; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Number-of-references] 19
  •  go-up   go-down


7. Sköld K, Gorlia T, Pellettieri L, Giusti V, H-Stenstam B, Hopewell JW: Boron neutron capture therapy for newly diagnosed glioblastoma multiforme: an assessment of clinical potential. Br J Radiol; 2010 Jul;83(991):596-603
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Boron neutron capture therapy for newly diagnosed glioblastoma multiforme: an assessment of clinical potential.
  • The purpose of this study was to assess the potential of boron neutron capture therapy (BNCT), with a 6-h infusion of the boron carrier l-boronophenylalanine as a fructose preparation (BPA-f), as first-line radiotherapy for newly diagnosed glioblastoma multiforme (GBM).

  • Genetic Alliance. consumer health - Glioblastoma.
  • Hazardous Substances Data Bank. BORON COMPOUNDS .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Appl Radiat Isot. 2009 Jul;67(7-8 Suppl):S80-3 [19394238.001]
  • [Cites] Radiother Oncol. 2008 Aug;88(2):183-91 [18336940.001]
  • [Cites] Radiother Oncol. 2002 Feb;62(2):227-31 [11937250.001]
  • [Cites] J Neurooncol. 2003 Mar-Apr;62(1-2):19-31 [12749700.001]
  • [Cites] J Natl Cancer Inst. 1993 May 5;85(9):704-10 [8478956.001]
  • [Cites] Radiat Res. 1995 Dec;144(3):310-7 [7494875.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] Clin Cancer Res. 2005 Jun 1;11(11):3987-4002 [15930333.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2563-9 [16735709.001]
  • [Cites] Radiother Oncol. 2007 Feb;82(2):119-22 [17291613.001]
  • [Cites] Acta Neurol Scand. 2007 Sep;116(3):169-76 [17714330.001]
  • [Cites] Lancet Oncol. 2008 Jan;9(1):29-38 [18082451.001]
  • [Cites] Acta Neurol Scand. 2008 Mar;117(3):191-7 [18297764.001]
  • [Cites] Acta Neurol Scand. 2010 Jul;122(1):58-62 [19951268.001]
  • (PMID = 20603410.001).
  • [ISSN] 1748-880X
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA011488; United States / NCI NIH HHS / CA / 5U10CA011488-40; United States / NCI NIH HHS / CA / 5U10CA11488-30
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 4-boronophenylalanine-fructose; 0 / Antineoplastic Agents, Alkylating; 0 / Boron Compounds; 30237-26-4 / Fructose; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  • [Other-IDs] NLM/ PMC3473677
  •  go-up   go-down


8. Prayson NF, Angelov L, Prayson RA: Microscopic thrombi in glioblastoma multiforme do not predict the development of deep venous thrombosis. Ann Diagn Pathol; 2009 Oct;13(5):291-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microscopic thrombi in glioblastoma multiforme do not predict the development of deep venous thrombosis.
  • Patients with glioblastoma multiforme (GBM) are known to be at risk for hypercoagulable events.
  • The purpose of this study was to assess whether there is a relationship between the number of thrombi identified microscopically at the time of tumor resection and the subsequent development of extremity deep venous thrombosis (DVT).
  • A retrospective review of 96 patients (53 men and 43 women; age range, 21-92 years; mean age, 60.2 years) with GBM (World Health Organization grade IV) was carried out.
  • Thrombi were counted (number of thrombi/blood vessels evaluated/10 high-power fields) in nonnecrotic areas of the resected tumor and correlated with a variety of clinical and pathological parameters, including the development of postoperative DVT, as detected by extremity ultrasound.
  • Eighty-one patients died of tumor (survival, 1-66 months; mean, 11.0 months), 12 patients were alive at last known follow-up (mean, 23 months), and 3 patients were lost to follow-up.
  • Of patients with DVT, 27 patients died of tumor (survival, 1-47 months; mean, 11.0 months), 3 patients were alive (18, 20, and 21 months), and 1 patient was lost to follow-up.
  • There was no correlation between the number of microscopic thrombi and the percentage of resected tumor that was necrotic (range, <5%-90%), presence of palisaded necrosis (36.8% of tumors), presurgical (mean, 78.3) or postsurgical (mean, 75.5) Karnofsky performance scores, or survival (mean, 8.9 months in patients with no microscopic thrombi vs 11.5 months in patients with thrombi).
  • [MeSH-major] Brain Neoplasms / pathology. Glioblastoma / pathology. Venous Thrombosis / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Ohio / epidemiology. Prognosis. Retrospective Studies. Survival Rate. Ultrasonography. Young Adult


9. Seiz M, Krafft U, Freyschlag CF, Weiss C, Schmieder K, Lohr F, Wenz F, Thomé C, Tuettenberg J: Long-term adjuvant administration of temozolomide in patients with glioblastoma multiforme: experience of a single institution. J Cancer Res Clin Oncol; 2010 Nov;136(11):1691-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term adjuvant administration of temozolomide in patients with glioblastoma multiforme: experience of a single institution.
  • In this study, we evaluate the feasibility and efficacy of long-term temozolomide in patients with glioblastoma multiforme treated at a single institution.
  • METHODS: One hundred and fourteen patients with newly diagnosed glioblastoma were followed for the course of their disease.
  • RESULTS: One hundred and fourteen patients with glioblastoma multiforme received a median of 6 cycles of adjuvant first-line temozolomide (range 1-57).
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Dacarbazine / analogs & derivatives. Glioblastoma / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Combined Modality Therapy. Disease Progression. Female. Humans. Male. Middle Aged. Safety. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Glioblastoma.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2001 Jan 11;344(2):114-23 [11150363.001]
  • [Cites] Neurology. 2007 Feb 27;68(9):688-90 [17325277.001]
  • [Cites] Semin Radiat Oncol. 2003 Jul;13(3):176-81 [12903007.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • [Cites] J Clin Neurosci. 2009 Jun;16(6):854-5 [19303779.001]
  • (PMID = 20177703.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; YF1K15M17Y / temozolomide
  •  go-up   go-down


10. Dhermain F, Ducreux D, Bidault F, Bruna A, Parker F, Roujeau T, Beaudre A, Armand JP, Haie-Meder C: [Use of the functional imaging modalities in radiation therapy treatment planning in patients with glioblastoma]. Bull Cancer; 2005 Apr;92(4):333-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Use of the functional imaging modalities in radiation therapy treatment planning in patients with glioblastoma].
  • Glioblastoma multiforme still remains, at present, the most frequent and deadly primary malignant glioma in adult.
  • Despite safer and larger neurosurgical resections, patients almost always relapse very close or inside the tumor bed.
  • If morbidity has decreased with "non whole-brain" volumes, RT is nearly always failing locally, as surgery.
  • [MeSH-major] Brain Neoplasms / diagnosis. Diagnostic Imaging / methods. Glioblastoma / diagnosis

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15888390.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 52
  •  go-up   go-down


11. Lee WH, Jin JS, Tsai WC, Chen YT, Chang WL, Yao CW, Sheu LF, Chen A: Biological inhibitory effects of the Chinese herb danggui on brain astrocytoma. Pathobiology; 2006;73(3):141-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biological inhibitory effects of the Chinese herb danggui on brain astrocytoma.
  • Our aim was to examine whether it might similarly be used to treat glioblastoma multiforme.
  • In nude mice, the growth of the tumor was inhibited by 30% by AS-CH or AS-AC (20 mg/kg; p < 0.05) and by 60% by AS-CH or AS-AC (60 mg/kg; p < 0.05).
  • CONCLUSIONS: Danggui may inhibit tumor growth by reducing the level of VEGF and the proapoptotic protein, cathepsin B.
  • Thus, danggui may be useful in the treatment of high-grade astrocytomas.
  • [MeSH-major] Angelica sinensis / chemistry. Antineoplastic Agents / pharmacology. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Drugs, Chinese Herbal / pharmacology. Phytotherapy
  • [MeSH-minor] Adult. Animals. Apoptosis / drug effects. Cathepsin B / metabolism. Cell Line, Tumor. Cell Survival / drug effects. Dose-Response Relationship, Drug. Drug Screening Assays, Antitumor. Female. Formazans / metabolism. Humans. Mice. Mice, Inbred BALB C. Mice, Nude. Neoplasm Transplantation. Neovascularization, Pathologic / drug therapy. Neovascularization, Pathologic / pathology. Plant Extracts / pharmacology. Tetrazolium Salts / metabolism. Vascular Endothelial Growth Factor A / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17085958.001).
  • [ISSN] 1015-2008
  • [Journal-full-title] Pathobiology : journal of immunopathology, molecular and cellular biology
  • [ISO-abbreviation] Pathobiology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drugs, Chinese Herbal; 0 / Formazans; 0 / Plant Extracts; 0 / Tetrazolium Salts; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 23305-68-2 / MTT formazan; EC 3.4.22.1 / Cathepsin B
  •  go-up   go-down


12. Affronti ML, Heery CR, Herndon JE 2nd, Rich JN, Reardon DA, Desjardins A, Vredenburgh JJ, Friedman AH, Bigner DD, Friedman HS: Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. Cancer; 2009 Aug 1;115(15):3501-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy.
  • BACKGROUND: Glioblastoma multiforme (GBM), the most lethal type of brain tumor, has a 1-year median survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Carmustine / administration & dosage. Dacarbazine / analogs & derivatives. Glioblastoma / drug therapy. Glioblastoma / radiotherapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 American Cancer Society.
  • (PMID = 19514083.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; U68WG3173Y / Carmustine
  •  go-up   go-down


13. Park P, Choksi VR, Gala VC, Kaza AR, Murphy HS, Ramnath S: Well-circumscribed, minimally enhancing glioblastoma multiforme of the trigone: a case report and review of the literature. AJNR Am J Neuroradiol; 2005 Jun-Jul;26(6):1475-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Well-circumscribed, minimally enhancing glioblastoma multiforme of the trigone: a case report and review of the literature.
  • Glioblastoma multiforme (GBM) is known to present within the lateral ventricle but is relatively infrequent and predominantly found in the frontal horn or body of the ventricle.
  • [MeSH-major] Cerebral Ventricle Neoplasms / diagnosis. Glioblastoma / diagnosis
  • [MeSH-minor] Adult. Female. Humans

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15956518.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 25
  •  go-up   go-down


14. Buckner JC, O'Fallon JR, Dinapoli RP, Schomberg PJ, Farr G, Schaefer P, Giannini C, Scheithauer BW, Ballman KV: Prognosis in patients with anaplastic oligoastrocytoma is associated with histologic grade. J Neurooncol; 2007 Sep;84(3):279-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis in patients with anaplastic oligoastrocytoma is associated with histologic grade.
  • BACKGROUND: Anaplastic oligoastrocytomas (AOA) are relatively uncommon high-grade gliomas.
  • METHODS: Between 1980 and 1999, Mayo Clinic and the NCCTG conducted 10 trials of radiation therapy and chemotherapy in adults with newly-diagnosed high-grade gliomas.
  • We grouped patients by cell type and grade, compared survival distributions by the log-rank statistic, and performed multiple variable analyses.
  • RESULTS: Of 1368 patients, 68 (5%) had AOA, including 21 Grade 3 (OA3) and 47 grade 4 (OA4), 153 (11%) had anaplastic astrocytoma (AA), and 1147 (84%) had glioblastoma multiforme (GBM).
  • CONCLUSIONS: Patients with anaplastic oligoastrocytoma have distinct outcomes based upon grade (OA3 vs. OA4) and in comparison with pure astrocytoma (AA or GBM).
  • Future trials which include more than one histologic entity need to report results by cell type and grade and account for the varying prognoses in interpreting treatment outcomes.
  • [MeSH-major] Astrocytoma / mortality. Astrocytoma / pathology. Brain Neoplasms / mortality. Brain Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Clinical Trials as Topic. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Prognosis

  • Genetic Alliance. consumer health - Anaplastic Oligoastrocytoma.
  • Genetic Alliance. consumer health - Oligoastrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]
  • [Cites] N Engl J Med. 1980 Dec 4;303(23):1323-9 [7001230.001]
  • [Cites] Stat Med. 1992 Dec;11(16):2093-109 [1293671.001]
  • [Cites] J Natl Cancer Inst. 1993 May 5;85(9):704-10 [8478956.001]
  • [Cites] Cancer Treat Rep. 1983 Feb;67(2):121-32 [6337710.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 Oct;56(10):1098-104 [9329453.001]
  • [Cites] Am J Pathol. 1994 Nov;145(5):1175-90 [7977648.001]
  • [Cites] Neurosurgery. 1993 Mar;32(3):365-70; discussion 371 [8455760.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Mar;60(3):248-62 [11245209.001]
  • [Cites] Biometrics. 1992 Jun;48(2):411-25 [1637970.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jul 15;38(5):911-4 [9276354.001]
  • [Cites] Int J Cancer. 1995 Jun 22;64(3):207-10 [7622310.001]
  • [Cites] Neurosurgery. 1994 Apr;34(4):577-82; discussion 582 [8008153.001]
  • [Cites] J Neurosurg. 1978 Sep;49(3):333-43 [355604.001]
  • [Cites] J Neurosurg. 1992 May;76(5):741-5 [1564535.001]
  • [Cites] J Clin Oncol. 2006 Dec 1;24(34):5419-26 [17135643.001]
  • [Cites] Int J Cancer. 1994 Apr 15;57(2):172-5 [8157354.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • (PMID = 17431544.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Eramo A, Pallini R, Lotti F, Sette G, Patti M, Bartucci M, Ricci-Vitiani L, Signore M, Stassi G, Larocca LM, Crinò L, Peschle C, De Maria R: Inhibition of DNA methylation sensitizes glioblastoma for tumor necrosis factor-related apoptosis-inducing ligand-mediated destruction. Cancer Res; 2005 Dec 15;65(24):11469-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of DNA methylation sensitizes glioblastoma for tumor necrosis factor-related apoptosis-inducing ligand-mediated destruction.
  • Life expectancy of patients affected by glioblastoma multiforme is extremely low.
  • The therapeutic use of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been proposed to treat this disease based on its ability to kill glioma cell lines in vitro and in vivo.
  • Here, we show that, differently from glioma cell lines, glioblastoma multiforme tumors were resistant to TRAIL stimulation because they expressed low levels of caspase-8 and high levels of the death receptor inhibitor PED/PEA-15.
  • Inhibition of methyltransferases by decitabine resulted in considerable up-regulation of TRAIL receptor-1 and caspase-8, down-regulation of PED/PEA-15, inhibition of cell growth, and sensitization of primary glioblastoma cells to TRAIL-induced apoptosis.
  • Exogenous caspase-8 expression was the main event able to restore TRAIL sensitivity in primary glioblastoma cells.
  • The antitumor activity of decitabine and TRAIL was confirmed in vivo in a mouse model of glioblastoma multiforme.
  • Evaluation of tumor size, apoptosis, and caspase activation in nude mouse glioblastoma multiforme xenografts showed dramatic synergy of decitabine and TRAIL in the treatment of glioblastoma, whereas the single agents were scarcely effective in terms of reduction of tumor mass, apoptosis induction, and caspase activation.
  • Thus, the combination of TRAIL and demethylating agents may provide a key tool to overcome glioblastoma resistance to therapeutic treatments.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Apoptosis / drug effects. DNA Methylation. DNA Modification Methylases / antagonists & inhibitors. Drug Resistance, Neoplasm / drug effects. Gene Expression Regulation, Neoplastic. Glioblastoma / drug therapy
  • [MeSH-minor] Adult. Aged. Animals. Apoptosis Regulatory Proteins / administration & dosage. Azacitidine / administration & dosage. Azacitidine / analogs & derivatives. Caspase 8. Caspases / metabolism. Female. Histocompatibility Antigens Class I / metabolism. Humans. Intracellular Signaling Peptides and Proteins. Male. Membrane Glycoproteins / administration & dosage. Mice. Mice, Nude. Middle Aged. Phosphoproteins / metabolism. Receptors, TNF-Related Apoptosis-Inducing Ligand. Receptors, Tumor Necrosis Factor / metabolism. Signal Transduction. TNF-Related Apoptosis-Inducing Ligand. Transplantation, Heterologous. Tumor Cells, Cultured. Tumor Necrosis Factor-alpha / administration & dosage

  • Genetic Alliance. consumer health - Glioblastoma.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16357155.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Histocompatibility Antigens Class I; 0 / Intracellular Signaling Peptides and Proteins; 0 / Membrane Glycoproteins; 0 / PEA15 protein, human; 0 / Phosphoproteins; 0 / Q surface antigens; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 0 / Receptors, Tumor Necrosis Factor; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFRSF10A protein, human; 0 / TNFSF10 protein, human; 0 / Tnfsf10 protein, mouse; 0 / Tumor Necrosis Factor-alpha; 776B62CQ27 / decitabine; EC 2.1.1.- / DNA Modification Methylases; EC 3.4.22.- / CASP8 protein, human; EC 3.4.22.- / Casp8 protein, mouse; EC 3.4.22.- / Caspase 8; EC 3.4.22.- / Caspases; M801H13NRU / Azacitidine
  •  go-up   go-down


16. Puri T, Goyal S, Julka PK, Nair O, Sharma DN, Rath GK: Lycopene in treatment of high-grade gliomas: a pilot study. Neurol India; 2010 Jan-Feb;58(1):20-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lycopene in treatment of high-grade gliomas: a pilot study.
  • BACKGROUND: The therapeutic benefit of lycopene is well established for carcinoma prostate in various clinical trials and has been proposed for other malignancies including high-grade gliomas.
  • MATERIALS AND METHODS: Fifty patients with high-grade gliomas were treated with surgery followed by adjuvant radiotherapy and concomitant paclitaxel.
  • Magnetic resonance imaging (MRI) of brain and Single Photon Emission Computed Tomograph (SPECT) were done three-monthly for two visits and six-monthly thereafter.
  • The commonest histology was glioblastoma multiforme (n = 32).
  • CONCLUSIONS: Addition of nutrition supplements such as lycopene may have potential therapeutic benefit in the adjuvant management of high-grade gliomas.
  • [MeSH-major] Antioxidants / administration & dosage. Brain Neoplasms / drug therapy. Carotenoids / administration & dosage. Glioma / drug therapy
  • [MeSH-minor] Administration, Oral. Adolescent. Adult. Aged. Analysis of Variance. Child. Double-Blind Method. Female. Follow-Up Studies. Humans. Male. Middle Aged. Pilot Projects. Radiotherapy / methods. Retrospective Studies. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20228458.001).
  • [ISSN] 0028-3886
  • [Journal-full-title] Neurology India
  • [ISO-abbreviation] Neurol India
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antioxidants; 36-88-4 / Carotenoids; SB0N2N0WV6 / lycopene
  •  go-up   go-down


17. Dally M, Rosenthal M, Drummond K, Murphy M, Cher L, Ashley D, Thursfield V, Giles G: Radiotherapy management of patients diagnosed with glioma in Victoria (1998-2000): a retrospective cohort study. J Med Imaging Radiat Oncol; 2009 Jun;53(3):318-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Median OS was 29.1 (SE 8.0) and 7.4 (SE 0.4) months for all patients with histological confirmation of World Health Organization Grades III (anaplastic astrocytoma) and IV (glioblastoma multiforme) histology, respectively.
  • While current best practice involves the use of chemotherapy in conjunction with RT for glioblastoma multiforme, advances in patient care may be undermined by this variation in the use of RT.
  • [MeSH-major] Brain Neoplasms / mortality. Brain Neoplasms / radiotherapy. Glioma / mortality. Glioma / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Australia / epidemiology. Cohort Studies. Female. Humans. Incidence. Male. Middle Aged. Retrospective Studies. Risk Assessment. Risk Factors. Survival Analysis. Survival Rate. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19624300.001).
  • [ISSN] 1754-9485
  • [Journal-full-title] Journal of medical imaging and radiation oncology
  • [ISO-abbreviation] J Med Imaging Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  •  go-up   go-down


18. Tramacere F, Gianicolo E, Serinelli M, Bambace S, De Luca M, Castagna R, Francavilla MC, Leone A, Monastero S, Fucilli F, Pili G, Distante A, Portaluri M: [Multivariate analysis of prognostic factors and survival in patients with "glioblastoma multiforme"]. Clin Ter; 2008 Jul-Aug;159(4):233-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multivariate analysis of prognostic factors and survival in patients with "glioblastoma multiforme"].
  • [Transliterated title] Multivariate analysis of prognostic factors and survival inpatients with "glioblastoma multiforme".
  • PURPOSE: The aim of this study was to evaluate the survival of patients with "glioblastoma multiforme", to analyse the prognostic factors influencing the survival rate and to review recent results in the literature.
  • Among the factors under investigation we ascertained that sex, chemotherapy, conformal treatment, surgery, and the choice of the irradiation area (whole brain or only the involved field) did not influence the survival in a statistically significant manner.
  • [MeSH-major] Brain Neoplasms / mortality. Glioblastoma / mortality
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Antineoplastic Agents, Alkylating / therapeutic use. Combined Modality Therapy. Cranial Irradiation. Craniotomy. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Female. Humans. Italy / epidemiology. Kaplan-Meier Estimate. Male. Middle Aged. Multivariate Analysis. Prognosis. Proportional Hazards Models. Radiotherapy Dosage. Radiotherapy, Conformal. Retrospective Studies. Survival Analysis. Young Adult

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18776979.001).
  • [ISSN] 1972-6007
  • [Journal-full-title] La Clinica terapeutica
  • [ISO-abbreviation] Clin Ter
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


19. Haas-Kogan DA, Prados MD, Tihan T, Eberhard DA, Jelluma N, Arvold ND, Baumber R, Lamborn KR, Kapadia A, Malec M, Berger MS, Stokoe D: Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst; 2005 Jun 15;97(12):880-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These associations were stronger and statistically significant among the 29 patients initially diagnosed with glioblastoma multiforme (P = .03 and P = .02, respectively).
  • Among six responders with sufficient tumor tissue, none had EGFRvIII mutations.
  • CONCLUSIONS: Among glioma patients, those with glioblastoma multiforme tumors who have high levels of EGFR expression and low levels of phosphorylated PKB/Akt had better response to erlotinib treatment than those with low levels of EGFR expression and high levels of phosphorylated PKB/Akt.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Cancer Inst. 2005 Jun 15;97(12):868-9 [15956643.001]
  • (PMID = 15956649.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA097257; United States / NCRR NIH HHS / RR / M01-RR00079; United States / NINDS NIH HHS / NS / P01 NS42927
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Proto-Oncogene Proteins; 0 / Quinazolines; 0 / Tumor Suppressor Proteins; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.1 / AKT1 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.1.3.- / Phosphoric Monoester Hydrolases; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


20. Tselis N, Kolotas C, Birn G, Röddiger S, Filipowicz I, Kontova M, Fountzilas G, Selviaridis P, Baltas D, Heyd R, Anagnostopoulos G, Zamboglou N: CT-guided interstitial HDR brachytherapy for recurrent glioblastoma multiforme. Long-term results. Strahlenther Onkol; 2007 Oct;183(10):563-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CT-guided interstitial HDR brachytherapy for recurrent glioblastoma multiforme. Long-term results.
  • BACKGROUND AND PURPOSE: Recurrences of glioblastoma multiforme (GBM) within previously irradiated volumes pose a serious therapeutic challenge.
  • This retrospective study evaluates the long-term tumor control of recurrent GBM treated with interstitial high-dose-rate brachytherapy (HDR-BRT).
  • The median recurrent tumor volume was 51 cm(3) (3-207 cm(3)), and the HDR-BRT consisted of an afterloading (192)Ir implant which delivered a median dose of 40 Gy (30-50 Gy).
  • [MeSH-major] Brachytherapy / methods. Brain Neoplasms / radiotherapy. Glioblastoma / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Follow-Up Studies. Humans. Iridium Radioisotopes / administration & dosage. Iridium Radioisotopes / therapeutic use. Kaplan-Meier Estimate. Karnofsky Performance Status. Magnetic Resonance Imaging. Male. Middle Aged. Prognosis. Radiotherapy Dosage. Radiotherapy Planning, Computer-Assisted. Radiotherapy, Adjuvant. Retrospective Studies. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17896088.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Iridium Radioisotopes
  •  go-up   go-down


21. Groves MD, Puduvalli VK, Chang SM, Conrad CA, Gilbert MR, Tremont-Lukats IW, Liu TJ, Peterson P, Schiff D, Cloughesy TF, Wen PY, Greenberg H, Abrey LE, DeAngelis LM, Hess KR, Lamborn KR, Prados MD, Yung WK: A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. J Neurooncol; 2007 Feb;81(3):271-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme.
  • BACKGROUND: Laboratory and clinical data suggest that the anti-angiogenic agent, thalidomide, if combined with cytotoxic agents, may be effective against recurrent glioblastoma multiforme (GBM).
  • There were 57 reports of toxicity of grade 3 or greater.
  • Non-fatal grade 3-4 granulocytopenia occurred in 15 patients (34%).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Glioblastoma / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Disease-Free Survival. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. North America. Survival Analysis. Thalidomide / therapeutic use

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AAPS J. 2005 Mar 22;7(1):E14-9 [16146335.001]
  • [Cites] Neurology. 2004 Oct 12;63(7):1281-4 [15477552.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):229-43 [15674480.001]
  • [Cites] Clin Cancer Res. 2001 Sep;7(9):2675-81 [11555579.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2299-304 [12805330.001]
  • [Cites] Drug Discov Today. 2005 Jan 15;10(2):107-14 [15718159.001]
  • [Cites] Semin Oncol. 2005 Aug;32(4 Suppl 5):S31-5 [16085015.001]
  • [Cites] Anticancer Res. 2003 May-Jun;23(3B):2481-7 [12894531.001]
  • [Cites] Arch Neurol. 1981 Nov;38(11):696-9 [6975612.001]
  • [Cites] J Neurooncol. 2003 Sep;64(3):193-201 [14558594.001]
  • [Cites] Arch Surg. 1975 Aug;110(8):888-91 [1171673.001]
  • [Cites] Surg Neurol. 1998 Feb;49(2):189-95; discussion 196 [9457270.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] Am J Med. 1983 Aug;75(2):289-94 [6881181.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):353-7 [15380566.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(7):1481-91 [10735896.001]
  • [Cites] J Neurooncol. 1994;19(3):245-50 [7807175.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1011-8 [11937180.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2585-97 [8453582.001]
  • [Cites] FEBS J. 2005 Nov;272(22):5723-41 [16279938.001]
  • [Cites] Semin Oncol. 2001 Aug;28(4 Suppl 13):43-6 [11550138.001]
  • [Cites] Br J Cancer. 2000 Sep;83(5):588-93 [10944597.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):997-1003 [15758010.001]
  • [Cites] J Neurooncol. 2001 Aug;54(1):31-8 [11763420.001]
  • [Cites] Immunopharmacology. 1996 Mar;31(2-3):213-21 [8861747.001]
  • [Cites] Neurosurgery. 2003 Sep;53(3):639-60; discussion 660-1 [12943581.001]
  • [Cites] Front Biosci. 2003 Jan 01;8:d100-16 [12456339.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(4):708-15 [10673511.001]
  • [Cites] Semin Oncol. 2004 Oct;31(5):635-44 [15497116.001]
  • [Cites] J Exp Med. 1993 Jun 1;177(6):1675-80 [8496685.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • [Cites] J Neurooncol. 1994;18(3):207-16 [7964981.001]
  • (PMID = 17031561.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA16672; United States / NCI NIH HHS / CA / CA62399; United States / NCI NIH HHS / CA / CA62412; United States / NCI NIH HHS / CA / CA62422; United States / NCRR NIH HHS / RR / M01-RR00042; United States / NCRR NIH HHS / RR / M01-RR00056; United States / NCRR NIH HHS / RR / M01-RR00079; United States / NCRR NIH HHS / RR / M01-RR0865; United States / NCI NIH HHS / CA / U01CA62405; United States / NCI NIH HHS / CA / U01CA62407
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 4Z8R6ORS6L / Thalidomide; 7GR28W0FJI / Dacarbazine; YF1K15M17Y / temozolomide
  •  go-up   go-down


22. Liu HE, Hsiao PY, Lee CC, Lee JA, Chen HY: NAT2*7 allele is a potential risk factor for adult brain tumors in Taiwanese population. Cancer Epidemiol Biomarkers Prev; 2008 Mar;17(3):661-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NAT2*7 allele is a potential risk factor for adult brain tumors in Taiwanese population.
  • The association of NAT2 polymorphisms with adult brain tumors has been unclear.
  • To investigate whether the NAT2 genotype is a risk factor of brain tumors, we determined the frequencies of three common polymorphisms in the NAT2 gene, NAT2*5 (T341C), NAT2*6 (G590A), and NAT2*7(G857A), in brain tumor patients and in age- and gender-matched control subjects (n = 27 in each group).
  • The odds ratio of NAT2*7 allele frequency was significantly higher in patients with brain tumor than in controls (odds ratio, 6.786; 95% confidence interval, 2.06-22.37; P = 0.003); in the mean time, NAT2*4/*7 genotype was significantly more common in the patient group than in controls (odds ratio, 6.19; 95% confidence interval, 1.68-22.79; P = 0.0039).
  • The tumors in the patients with NAT2*7 allele tended to be high-grade astrocytoma or glioblastoma multiforme (P = 0.016).
  • In conclusion, these data suggest that the presence of NAT2*7 allele might be a potential risk factor for the development of brain tumors in Taiwan.
  • [MeSH-major] Arylamine N-Acetyltransferase / genetics. Brain Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18349284.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.3.1.5 / Arylamine N-Acetyltransferase; EC 2.3.1.5 / NAT2 protein, human
  •  go-up   go-down


23. Schrot RJ, Ma JH, Greco CM, Arias AD, Angelastro JM: Organotypic distribution of stem cell markers in formalin-fixed brain harboring glioblastoma multiforme. J Neurooncol; 2007 Nov;85(2):149-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Organotypic distribution of stem cell markers in formalin-fixed brain harboring glioblastoma multiforme.
  • The role of stem cells in the origin, growth patterns, and infiltration of glioblastoma multiforme is a subject of intense investigation.
  • One possibility is that glioblastoma may arise from transformed stem cells in the ventricular zone.
  • To explore this hypothesis, we examined the distribution of two stem cell markers, activating transcription factor 5 (ATF5) and CD133, in an autopsy brain specimen from an individual with glioblastoma multiforme.
  • A 41-year-old male with a right posterior temporal glioblastoma had undergone surgery, radiation, and chemotherapy.
  • The brain was harvested within several hours after death.
  • After formalin fixation, sectioning, and mapping of tumor location in the gross specimen, histologic specimens were prepared from tumor-bearing and grossly normal hemispheres.
  • Both markers co-localized to the ependymal and subependymal zones on the side of the tumor, but not in the normal hemisphere or more rostrally in the affected hemisphere.
  • To our knowledge, this is the first in situ demonstration of stem cell markers in whole human brain.
  • The robust staining for ATF5 and CD133 in histologically normal ventricular zone suggests that an increase in periventricular stem cell activity occurred in this patient on the side of the tumor, either as a localized response to brain injury or as an integral component of oncogenesis and tumor recurrence.
  • [MeSH-major] Activating Transcription Factors / metabolism. Antigens, CD / metabolism. Brain / metabolism. Brain Neoplasms / metabolism. Glioblastoma / metabolism. Glycoproteins / metabolism. Peptides / metabolism
  • [MeSH-minor] AC133 Antigen. Adult. Biomarkers / metabolism. Cerebral Ventricles / metabolism. Fatal Outcome. Humans. Immunohistochemistry. Male. Tissue Distribution

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurooncol. 2008 Sep;89(2):247-8; author reply 249 [18568293.001]
  • [Cites] J Neurosci. 2006 Jun 21;26(25):6781-90 [16793885.001]
  • [Cites] Cancer Cell. 2005 Aug;8(2):119-30 [16098465.001]
  • [Cites] Acta Neuropathol. 1979 Mar 15;45(3):177-85 [442983.001]
  • [Cites] Nat Rev Cancer. 2006 Jun;6(6):425-36 [16723989.001]
  • [Cites] J Comp Neurol. 2006 Jan 20;494(3):415-34 [16320258.001]
  • [Cites] Mol Cell Neurosci. 2005 Jul;29(3):372-80 [15950153.001]
  • [Cites] J Neurosci. 2003 Jun 1;23(11):4590-600 [12805299.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Nature. 1966 Jun 25;210(5043):1378-9 [6007120.001]
  • [Cites] Oncogene. 2006 Feb 9;25(6):907-16 [16170340.001]
  • [Cites] J Neurosci. 2005 Apr 13;25(15):3889-99 [15829641.001]
  • [Cites] N Engl J Med. 2005 Aug 25;353(8):811-22 [16120861.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5821-8 [14522905.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] J Neurosci. 2005 Jan 5;25(1):10-8 [15634762.001]
  • [Cites] Nature. 2004 Feb 19;427(6976):740-4 [14973487.001]
  • [Cites] Experientia. 1976 Nov 15;32(11):1467-8 [992001.001]
  • [Cites] Nat Med. 1998 Nov;4(11):1313-7 [9809557.001]
  • [Cites] Cell. 1999 Jan 8;96(1):25-34 [9989494.001]
  • (PMID = 17516028.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AC133 Antigen; 0 / ATF5 protein, human; 0 / Activating Transcription Factors; 0 / Antigens, CD; 0 / Biomarkers; 0 / Glycoproteins; 0 / PROM1 protein, human; 0 / Peptides
  •  go-up   go-down


24. Bhatti P, Stewart PA, Hutchinson A, Rothman N, Linet MS, Inskip PD, Rajaraman P: Lead exposure, polymorphisms in genes related to oxidative stress, and risk of adult brain tumors. Cancer Epidemiol Biomarkers Prev; 2009 Jun;18(6):1841-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lead exposure, polymorphisms in genes related to oxidative stress, and risk of adult brain tumors.
  • Mechanisms for dealing with oxidative stress may be of particular relevance in the brain given the high rate of oxygen metabolism.
  • Using a hospital-based case-control study, we investigated the role of oxidative stress in the potential carcinogenicity of lead through examination of effect modification of the association between occupational lead exposure and brain tumors by single nucleotide polymorphisms in genes with functions related to oxidative stress.
  • The study included 362 patients with glioma (176 of which had glioblastoma multiforme), 134 patients with meningioma, and 494 controls.
  • When the analyses were restricted to cases with glioblastoma multiforme, RAC2 rs2239774 and two highly correlated GPX1 polymorphisms (rs1050450 and rs18006688) were found to significantly modify the association with lead exposure (P <or= 0.05) after adjustment for multiple comparisons.
  • Although the results of this study provide some evidence that lead may cause glioblastoma multiforme and meningioma through mechanisms related to oxidative damage, the results must be confirmed in other populations.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Lead, elemental .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Chim Acta. 2007 Aug;383(1-2):57-64 [17573057.001]
  • [Cites] Drug Resist Updat. 2006 Dec;9(6):274-87 [17234445.001]
  • [Cites] Annu Rev Nutr. 2007;27:41-61 [17465855.001]
  • [Cites] J Neurooncol. 2008 May;87(3):365-6 [18217210.001]
  • [Cites] FEBS J. 2008 Jul;275(13):3278-89 [18513323.001]
  • [Cites] Neuro Oncol. 2008 Oct;10(5):709-15 [18682580.001]
  • [Cites] Am J Ind Med. 2000 Sep;38(3):255-70 [10940963.001]
  • [Cites] N Engl J Med. 2001 Jan 11;344(2):79-86 [11150357.001]
  • [Cites] J Occup Environ Med. 2002 Jul;44(7):663-8 [12134530.001]
  • [Cites] Am J Ind Med. 2002 Sep;42(3):214-27 [12210690.001]
  • [Cites] Cancer Res. 2003 Jun 15;63(12):3347-51 [12810669.001]
  • [Cites] Mutat Res. 2003 Dec 10;533(1-2):121-33 [14643416.001]
  • [Cites] Occup Environ Med. 1995 Oct;52(10):667-72 [7489057.001]
  • [Cites] J Occup Environ Med. 1996 Feb;38(2):131-6 [8673517.001]
  • [Cites] Int J Epidemiol. 1996 Aug;25(4):744-52 [8921451.001]
  • [Cites] Cancer Detect Prev. 1998;22(2):100-8 [9544430.001]
  • [Cites] Environ Mol Mutagen. 1998;31(4):352-61 [9654245.001]
  • [Cites] J Occup Environ Med. 1998 Nov;40(11):937-42 [9830598.001]
  • [Cites] Am J Ind Med. 1999 Jul;36(1):70-4 [10361589.001]
  • [Cites] Int J Cancer. 1999 Oct 29;83(3):299-304 [10495419.001]
  • [Cites] Bioinformatics. 2005 Jan 15;21(2):263-5 [15297300.001]
  • [Cites] Acta Neurochir (Wien). 2005 May;147(5):551-4; discussion 554 [15812594.001]
  • [Cites] Int J Cancer. 2006 Sep 1;119(5):1136-44 [16570286.001]
  • [Cites] J Neurochem. 2006 Jun;97(6):1634-58 [16805774.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Dec;15(12):2514-20 [17164378.001]
  • [Cites] Clin Nutr. 2007 Aug;26(4):400-8 [17499891.001]
  • (PMID = 19505917.001).
  • [ISSN] 1538-7755
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / N01CO12400; United States / Intramural NIH HHS / / NIH0011946573; United States / Intramural NIH HHS / / Z01 CP010135-12; United States / NCI NIH HHS / CO / N01-CO-12400
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 2P299V784P / Lead; EC 1.11.1.- / glutathione peroxidase GPX1; EC 1.11.1.9 / Glutathione Peroxidase; EC 3.6.1.- / rac2 GTP-binding protein; EC 3.6.5.2 / rac GTP-Binding Proteins
  • [Other-IDs] NLM/ NIHMS129928; NLM/ PMC2750838
  •  go-up   go-down


25. Birol Sarica F, Tufan K, Cekinmez M, Sen O, Cem Onal H, Mertsoylu H, Topkan E, Pehlivan B, Erdogan B, Nur Altinors M: Effectiveness of temozolomide treatment used at the same time with radiotherapy and adjuvant temozolomide; concomitant therapy of glioblastoma multiforme: multivariate analysis and other prognostic factors. J Neurosurg Sci; 2010 Mar;54(1):7-19
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effectiveness of temozolomide treatment used at the same time with radiotherapy and adjuvant temozolomide; concomitant therapy of glioblastoma multiforme: multivariate analysis and other prognostic factors.
  • AIM: Prognostic factors which affect treatment results of glioblastoma multiforme (GBM; WHO Grade IV) patients has been investigated in many researches.
  • Frontal lobe was the most involved part of the tumor,and biggest tumor has the diameter of 4.8 (+/-1.42) cm.
  • After treatment, relapse occurred in 12 patient at the site of the tumor and these patients had been reoperated.
  • After univariate statistical analysis preoperative KPS was >or=70 (P=0.0000) , postoperative KPS 2 was >or=70 (P=0.0000), type of tumor resection (P=0.00002), multiple operations (P=0.001), adjuvant RT (P=0.0000) and ConcT with adjuvant TMZ (P=0.0000) were all positive prognostic factors which extend the survival.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Dacarbazine / analogs & derivatives. Glioblastoma / drug therapy. Glioblastoma / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant / methods. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Multivariate Analysis. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20436394.001).
  • [ISSN] 0390-5616
  • [Journal-full-title] Journal of neurosurgical sciences
  • [ISO-abbreviation] J Neurosurg Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; YF1K15M17Y / temozolomide
  •  go-up   go-down


26. Umesh S, Tandon A, Santosh V, Anandh B, Sampath S, Chandramouli BA, Sastry Kolluri VR: Clinical and immunohistochemical prognostic factors in adult glioblastoma patients. Clin Neuropathol; 2009 Sep-Oct;28(5):362-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and immunohistochemical prognostic factors in adult glioblastoma patients.
  • OBJECTIVE: Glioblastomas are the commonest and the most malignant of all adult brain tumors, characterized by genetic instability, intratumoral histopathological variability, and unpredictable clinical behavior.
  • The utility of tumor markers that reflect their underlying biology is becoming increasingly important with respect to patient prognostication and their potential role as molecular targets of therapy is being recognized.
  • MATERIALS AND METHODS: We evaluated 54 cases of adult supratentorial glioblastomas operated over a span of 1 year, with respect to clinical features such as age, Karnofsky performance score (KPS), extent of resection, adjuvant therapy, and immunohistochemical expression of p53, EGFR (Epidermal Growth Factor Receptor) and PTEN (Phosphatase and Tensin homolog).
  • CONCLUSIONS: Our study shows that EGFR and p53 overexpression along with loss of PTEN expression are important adjuncts to clinical variables in prognosticating glioblastoma patients.
  • [MeSH-major] Glioblastoma / diagnosis. Supratentorial Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. PTEN Phosphohydrolase / metabolism. Prognosis. Receptor, Epidermal Growth Factor / metabolism. Severity of Illness Index. Treatment Outcome. Tumor Suppressor Protein p53 / metabolism. Young Adult


27. Brown PD, Krishnan S, Sarkaria JN, Wu W, Jaeckle KA, Uhm JH, Geoffroy FJ, Arusell R, Kitange G, Jenkins RB, Kugler JW, Morton RF, Rowland KM Jr, Mischel P, Yong WH, Scheithauer BW, Schiff D, Giannini C, Buckner JC, North Central Cancer Treatment Group Study N0177: Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol; 2008 Dec 01;26(34):5603-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177.
  • PURPOSE: Epidermal growth factor receptor (EGFR) amplification in glioblastoma multiforme (GBM) is a common occurrence and is associated with treatment resistance.
  • However, there was no sign of benefit in overall survival when comparing N0177 with the RT/TMZ arm of the European Organisation for Research and Treatment of Cancer/National Cancer Institute of Canada trial 26981/22981 (recursive partitioning analysis [RPA] class III, 19 v 21 months; RPA class IV, 16 v 16 months; RPA class V, 8 v 10 months, respectively).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dacarbazine / analogs & derivatives. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Quinazolines / administration & dosage. Radiotherapy / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Combined Modality Therapy / methods. Disease Progression. Erlotinib Hydrochloride. Female. Humans. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1985 Jan 10-18;313(5998):144-7 [2981413.001]
  • [Cites] Biometrics. 1982 Mar;38(1):143-51 [7082756.001]
  • [Cites] J Neurooncol. 1996 Jan;27(1):11-22 [8699221.001]
  • [Cites] Oncogene. 1997 Sep 4;15(10):1191-7 [9294612.001]
  • [Cites] Biochim Biophys Acta. 1997 Oct 11;1358(3):289-99 [9366260.001]
  • [Cites] Brain Tumor Pathol. 1998;15(1):53-7 [9879464.001]
  • [Cites] Cancer Res. 1999 Apr 15;59(8):1935-40 [10213503.001]
  • [Cites] Mol Biol Cell. 1999 Aug;10(8):2493-506 [10436007.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] N Engl J Med. 2005 Nov 10;353(19):2012-24 [16282176.001]
  • [Cites] Neuro Oncol. 2006 Jan;8(1):67-78 [16443950.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2563-9 [16735709.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):1192-9 [16626884.001]
  • [Cites] N Engl J Med. 2007 Apr 12;356(15):1527-35 [17429084.001]
  • [Cites] Clin Cancer Res. 2008 Jan 15;14(2):488-93 [18223223.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):987-92 [17967509.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1383-7 [10728703.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2166-74 [10873065.001]
  • [Cites] N Engl J Med. 2000 Nov 9;343(19):1350-4 [11070098.001]
  • [Cites] N Engl J Med. 2001 Jan 11;344(2):114-23 [11150363.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3):682-90 [11297265.001]
  • [Cites] J Natl Cancer Inst. 2001 Aug 15;93(16):1246-56 [11504770.001]
  • [Cites] Neurogenetics. 2001 Jul;3(3):159-62 [11523567.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Oct 1;51(2):410-8 [11567815.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1375-82 [11870182.001]
  • [Cites] Neuro Oncol. 2004 Jan;6(1):44-54 [14769140.001]
  • [Cites] Cancer Res. 1990 Sep 15;50(18):6039-44 [2393868.001]
  • (PMID = 18955445.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00039494
  • [Grant] United States / NCI NIH HHS / CA / CA-37404; United States / NCI NIH HHS / CA / CA-35431; United States / NCI NIH HHS / CA / CA-35195; United States / NCI NIH HHS / CA / CA-114740; United States / NCI NIH HHS / CA / CA-35103; United States / NCI NIH HHS / CA / CA-25224; United States / NCI NIH HHS / CA / CA-60276; United States / NCI NIH HHS / CA / CA-108961; United States / NCI NIH HHS / CA / R01 CA127716; United States / NCI NIH HHS / CA / CA-35113; United States / NCI NIH HHS / CA / CA-63848; United States / NCI NIH HHS / CA / CA-37417; United States / NCI NIH HHS / CA / CA-35269; United States / NCI NIH HHS / CA / CA-35101; United States / NCI NIH HHS / CA / CA-35267; United States / NCI NIH HHS / CA / CA-63849
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Quinazolines; 7GR28W0FJI / Dacarbazine; DA87705X9K / Erlotinib Hydrochloride; YF1K15M17Y / temozolomide
  • [Other-IDs] NLM/ PMC2651097
  • [Investigator] Soori GS; Dakhil SR; Fitch TR; Windschitl HE; Flynn PJ; Anderson DM; Nair S; Nikcevich DA; Wender DB; Stella PJ; Jillella AP
  •  go-up   go-down


28. Johansson FK, Göransson H, Westermark B: Expression analysis of genes involved in brain tumor progression driven by retroviral insertional mutagenesis in mice. Oncogene; 2005 Jun 2;24(24):3896-905
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression analysis of genes involved in brain tumor progression driven by retroviral insertional mutagenesis in mice.
  • Retroviral tagging previously identified putative cancer-causing genes in a mouse brain tumor model where a recombinant Moloney murine leukemia virus encoding the platelet-derived growth factor B-chain (MMLV/PDGFB) was intracerebrally injected in newborn mice.
  • In the present study, expression analysis using cDNA arrays revealed several similarities of virus-induced mouse gliomas with human brain tumors.
  • Brain tumors with short latency contained on average 8.0 retroviral insertions and resembled human glioblastoma multiforme (GBM) whereas long-latency gliomas were of lower grade, similar to human oligodendroglioma (OD) and had 2.3 insertions per tumor.
  • Several known and novel genes of tumor progression or cell markers were differentially expressed between OD- and GBM-like tumors.
  • Array and quantitative real-time PCR analysis demonstrated elevated expression similar to Pdgfralpha of retrovirally tagged genes Abhd2, Ddr1, Fos, Ng2, Ppfibp1, Rad51b and Sulf2 in both glioma types compared to neonatal and adult normal brain.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Mutagenesis, Insertional. Retroviridae / genetics
  • [MeSH-minor] Animals. Animals, Newborn. Disease Progression. Glioma / genetics. Glioma / pathology. Humans. Mice. Mice, Inbred C57BL. Oligodendroglia / pathology. Oligonucleotide Array Sequence Analysis. Platelet-Derived Growth Factor / genetics. Polymerase Chain Reaction. Proto-Oncogene Proteins c-sis. RNA, Neoplasm / genetics. RNA, Neoplasm / isolation & purification

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15750623.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Platelet-Derived Growth Factor; 0 / Proto-Oncogene Proteins c-sis; 0 / RNA, Neoplasm; 0 / platelet-derived growth factor BB
  •  go-up   go-down


29. Ruano Y, Mollejo M, Camacho FI, Rodríguez de Lope A, Fiaño C, Ribalta T, Martínez P, Hernández-Moneo JL, Meléndez B: Identification of survival-related genes of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma multiforme. Cancer; 2008 Apr 1;112(7):1575-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of survival-related genes of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma multiforme.
  • BACKGROUND: Knowledge of the molecular mechanisms involved in the biology of glioblastoma multiforme (GBM) is essential for the identification of candidate prognostic markers, new putative therapeutic targets, and early detection strategies predictive of survival.
  • [MeSH-major] Biomarkers, Tumor / genetics. Gene Expression Profiling. Glioblastoma / genetics. Phosphatidylinositol 3-Kinases / genetics. Signal Transduction
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Apoptosis. Astrocytoma / genetics. Astrocytoma / metabolism. Blotting, Western. Cell Survival. Female. Glioma / genetics. Glioma / metabolism. Humans. Immunoenzyme Techniques. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Prognosis. Proto-Oncogene Proteins c-akt / genetics. Proto-Oncogene Proteins c-akt / metabolism. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tissue Array Analysis


30. Lasky JL 3rd, Choe M, Nakano I: Cancer stem cells in pediatric brain tumors. Curr Stem Cell Res Ther; 2009 Dec;4(4):298-305
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer stem cells in pediatric brain tumors.
  • Central nervous system (CNS) tumors remain the leading cause of death among pediatric neoplasms.
  • Although standard therapies cure many pediatric CNS tumors, the long-term cognitive and physical consequences of these therapies are devastating.
  • Although recent studies have focused on molecular mechanisms that underlie the initiation and progression of adult glioblastoma multiforme (GBM), these tumors differ phenotypically and at a molecular level from pediatric brain tumors.
  • Recent investigations have identified a stem cell population, termed "brain tumor stem cells" (BTSC) within the heterogeneous cell populations that comprise malignant brain tumors which may be partly responsible for the resistance to current therapies.
  • By exploiting molecular differences present within these heterogeneous populations of brain tumor cells, we may be able to achieve specific eradication of BTSC and long-lasting remissions, while causing less toxicity to normal tissues.
  • In this review, we describe the issues surrounding the identification and characterization of BTSC, the molecular biology of BTSC for different pediatric brain tumors, and suggest future avenues for the development of treatments for this devastating disease.
  • [MeSH-major] Brain Neoplasms / pathology. Ependymoma / pathology. Medulloblastoma / pathology. Neoplastic Stem Cells / pathology. Optic Nerve Glioma / pathology
  • [MeSH-minor] Adult Stem Cells / pathology. Biomarkers / metabolism. Cell Differentiation. Chemotherapy, Adjuvant. Child. Humans. Surgical Procedures, Operative


31. Saikali S, Avril T, Collet B, Hamlat A, Bansard JY, Drenou B, Guegan Y, Quillien V: Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13Ralpha2, gp100 and TRP-2 for immunotherapy. J Neurooncol; 2007 Jan;81(2):139-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13Ralpha2, gp100 and TRP-2 for immunotherapy.
  • In this study, we investigated the mRNA and protein expression of nine tumour antigens in human glioblastoma multiforme with a view to their possible use in dendritic cell-based immunotherapy.
  • Expression of ALK, EGFRvIII, GALT3, gp100, IL-13Ralpha2, MAGE-A3, NA17-A, TRP-2 and tyrosinase were studied by real-time RT-PCR on frozen tissues using a series of 47 tumour samples from patients with glioblastoma.
  • Results were compared with non-neoplastic brain expression or glioblastoma samples with very low levels of expression near the limits of detection for EGFRvIII and MAGE-A3, as these latter two antigens were not detected in non-neoplastic brain.
  • These results point out the importance of EGFRvIII, IL-13Ralpha2 and, to a less extent gp100 and TRP-2, for developing an immunotherapy strategy against glioblastoma.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Brain Neoplasms / metabolism. Glioblastoma / metabolism. Interleukin-13 Receptor alpha2 Subunit / metabolism. Membrane Glycoproteins / metabolism. Membrane Proteins / metabolism. Receptor, Epidermal Growth Factor / metabolism
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Female. Humans. Immunotherapy. Male. Middle Aged. Prognosis. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate. gp100 Melanoma Antigen

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Immunol Immunother. 2006 Oct;55(10):1209-18 [16331519.001]
  • [Cites] Lab Invest. 2001 Sep;81(9):1223-31 [11555670.001]
  • [Cites] Int J Cancer. 2002 Jul 1;100(1):49-56 [12115586.001]
  • [Cites] Clin Cancer Res. 2002 Sep;8(9):2851-5 [12231526.001]
  • [Cites] J Clin Oncol. 2004 Nov 1;22(21):4272-81 [15452186.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6962-70 [14583498.001]
  • [Cites] J Immunother. 2003 Jul-Aug;26(4):301-12 [12843792.001]
  • [Cites] Am J Pathol. 1997 Jun;150(6):2143-52 [9176405.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):842-7 [11221866.001]
  • [Cites] Clin Cancer Res. 2005 Aug 1;11(15):5515-25 [16061868.001]
  • [Cites] J Biol Chem. 2002 Apr 19;277(16):14153-8 [11809760.001]
  • [Cites] Cancer Res. 1995 Jul 15;55(14):3140-8 [7606735.001]
  • [Cites] Br J Cancer. 2002 Oct 21;87(9):1006-12 [12434293.001]
  • [Cites] Curr Cancer Drug Targets. 2002 Jun;2(2):91-102 [12188912.001]
  • [Cites] Clin Cancer Res. 1999 Feb;5(2):335-41 [10037183.001]
  • [Cites] Br J Cancer. 2004 Nov 1;91(9):1656-62 [15477864.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 Jul;63(7):700-7 [15290895.001]
  • [Cites] Cancer Immunol Immunother. 2001 Sep;50(7):337-44 [11676393.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4980-6 [15256472.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):3916-22 [11051238.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4973-9 [15256471.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1168-72 [10728667.001]
  • [Cites] J Allergy Clin Immunol. 2003 Apr;111(4):677-90; quiz 691 [12704343.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1462-6 [15746047.001]
  • [Cites] Oncogene. 2005 Aug 4;24(33):5226-34 [15897911.001]
  • [Cites] Cancer Res. 1995 Dec 1;55(23):5536-9 [7585629.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6242-4 [10841526.001]
  • [Cites] J Exp Med. 1996 Mar 1;183(3):1173-83 [8642259.001]
  • [Cites] N Engl J Med. 2005 Aug 25;353(8):811-22 [16120861.001]
  • [Cites] Int J Oncol. 1999 Sep;15(3):481-6 [10427128.001]
  • [Cites] J Neurooncol. 2006 Jan;76(1):23-30 [16155724.001]
  • [Cites] Clin Cancer Res. 2005 Jun 1;11(11):4160-7 [15930352.001]
  • [Cites] Oncogene. 1997 Jan 30;14(4):439-49 [9053841.001]
  • [Cites] Neuropathol Appl Neurobiol. 2005 Aug;31(4):384-94 [16008822.001]
  • [Cites] J Immunother. 2004 Nov-Dec;27(6):452-9 [15534489.001]
  • [Cites] Br J Cancer. 2003 Oct 6;89(7):1172-9 [14520441.001]
  • [Cites] Brain Pathol. 2004 Apr;14(2):131-6 [15193025.001]
  • [Cites] Brain Tumor Pathol. 2004;21(2):53-6 [15700833.001]
  • [Cites] Brain Pathol. 2004 Jan;14(1):43-50 [14997936.001]
  • [Cites] Oncogene. 1994 Aug;9(8):2313-20 [8036013.001]
  • [Cites] Cancer. 2004 Sep 1;101(5):1036-42 [15329913.001]
  • [Cites] Neurosurgery. 1999 Dec;45(6):1442-53 [10598712.001]
  • (PMID = 17004103.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Interleukin-13 Receptor alpha2 Subunit; 0 / Membrane Glycoproteins; 0 / Membrane Proteins; 0 / PMEL protein, human; 0 / RNA, Messenger; 0 / Trp2 protein, vertebrate; 0 / epidermal growth factor receptor VIII; 0 / gp100 Melanoma Antigen; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


32. Lopez-Gines C, Cerda-Nicolas M, Gil-Benso R, Pellin A, Lopez-Guerrero JA, Callaghan R, Benito R, Roldan P, Piquer J, Llacer J, Barbera J: Association of chromosome 7, chromosome 10 and EGFR gene amplification in glioblastoma multiforme. Clin Neuropathol; 2005 Sep-Oct;24(5):209-18
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of chromosome 7, chromosome 10 and EGFR gene amplification in glioblastoma multiforme.
  • Glioblastoma multiforme (GBM) is characterized by intratumoral heterogeneity in both histomorphological and genetic changes, displaying a wide variety of numerical chromosome aberrations, the most common of which are trisomy 7 and monosomy 10.
  • The combination of both anomalies is probably important in the tumorigenesis of glioblastoma.
  • [MeSH-major] Brain Neoplasms / genetics. Chromosomes, Human, Pair 10 / genetics. Chromosomes, Human, Pair 7 / genetics. Gene Amplification. Glioblastoma / genetics. Receptor, Epidermal Growth Factor / biosynthesis
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Child. Female. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Polymerase Chain Reaction. Prognosis. Survival Analysis


33. Ulutin C, Fayda M, Aksu G, Cetinayak O, Kuzhan O, Ors F, Beyzadeoglu M: Primary glioblastoma multiforme in younger patients: a single-institution experience. Tumori; 2006 Sep-Oct;92(5):407-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary glioblastoma multiforme in younger patients: a single-institution experience.
  • AIMS AND BACKGROUND: To report our experience of patients with primary glioblastoma multiforme of young age by evaluating the characteristics, prognostic factors, and treatment outcomes.
  • PATIENTS AND METHODS: Seventy patients with primary glioblastoma multiforme (GBM) treated at our department between 1996 and 2004 were studied.
  • Karnofsky performance status (> or = 70 vs < 70), age (< or = 35 vs > 35 years), gender, tumor size (< or = 4 vs > 4 cm), number of involved brain lobes (1 vs more than 1), type of surgery (total vs subtotal), preoperative seizure history (present vs absent), radiotherapy field (total cranium vs partial), total radiotherapy dose (60 vs 66 Gy), and adjuvant chemotherapy (present vs absent) were evaluated in univariate analysis.
  • CONCLUSIONS: Younger patients with primary glioblastoma multiforme had a relatively long survival (median, 19.5 months, with a 2-year survival rate of 30%) compared to older patients.
  • [MeSH-major] Brain Neoplasms / therapy. Glioblastoma / therapy
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Chemotherapy, Adjuvant. Craniotomy. Female. Humans. Kaplan-Meier Estimate. Karnofsky Performance Status. Male. Middle Aged. Predictive Value of Tests. Prognosis. Proportional Hazards Models. Radiotherapy Dosage. Radiotherapy, Adjuvant. Reoperation. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17168433.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Reardon DA, Wen PY, Desjardins A, Batchelor TT, Vredenburgh JJ: Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy. Expert Opin Biol Ther; 2008 Apr;8(4):541-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy.
  • BACKGROUND: Adults with malignant glioma, especially the most common subtype, glioblastoma multiforme, have an unacceptably poor outcome with current therapies.

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 2002 Mar;178(3):711-6 [11856703.001]
  • [Cites] J Clin Invest. 2002 Mar;109(6):777-85 [11901186.001]
  • [Cites] J Neurooncol. 2002 Jan;56(2):183-8 [11995820.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11393-8 [12177445.001]
  • [Cites] Acta Radiol. 2002 Jul;43(4):354-9 [12225474.001]
  • [Cites] Neurosurgery. 2002 Oct;51(4):912-9; discussion 919-20 [12234397.001]
  • [Cites] Neurology. 2006 Apr 25;66(8):1258-60 [16636248.001]
  • [Cites] Science. 2006 May 26;312(5777):1171-5 [16728631.001]
  • [Cites] J Nucl Med. 2006 Jun;47(6):904-11 [16741298.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Jun;65(6):529-39 [16783163.001]
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):3935-41 [16818690.001]
  • [Cites] J Neurooncol. 2006 Jul;78(3):281-93 [16554966.001]
  • [Cites] Cancer Res. 1991 Oct 15;51(20):5760-5 [1717153.001]
  • [Cites] Nature. 1992 Oct 29;359(6398):843-5 [1279431.001]
  • [Cites] Expert Rev Anticancer Ther. 2006 Nov;6(11):1593-607 [17134364.001]
  • [Cites] Hum Gene Ther. 2003 Jun 10;14(9):883-95 [12828859.001]
  • [Cites] Semin Oncol. 2006 Oct;33(5 Suppl 10):S35-40 [17145523.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2542-50 [17167137.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):125-34 [17215530.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):69-82 [17222791.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Feb 1;67(2):323-6 [17236958.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1253-9 [17317837.001]
  • [Cites] Neuro Oncol. 2007 Apr;9(2):89-95 [17327573.001]
  • [Cites] J Neurooncol. 2007 Apr;82(2):141-50 [17115285.001]
  • [Cites] Neuroscience. 2007 Mar 30;145(3):795-811 [17320297.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Apr 1;67(5):1526-37 [17234361.001]
  • [Cites] J Neurosurg. 2007 Apr;106(4):601-8 [17432710.001]
  • [Cites] Cancer Res. 2007 Apr 15;67(8):3560-4 [17440065.001]
  • [Cites] Clin Cancer Res. 2007 Jun 15;13(12):3449-59 [17575207.001]
  • [Cites] Cancer Res. 2007 Aug 1;67(15):7055-8 [17671170.001]
  • [Cites] Neuroimage. 2007;37 Suppl 1:S116-9 [17512217.001]
  • [Cites] Neuro Oncol. 2007 Oct;9(4):412-23 [17622648.001]
  • [Cites] Nat Rev Cancer. 2007 Oct;7(10):733-6 [17882276.001]
  • [Cites] Clin Cancer Res. 2007 Oct 1;13(19):5670-4 [17908955.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4714-21 [17947718.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4722-9 [17947719.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2762-71 [10561351.001]
  • [Cites] Br J Cancer. 2000 Feb;82(3):635-41 [10682677.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2606-18 [10861440.001]
  • [Cites] Cancer. 2000 Aug 1;89(3):640-6 [10931464.001]
  • [Cites] Br J Cancer. 2000 Sep;83(5):588-93 [10944597.001]
  • [Cites] Neoplasia. 2000 Jul-Aug;2(4):306-14 [11005565.001]
  • [Cites] Nat Cell Biol. 2000 Oct;2(10):737-44 [11025665.001]
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5879-86 [11059786.001]
  • [Cites] Br J Cancer. 2001 May 18;84(10):1322-9 [11355942.001]
  • [Cites] Neurosurgery. 2001 Aug;49(2):380-9; discussion 390 [11504114.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):6020-4 [11507045.001]
  • [Cites] Nat Med. 2001 Sep;7(9):987-9 [11533692.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6624-8 [11559524.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Oct 1;51(2):478-82 [11567824.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7501-6 [11606386.001]
  • [Cites] Science. 2002 Feb 1;295(5556):858-61 [11823643.001]
  • [Cites] J Clin Oncol. 2002 Nov 1;20(21):4368-80 [12409337.001]
  • [Cites] Cancer Res. 2003 Jan 1;63(1):236-41 [12517803.001]
  • [Cites] Cancer. 2003 May 1;97(9 Suppl):2381-6 [12712460.001]
  • [Cites] Cancer Cell. 2003 Apr;3(4):347-61 [12726861.001]
  • [Cites] J Clin Invest. 2003 May;111(9):1287-95 [12727920.001]
  • [Cites] Nat Med. 2003 Jun;9(6):669-76 [12778165.001]
  • [Cites] Cancer Res. 1993 Dec 1;53(23):5822-7 [7694795.001]
  • [Cites] Mol Biol Cell. 1993 Dec;4(12):1317-26 [8167412.001]
  • [Cites] Lancet. 1994 Jul 9;344(8915):82-6 [7516992.001]
  • [Cites] Int J Cancer. 1994 Nov 15;59(4):520-9 [7525492.001]
  • [Cites] Cancer Res. 1995 Mar 1;55(5):1189-93 [7532545.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5510-4 [7539918.001]
  • [Cites] Glia. 1995 Nov;15(3):339-47 [8586468.001]
  • [Cites] J Biol Chem. 1996 Mar 29;271(13):7788-95 [8631822.001]
  • [Cites] Cancer. 1996 Jan 15;77(2):362-72 [8625246.001]
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):663-8 [9012841.001]
  • [Cites] Science. 1997 Feb 14;275(5302):964-7 [9020076.001]
  • [Cites] J Clin Invest. 1997 Dec 15;100(12):3131-9 [9399960.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10820-5 [9724788.001]
  • [Cites] Clin Cancer Res. 1997 Dec;3(12 Pt 1):2187-90 [9815613.001]
  • [Cites] Int J Cancer. 1999 Feb 19;84(1):10-8 [9988225.001]
  • [Cites] Clin Cancer Res. 1999 Mar;5(3):487-91 [10100697.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1516-25 [10334539.001]
  • [Cites] Cancer Res. 1999 Jul 15;59(14):3374-8 [10416597.001]
  • [Cites] Cancer Cell. 2004 Dec;6(6):553-63 [15607960.001]
  • [Cites] Science. 2005 Jan 7;307(5706):58-62 [15637262.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):229-43 [15674480.001]
  • [Cites] J Neurosurg. 2005 Feb;102(2):363-70 [15739567.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Ann Oncol. 2005 Apr;16(4):558-65 [15705616.001]
  • [Cites] Neuro Oncol. 2005 Apr;7(2):134-53 [15831232.001]
  • [Cites] J Nucl Med. 2005 Jun;46(6):945-52 [15937304.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4162-71 [15867205.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5523-34 [15994924.001]
  • [Cites] Clin Cancer Res. 2005 Sep 1;11(17):6270-9 [16144931.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8218-23 [16166297.001]
  • [Cites] Neuro Oncol. 2005 Oct;7(4):436-51 [16212809.001]
  • [Cites] Neuro Oncol. 2005 Oct;7(4):452-64 [16212810.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):8033-40 [16258101.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):8136-9 [16258121.001]
  • [Cites] Clin Cancer Res. 2005 Nov 15;11(22):8145-57 [16299247.001]
  • [Cites] Oncology. 2005;69 Suppl 3:11-6 [16301831.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):25-35 [16314617.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):16-24 [16330672.001]
  • [Cites] Brain Pathol. 2005 Oct;15(4):297-310 [16389942.001]
  • [Cites] Brain Pathol. 2005 Oct;15(4):318-26 [16389944.001]
  • [Cites] Brain Pathol. 2005 Oct;15(4):327-41 [16389945.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):217-27 [16365183.001]
  • [Cites] Nat Clin Pract Oncol. 2006 Jan;3(1):24-40 [16407877.001]
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):769-77 [16391297.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Feb;27(2):409-17 [16484420.001]
  • [Cites] Exp Cell Res. 2006 Mar 10;312(5):651-8 [16325811.001]
  • [Cites] J Nucl Med. 2006 Mar;47(3):393-403 [16513607.001]
  • [Cites] J Clin Oncol. 2006 Mar 20;24(9):1449-53 [16549839.001]
  • [Cites] Neuro Oncol. 2006 Apr;8(2):189-93 [16533878.001]
  • [Cites] Cancer Cell. 2006 Apr;9(4):287-300 [16616334.001]
  • [Cites] Clin Neurosurg. 2005;52:384-8 [16626098.001]
  • [Cites] J Clin Oncol. 2006 Jul 10;24(20):3293-8 [16829653.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7843-8 [16912155.001]
  • [Cites] Clin Cancer Res. 2006 Sep 1;12(17):5018-22 [16951216.001]
  • [Cites] Nat Rev Cancer. 2006 Nov;6(11):835-45 [17036040.001]
  • [Cites] Radiology. 2003 Aug;228(2):523-32 [12819338.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2940-9 [12912940.001]
  • [Cites] Acta Neurochir Suppl. 2003;88:169-77 [14531575.001]
  • [Cites] Mol Cancer Res. 2004 Jan;2(1):36-42 [14757844.001]
  • [Cites] Nat Med. 2004 Feb;10(2):145-7 [14745444.001]
  • [Cites] FASEB J. 2004 Feb;18(2):338-40 [14657001.001]
  • [Cites] Neuro Oncol. 2004 Jan;6(1):21-7 [14769136.001]
  • [Cites] Cancer Treat Res. 2004;117:169-90 [15015561.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3731-6 [15172975.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • [Cites] Cytokine Growth Factor Rev. 2004 Aug;15(4):275-86 [15207817.001]
  • [Cites] Blood. 2004 Oct 1;104(7):2084-6 [15191949.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Oct;5(10):816-26 [15459662.001]
  • [Cites] Clin Colorectal Cancer. 2004 Oct;4 Suppl 2:S81-5 [15479484.001]
  • [Cites] N Engl J Med. 1971 Nov 18;285(21):1182-6 [4938153.001]
  • [Cites] J Natl Cancer Inst. 1972 Feb;48(2):347-56 [4347034.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [CommentIn] Expert Opin Biol Ther. 2008 Oct;8(10):1449-53 [18774913.001]
  • (PMID = 18352856.001).
  • [ISSN] 1744-7682
  • [Journal-full-title] Expert opinion on biological therapy
  • [ISO-abbreviation] Expert Opin Biol Ther
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA108786-029003; United States / NCI NIH HHS / CA / P50 CA108786; United States / NINDS NIH HHS / NS / NS20023; United States / NCI NIH HHS / CA / CA108786-059003; United States / NINDS NIH HHS / NS / P50 NS020023; United States / NINDS NIH HHS / NS / NS020023-268626; United States / NINDS NIH HHS / NS / NS020023-240020; United States / NINDS NIH HHS / NS / NS020023-220020; United States / NCI NIH HHS / CA / 1-P50-CA108786-01; United States / NCI NIH HHS / CA / P50 CA108786-039003; United States / NINDS NIH HHS / NS / NS020023-250020; United States / NINDS NIH HHS / NS / P50 NS020023-210020; United States / NCI NIH HHS / CA / CA108786-049003; United States / NCI NIH HHS / CA / P50 CA108786-059003; United States / NCI NIH HHS / CA / P50 CA108786-029003; United States / NINDS NIH HHS / NS / P50 NS020023-230020; United States / NCI NIH HHS / CA / CA108786-05S19003; United States / NCI NIH HHS / CA / P50 CA108786-049003; United States / NCI NIH HHS / CA / CA11898; United States / NCI NIH HHS / CA / CA108786-039003; United States / NINDS NIH HHS / NS / P50 NS020023-240020; United States / NINDS NIH HHS / NS / P50 NS020023-268626; United States / NCI NIH HHS / CA / P50 CA108786-019003; United States / NINDS NIH HHS / NS / P50 NS020023-220020; United States / NCI NIH HHS / CA / P50 CA108786-05S19003; United States / NCI NIH HHS / CA / CA108786-019003; United States / NCRR NIH HHS / RR / MO1 RR 30; United States / NINDS NIH HHS / NS / P50 NS020023-250020; United States / NCI NIH HHS / CA / R37 CA011898; United States / NINDS NIH HHS / NS / NS020023-210020; United States / NINDS NIH HHS / NS / NS020023-230020
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  • [Number-of-references] 139
  • [Other-IDs] NLM/ NIHMS180495; NLM/ PMC2871667
  •  go-up   go-down


35. Dresemann G: Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. Ann Oncol; 2005 Oct;16(10):1702-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series.
  • BACKGROUND: Grade IV malignancies of the brain, such as glioblastoma multiforme (GBM), are associated with a dismal prognosis.
  • Autocrine and paracrine loops of platelet-derived growth factor (PDGF) signaling, as well as other signal transduction pathways, have been postulated to play a role in glioblastoma transformation, and molecules involved in these pathways can potentially serve as targets for therapeutic inhibitory agents.
  • Imatinib, an inhibitor of PDGF receptors alpha and beta, as well as other selected tyrosine kinases, is indicated for treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST).
  • PATIENTS AND METHODS: We tested the combination of hydroxyurea and imatinib in 30 grade IV progressive GBM patients refractory to chemo- and radiotherapy.

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16033874.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


36. Kasuya H, Matsumoto M, Munakata R, Muramatsu H, Ichikawa T, Sato T, Endo Y, Sakuma J, Suzuki K, Sasaki T, Kodama N: Separate demonstration of arterial- and venous-phase by 3D-CT angiography for brain tumors using 64-multidetector row CT: 3D-CT arteriography and 3D-CT venography. Fukushima J Med Sci; 2009 Jun;55(1):7-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Separate demonstration of arterial- and venous-phase by 3D-CT angiography for brain tumors using 64-multidetector row CT: 3D-CT arteriography and 3D-CT venography.
  • We assessed the usefulness of the separate demonstration of the arterial- and venous phase on 3D-CT angiography (3D-CTA) using a 64-multidetector row CT (MDCT) scanner for the surgery of brain tumors.
  • Nineteen patients with meningiomas (n=11), schwannomas, metastatic brain tumors (n=2 each), glioblastoma multiforme, malignant lymphoma, craniopharyngioma, and embryonal carcinoma (n=1 each) underwent scanning on a 64-MDCT scanner.
  • The 3D-CT arteriographs, 3D-CT venographs, and the fused 3D-CT images facilitated our understanding of the 3D anatomic relationship among the tumor, arteries, veins, and bony structures.
  • In 14 of 19 cases our method provided the surgically valuable findings; the information on the anatomical relation between tumor and the surrounding arteries and veins (in 13 cases) the identification of anatomical course of the encased vessels (in one), and feeding arteries and draining veins (in one), and discrimination between the venous sinus and tumor (in one).
  • [MeSH-major] Brain Neoplasms / radiography. Imaging, Three-Dimensional / methods. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adult. Aged. Angiography / methods. Arteries. Female. Humans. Male. Middle Aged. Phlebography / methods. Veins

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19999165.001).
  • [ISSN] 0016-2590
  • [Journal-full-title] Fukushima journal of medical science
  • [ISO-abbreviation] Fukushima J Med Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Japan
  •  go-up   go-down


37. Varghese M, Olstorn H, Sandberg C, Vik-Mo EO, Noordhuis P, Nistér M, Berg-Johnsen J, Moe MC, Langmoen IA: A comparison between stem cells from the adult human brain and from brain tumors. Neurosurgery; 2008 Dec;63(6):1022-33; discussion 1033-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparison between stem cells from the adult human brain and from brain tumors.
  • OBJECTIVE: To directly compare stem cells from the normal adult human brain (adult human neural stem cells [AHNSC]), Grade II astrocytomas (AC II), and glioblastoma multiforme (GBM), with respect to proliferative and tumor-forming capacity and differentiation potential.
  • METHODS: Cells were isolated from tissue obtained during epilepsy surgery (AHNSCs) or tumor surgery (glioma stem cells [GSC]).
  • 1) GBM stem cells formed tumors after orthotopic transplantation; AHNSCs showed no sign of tumor formation;.
  • 3) both the growth rate and telomerase expression were high in GSCs and correlated with malignancy grade (GBM higher than AC II); AHNSCs had low telomerase expression;.
  • CONCLUSION: AHNSCs and stem cells from AC II and GBM differ with respect to proliferation, tumor-forming capacity, and rate and pattern of differentiation.
  • [MeSH-major] Brain Neoplasms / pathology. Brain Neoplasms / physiopathology. Neurons / pathology. Neurons / physiology. Stem Cells / pathology. Stem Cells / physiology
  • [MeSH-minor] Adult. Cell Differentiation. Cell Proliferation. Cells, Cultured. Female. Humans. Male


38. Singh PK, Singh VK, Tomar J, Azam A, Gupta S, Kumar S: Spinal glioblastoma multiforme: unusual cause of post-traumatic tetraparesis. J Spinal Cord Med; 2009;32(5):583-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal glioblastoma multiforme: unusual cause of post-traumatic tetraparesis.
  • BACKGROUND/OBJECTIVE: Glioblastoma multiforme (GBM) is the most common glial cell tumor of the adult brain.
  • A magnetic resonance scan showed the typical appearance of a high-grade intramedullary tumor with fusiform expansion of the entire cervical cord.
  • CONCLUSIONS: This presentation of GBM of the cervical cord is rare; an intramedullary tumor should be considered when minor cervical trauma results in disproportionate neurologic deficit.
  • [MeSH-major] Glioblastoma / complications. Quadriplegia / etiology. Quadriplegia / therapy. Spinal Neoplasms / complications
  • [MeSH-minor] Decompression, Surgical. Humans. Laminectomy. Magnetic Resonance Imaging. Male. Radiotherapy. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1982 Aug 15;50(4):732-5 [7093908.001]
  • [Cites] No Shinkei Geka. 1985 Mar;13(3):301-5 [2989721.001]
  • [Cites] Neurosurgery. 1987 Mar;20(3):416-20 [3574617.001]
  • [Cites] Neurol Med Chir (Tokyo). 1990 Jul;30(7):489-94 [1701860.001]
  • [Cites] No Shinkei Geka. 1992 Jan;20(1):85-9 [1310803.001]
  • [Cites] Arch Neurol. 1978 Apr;35(4):244-5 [205201.001]
  • [Cites] Radiology. 1965 Mar;84:401-8 [14283212.001]
  • [Cites] Spinal Cord. 2005 Sep;43(9):565-7 [15838531.001]
  • [Cites] Acta Oncol. 2006;45(1):87-90 [16464801.001]
  • [Cites] J Neurosurg Spine. 2007 Dec;7(6):656-9 [18074692.001]
  • [Cites] Rinsho Shinkeigaku. 1995 Nov;35(11):1235-40 [8720335.001]
  • (PMID = 20025156.001).
  • [ISSN] 1079-0268
  • [Journal-full-title] The journal of spinal cord medicine
  • [ISO-abbreviation] J Spinal Cord Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2792466
  •  go-up   go-down


39. Lucena Rde C, de Mello RJ, Lessa JR Jr, Cavalcante GM, Ribeiro M: [Clinical topographic findings in glioblastoma multiforme and the relation with motor impairment]. Arq Neuropsiquiatr; 2006 Jun;64(2B):441-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical topographic findings in glioblastoma multiforme and the relation with motor impairment].
  • Glioblastoma multiforme (GBM) is the glial tumor with the highest grade of malignity.
  • It mainly affects the cerebral hemispheres, presenting general or focal signs and symptoms, which depend on the size, the location of the lesion and rate of growth of the tumor.
  • RESULTS: The occurrence of the tumor was preponderant in adults (mean age 55 years old), men (55.82%), and frontal lobe (approximately 40%).
  • [MeSH-major] Brain Neoplasms / complications. Glioblastoma / complications. Movement Disorders / etiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Retrospective Studies. Tomography, Emission-Computed

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Movement Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16917616.001).
  • [ISSN] 0004-282X
  • [Journal-full-title] Arquivos de neuro-psiquiatria
  • [ISO-abbreviation] Arq Neuropsiquiatr
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


40. Martinez R, Martin-Subero JI, Rohde V, Kirsch M, Alaminos M, Fernandez AF, Ropero S, Schackert G, Esteller M: A microarray-based DNA methylation study of glioblastoma multiforme. Epigenetics; 2009 May 16;4(4):255-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A microarray-based DNA methylation study of glioblastoma multiforme.
  • Glioblastoma multiforme (GBM) is the most frequent and devastating primary brain tumor in adults.
  • The presence of epigenetic lesions, like hypermethylation of known tumor suppressor genes such as MGMT, has been widely described in GBM, but to our knowledge, a genome-wide profile of DNA methylation changes in these lethal tumors is not yet available.
  • [MeSH-major] DNA Methylation. Glioblastoma / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line, Tumor. Cluster Analysis. CpG Islands. Epigenesis, Genetic. Female. Gene Expression Profiling. Humans. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Polycomb-Group Proteins. Repressor Proteins / metabolism

  • Genetic Alliance. consumer health - Glioblastoma.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19550145.001).
  • [ISSN] 1559-2308
  • [Journal-full-title] Epigenetics
  • [ISO-abbreviation] Epigenetics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Polycomb-Group Proteins; 0 / Repressor Proteins
  •  go-up   go-down


41. Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE 2nd, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Vredenburgh JJ, Desjardins A, Gururangan S, Badruddoja M, Dowell JM, Wong TZ, Zhao XG, Zalutsky MR, Bigner DD: Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol; 2006 Jan 1;24(1):115-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.
  • PURPOSE: To assess the efficacy and toxicity of intraresection cavity iodine-131-labeled murine antitenascin monoclonal antibody 81C6 (131I-m81C6) among recurrent malignant brain tumor patients.
  • PATIENTS AND METHODS: In this phase II trial, 100 mCi of 131I-m81C6 was injected directly into the surgically created resection cavity (SCRC) of 43 patients with recurrent malignant glioma (glioblastoma multiforme [GBM], n = 33; anaplastic astrocytoma [AA], n = 6; anaplastic oligodendroglioma [AO], n = 2; gliosarcoma [GS], n = 1; and metastatic adenocarcinoma, n = 1) followed by chemotherapy.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Brain Neoplasms / radiotherapy. Iodine Radioisotopes / therapeutic use. Neoplasm Recurrence, Local / radiotherapy. Radioimmunotherapy. Tenascin / immunology
  • [MeSH-minor] Adult. Aged. Biopsy. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Salvage Therapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Clin Oncol. 2006 Mar 20;24(9):1484. Guruangan, Sri [corrected to Gururangan, Sridharan]
  • (PMID = 16382120.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1-P50-CA108786-01; United States / NCI NIH HHS / CA / CA11898; United States / NCRR NIH HHS / RR / MO1 RR 30; United States / NINDS NIH HHS / NS / NS20023
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Iodine Radioisotopes; 0 / Tenascin
  •  go-up   go-down


42. Omura Y: Asbestos as a possible major cause of malignant lung tumors (including small cell carcinoma, adenocarcinoma & mesothelioma), brain tumors (i.e. astrocytoma & glioblastoma multiforme), many other malignant tumors, intractable pain including fibromyalgia, & some cardio-vascular pathology: Safe & effective methods of reducing asbestos from normal & pathological areas. Acupunct Electrother Res; 2006;31(1-2):61-125
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Asbestos as a possible major cause of malignant lung tumors (including small cell carcinoma, adenocarcinoma & mesothelioma), brain tumors (i.e. astrocytoma & glioblastoma multiforme), many other malignant tumors, intractable pain including fibromyalgia, & some cardio-vascular pathology: Safe & effective methods of reducing asbestos from normal & pathological areas.
  • High incidences of Small Cell Carcinoma & Adenocarcinoma of the lung, Astrocytoma & Glioblastoma Multiforme of the brain and Mesothelioma of the lung were found in those who had a high accumulation of Asbestos in the eyes and upper respiratory system (nose, larynx, trachea, etc.).
  • When measured non-invasively using the Bi-Digital O-Ring Test (BDORT), brain tumors had the highest concentration of Asbestos (0.2 approximately 2.1 mg BDORT units).
  • A small, round or ellipsoidal area, with diameter of 5 mm or less, was found near the center of every cancer tissue with a higher level of Asbestos (1 approximately 3 mg), As, Zn, Cr and Se, than in the rest of the tumor; this small area may be where the cancer initiated.
  • The author found that in the Astrocytoma and many other cancer patients, the optimal dose of DHEA produced very significant reductions of cancer cell telomere from over 1400 ng in the brain tumors (and over 900 ng in other cancers) to close to or less than 1 yg (=10(-24) g), with circulatory improvement by reduction of TXB2.
  • [MeSH-minor] Adult. Aged. Female. Humans. Inhalation Exposure / adverse effects. Lung Neoplasms / chemically induced. Lung Neoplasms / genetics. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Male. Microscopy, Electron, Transmission. Middle Aged. Occupational Exposure / adverse effects


43. Bullitt E, Ewend M, Vredenburgh J, Friedman A, Lin W, Wilber K, Zeng D, Aylward SR, Reardon D: Computerized assessment of vessel morphological changes during treatment of glioblastoma multiforme: report of a case imaged serially by MRA over four years. Neuroimage; 2009 Aug;47 Suppl 2:T143-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Computerized assessment of vessel morphological changes during treatment of glioblastoma multiforme: report of a case imaged serially by MRA over four years.
  • A patient with glioblastoma multiforme underwent serial computerized analysis of tumor-associated vasculature defined from magnetic resonance angiographic (MRA) scans obtained over almost a four year period.
  • The clinical course included tumor resection with subsequent radiation therapy, a long symptom-free interval, emergence of a new malignant focus, resection of that focus, a stroke, and treatment with chemotherapy and anti-angiogenic therapy.
  • Image analysis methods included segmentation of vessels from each MRA and statistical comparison of vessel morphology over 4 regions of interest (the initial tumor site, the second tumor site, a distant control region, and the entire brain) to the same 4 regions of interest in 50 healthy volunteers (26 females and 24 males; mean age 39 years).
  • Quantitative measurements of vessel morphology as defined from MRA may provide useful insights into tumor development and response to therapy.

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Jan 19;92(2):94-5 [10639502.001]
  • [Cites] Technol Cancer Res Treat. 2008 Jun;7(3):241-8 [18473496.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Cancer Biother Radiopharm. 1999 Feb;14(1):31-6 [10850285.001]
  • [Cites] Cancer Res. 2000 Jul 15;60(14):3683-8 [10919633.001]
  • [Cites] Nat Med. 2001 Sep;7(9):987-9 [11533692.001]
  • [Cites] J Natl Cancer Inst. 2001 Sep 19;93(18):1401-5 [11562391.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1375-82 [11870182.001]
  • [Cites] IEEE Trans Med Imaging. 2002 Feb;21(2):61-75 [11929106.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1284-91 [11948144.001]
  • [Cites] FASEB J. 2002 Jul;16(9):1041-9 [12087065.001]
  • [Cites] Cancer Res. 2002 Sep 15;62(18):5381-5 [12235011.001]
  • [Cites] Br J Cancer. 2003 Jun 16;88(12):1979-86 [12799646.001]
  • [Cites] Neurology. 2003 Jul 22;61(2):270-1 [12874421.001]
  • [Cites] IEEE Trans Med Imaging. 2003 Sep;22(9):1163-71 [12956271.001]
  • [Cites] Br J Cancer. 2003 Nov 17;89(10):1896-900 [14612899.001]
  • [Cites] Nat Med. 2004 Feb;10(2):145-7 [14745444.001]
  • [Cites] N Engl J Med. 1971 Nov 18;285(21):1182-6 [4938153.001]
  • [Cites] Nature. 1996 Apr 4;380(6573):439-42 [8602242.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14765-70 [8962129.001]
  • [Cites] Technol Cancer Res Treat. 2004 Dec;3(6):577-84 [15560715.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 Apr;26(4):770-6 [15814919.001]
  • [Cites] Acad Radiol. 2005 Oct;12(10):1232-40 [16179200.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2005 Dec;46(12):4780-7 [16303979.001]
  • [Cites] J Clin Oncol. 2006 Mar 10;24(8):1253-65 [16525180.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Mar;27(3):612-9 [16552004.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Oct;27(9):1969-74 [17032877.001]
  • [Cites] J Clin Neurosci. 2007 Apr;14(4):301-8 [17276069.001]
  • [Cites] Brain. 2007 Oct;130(Pt 10):2596-606 [17785346.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4705-6 [17947716.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4722-9 [17947719.001]
  • [Cites] J Cancer Res Ther. 2005 Oct-Dec;1(4):235-8 [17998661.001]
  • [Cites] Radiology. 2007 Dec;245(3):824-30 [17954616.001]
  • [Cites] J Natl Cancer Inst. 2000 Jan 19;92(2):143-7 [10639516.001]
  • (PMID = 19103295.001).
  • [ISSN] 1095-9572
  • [Journal-full-title] NeuroImage
  • [ISO-abbreviation] Neuroimage
  • [Language] ENG
  • [Grant] United States / NIBIB NIH HHS / EB / EB000219-10; United States / NCI NIH HHS / CA / R01 CA124608; United States / NCI NIH HHS / CA / CA124608-03; United States / NCI NIH HHS / CA / R01 CA124608-03; United States / NIBIB NIH HHS / EB / R01 EB000219; United States / NIBIB NIH HHS / EB / R01 EB000219-11; United States / NIBIB NIH HHS / EB / R01 EB000219-10; United States / NIBIB NIH HHS / EB / EB000219-11
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors
  • [Other-IDs] NLM/ NIHMS138759; NLM/ PMC2752720
  •  go-up   go-down


44. Chen AM, Chang S, Pouliot J, Sneed PK, Prados MD, Lamborn KR, Malec MK, McDermott MW, Berger MS, Larson DA: Phase I trial of gross total resection, permanent iodine-125 brachytherapy, and hyperfractionated radiotherapy for newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys; 2007 Nov 1;69(3):825-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of gross total resection, permanent iodine-125 brachytherapy, and hyperfractionated radiotherapy for newly diagnosed glioblastoma multiforme.
  • PURPOSE: To evaluate the feasibility of gross total resection and permanent I-125 brachytherapy followed by hyperfractionated radiotherapy for patients with newly diagnosed glioblastoma.
  • METHODS AND MATERIALS: From April 1999 to May 2002, 21 patients with glioblastoma multiforme were enrolled on a Phase I protocol investigating planned gross total resection and immediate placement of permanent I-125 seeds, followed by postoperative hyperfractionated radiotherapy to a dose of 60 Gy at 100 cGy b.i.d., 5 days per week.
  • The median preoperative tumor volume on magnetic resonance imaging was 18.6 cm(3) (range, 4.4-41.2 cm(3)).
  • Ten patients underwent 12 reoperations, with 11 of 12 reoperations demonstrating necrosis without evidence of tumor.
  • [MeSH-major] Brachytherapy / methods. Brain Neoplasms / radiotherapy. Brain Neoplasms / surgery. Glioblastoma / radiotherapy. Glioblastoma / surgery
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy / methods. Dose Fractionation. Feasibility Studies. Humans. Iodine Radioisotopes / therapeutic use. Middle Aged. Prospective Studies. Survival Analysis. Tumor Burden

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17512132.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  •  go-up   go-down


45. Khan MK, Hunter GK, Vogelbaum M, Suh JH, Chao ST: Evidence-based adjuvant therapy for gliomas: current concepts and newer developments. Indian J Cancer; 2009 Apr-Jun;46(2):96-107
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of the 18,820 new cases of primary central nervous system (CNS) tumors diagnosed annually in the United States, gliomas account for over 60% with 30-40% of them being glioblastoma multiforme (GBM), 10% being anaplastic astrocytoma (AA), and 10% being low grade gliomas (LGGs).
  • This is in contrast to one study from West Bengal, India, in which only 7.9% of the brain tumors were GBMs, while 46.8% were astrocytomas.
  • Of all adult primary CNS tumors, GBM is the most common and the most malignant with about 7,000 to 8,000 new cases annually in the United States.
  • Common to these approaches is the use of adjuvant radiation therapy, even as surgery alone, with or without chemotherapy, may be the mainstay for some lower grade and low-risk gliomas.
  • Specifically, the database is searched using the following keywords, with various combinations: glioma, low-grade, anaplastic, astrocytoma, oligodendroglioma, oligoastrocytoma, glioblastoma multiforme, chemotherapy, radiation, new concepts, phase III, MGMT, CDX-110 (Celldex), temozolomide, 1p/19q deletion, and bevacizumab.
  • [MeSH-major] Central Nervous System Neoplasms / therapy. Chemotherapy, Adjuvant. Evidence-Based Medicine. Glioma / therapy. Radiotherapy, Adjuvant
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Astrocytoma / drug therapy. Astrocytoma / radiotherapy. Astrocytoma / therapy. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Glioblastoma / therapy. Humans

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19346643.001).
  • [ISSN] 0019-509X
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 64
  •  go-up   go-down


46. Metellus P, Coulibaly B, Nanni I, Fina F, Eudes N, Giorgi R, Barrie M, Chinot O, Fuentes S, Dufour H, Ouafik L, Figarella-Branger D: Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort. Cancer; 2009 Oct 15;115(20):4783-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort.
  • Epigenetic silencing of the MGMT gene by promoter methylation has been associated with longer survival in patients with newly diagnosed glioblastoma multiforme (GBM) who receive alkylating agents.
  • The authors investigated the correlation between MGMT silencing in the tumor at recurrence and survival taking into account other clinically recognized prognostic factors.
  • In addition, expression analyses of human mutL homolog 1, human mutS homolog 2, and tumor necrosis factor alpha-induced protein 3 at recurrence were conducted with regard to their prognostic impact.
  • [MeSH-major] Brain Neoplasms / drug therapy. Brain Neoplasms / surgery. Carmustine / administration & dosage. Glioblastoma / drug therapy. O(6)-Methylguanine-DNA Methyltransferase / metabolism
  • [MeSH-minor] Adult. Age Factors. Aged. Biomarkers, Tumor / metabolism. DNA Methylation. Drug Implants / administration & dosage. Female. Gene Silencing. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Prospective Studies

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. Carmustine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 American Cancer Society.
  • (PMID = 19637364.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Drug Implants; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase; U68WG3173Y / Carmustine
  •  go-up   go-down


47. Mangiola A, Lama G, Giannitelli C, De Bonis P, Anile C, Lauriola L, La Torre G, Sabatino G, Maira G, Jhanwar-Uniyal M, Sica G: Stem cell marker nestin and c-Jun NH2-terminal kinases in tumor and peritumor areas of glioblastoma multiforme: possible prognostic implications. Clin Cancer Res; 2007 Dec 1;13(23):6970-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stem cell marker nestin and c-Jun NH2-terminal kinases in tumor and peritumor areas of glioblastoma multiforme: possible prognostic implications.
  • PURPOSE: It has been hypothesized that brain tumors are derived from stem cell or transiently dividing precursor transformation.
  • This study analyzes stem cell marker nestin and JNK expression in glioblastoma multiforme (GBM) and peritumor tissue and assesses their possible prognostic implications.
  • Samples were derived from tumors (first area), from tissues at a distance <1 cm (second area), and between 1 and 3.5 cm (third area) from the macroscopic tumor border.
  • RESULTS: Nestin cytoplasmic immunoreactivity was observed in the majority of cells in tumor but infrequently in peritumor areas. tJNK, observed in the nucleus and cytoplasm, was widely expressed in the three areas; pJNK, mostly located in the nuclei, was found in a variable percentage of cells in the tumor and peritumor tissue.
  • [MeSH-major] Glioblastoma / metabolism. Glioblastoma / pathology. Intermediate Filament Proteins / biosynthesis. JNK Mitogen-Activated Protein Kinases / biosynthesis. Nerve Tissue Proteins / biosynthesis. Supratentorial Neoplasms / metabolism. Supratentorial Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Enzyme Activation. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Multivariate Analysis. Nestin. Prognosis. Stem Cells / metabolism. Stem Cells / pathology

  • Genetic Alliance. consumer health - Glioblastoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Clin Cancer Res. 2008 Aug 1;14(15):4995-6
  • (PMID = 18056172.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases
  •  go-up   go-down


48. Kohshi K, Yamamoto H, Nakahara A, Katoh T, Takagi M: Fractionated stereotactic radiotherapy using gamma unit after hyperbaric oxygenation on recurrent high-grade gliomas. J Neurooncol; 2007 May;82(3):297-303
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fractionated stereotactic radiotherapy using gamma unit after hyperbaric oxygenation on recurrent high-grade gliomas.
  • BACKGROUND: To reduce this complication and to enhance the radiation effect to hypoxic cells of high-grade gliomas, the authors performed noninvasive fractionated stereotactic radiotherapy (FSRT) using a Gamma unit combined with hyperbaric oxygen (HBO) therapy for the treatment of recurrent disease.
  • PATIENTS AND METHODS: Twenty-five consecutive patients who had previously received radiotherapy with chemotherapy for recurrent high-grade gliomas, including 14 patients with anaplastic astrocytoma (AA) and 11 with glioblastoma multiforme (GBM), underwent Gamma FSRT immediately after HBO therapy (2.5 atmospheres absolute for 60 min).
  • Median tumor volume was 8.7 cc (range, 1.7-159.3 cc), and the median total radiation dose was 22 Gy (range, 18-27 Gy) to the tumor margin in 8 fractions.
  • CONCLUSION: Gamma FSRT after HBO therapy appears to confer a survival benefit for patients with recurrent high-grade gliomas and warrants further investigation.
  • [MeSH-major] Brain Neoplasms / therapy. Glioma / therapy. Hyperbaric Oxygenation. Neoplasm Recurrence, Local / surgery. Radiosurgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1999 Apr;80(1-2):236-41 [10390002.001]
  • [Cites] Br J Cancer. 2000 Jan;82(1):88-92 [10638972.001]
  • [Cites] Int J Cancer. 2001 Oct 20;96(5):320-5 [11582585.001]
  • [Cites] Radiother Oncol. 2003 Apr;67(1):63-7 [12758241.001]
  • [Cites] Br J Radiol. 1989 Aug;62(740):679-94 [2670032.001]
  • [Cites] J Neurooncol. 2002 May;58(1):47-52 [12160140.001]
  • [Cites] Stereotact Funct Neurosurg. 1995;64 Suppl 1:249-57 [8584835.001]
  • [Cites] Neurosurgery. 1997 Oct;41(4):776-83; discussion 783-5 [9316038.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):67-74 [12007943.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Jun;16(6):1405-9 [2542195.001]
  • [Cites] Neurosurgery. 2000 May;46(5):1123-8; discussion 1128-30 [10807244.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):393-8 [9069312.001]
  • [Cites] Cancer Lett. 2001 Mar 26;164(2):149-54 [11179829.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jan 15;43(2):293-8 [10030252.001]
  • [Cites] Radiother Oncol. 1999 Nov;53(2):127-31 [10665789.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Sep 1;48(2):421-6 [10974456.001]
  • [Cites] Neurosurgery. 1995 Feb;36(2):275-82; discussion 282-4 [7731507.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Dec 1;45(5):1133-41 [10613305.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jun 15;29(3):427-31 [8005794.001]
  • [Cites] Radiother Oncol. 1995 Nov;37(2):108-16 [8747934.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Dec 1;36(5):1045-53 [8985026.001]
  • (PMID = 17120158.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Tuettenberg J, Grobholz R, Korn T, Wenz F, Erber R, Vajkoczy P: Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme. J Cancer Res Clin Oncol; 2005 Jan;131(1):31-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme.
  • PURPOSE: Glioblastoma multiforme (GBM) represents the prototype of an angiogenic tumor.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclooxygenase Inhibitors / therapeutic use. Dacarbazine / analogs & derivatives. Glioblastoma / drug therapy. Isoenzymes / antagonists & inhibitors. Neovascularization, Pathologic / prevention & control
  • [MeSH-minor] Adult. Antineoplastic Agents, Alkylating / administration & dosage. Brain Neoplasms / secondary. Cyclooxygenase 2. Cyclooxygenase 2 Inhibitors. Disease-Free Survival. Drug Administration Schedule. Female. Humans. Immunohistochemistry. Lactones / administration & dosage. Male. Membrane Proteins. Middle Aged. Prostaglandin-Endoperoxide Synthases. Sulfones / administration & dosage. Survival Analysis

  • Genetic Alliance. consumer health - Glioblastoma.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2001 Feb;12 (2):259-66 [11300335.001]
  • [Cites] Prog Exp Tumor Res. 2003;37:179-92 [12795055.001]
  • [Cites] Cancer Res. 2002 May 15;62(10 ):2749-52 [12019148.001]
  • [Cites] Acta Neuropathol. 1999 Sep;98(3):240-4 [10483780.001]
  • [Cites] J Clin Invest. 1999 Jan;103(2):159-65 [9916127.001]
  • [Cites] J Natl Cancer Inst. 1993 May 5;85(9):704-10 [8478956.001]
  • [Cites] Lancet. 2002 Mar 9;359(9309):852-3 [11897288.001]
  • [Cites] Cancer Res. 1999 Sep 15;59(18):4574-7 [10493510.001]
  • [Cites] Cancer. 1992 Dec 1;70(11):2673-80 [1423198.001]
  • [Cites] Nat Med. 2001 Sep;7(9):1041-7 [11533708.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6624-8 [11559524.001]
  • [Cites] Cancer Res. 1992 Dec 1;52(23):6702-4 [1384969.001]
  • [Cites] Cancer Res. 2000 Aug 1;60(15):4152-60 [10945623.001]
  • [Cites] Cancer Res. 1996 Jan 15;56(2):393-401 [8542597.001]
  • [Cites] Glia. 1995 Nov;15(3):339-47 [8586468.001]
  • [Cites] J Clin Invest. 1973 Nov;52(11):2745-56 [4355998.001]
  • [Cites] J Neurosurg. 1983 Feb;58(2):159-69 [6294260.001]
  • [Cites] Hum Pathol. 2002 Jul;33(7):708-14 [12196922.001]
  • [Cites] Cancer Cell. 2003 Apr;3(4):347-61 [12726861.001]
  • [Cites] N Engl J Med. 1971 Nov 18;285(21):1182-6 [4938153.001]
  • [Cites] Nat Med. 1999 Dec;5(12):1418-23 [10581086.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3276-84 [12947063.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):221-32 [11801563.001]
  • [Cites] Int J Cancer. 2002 Oct 20;101(6):567-75 [12237899.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7501-6 [11606386.001]
  • [Cites] J Clin Invest. 2000 Apr;105(8):R15-24 [10772661.001]
  • [Cites] Am J Clin Oncol. 2003 Aug;26(4):S46-7 [12902855.001]
  • [Cites] Clin Cancer Res. 2003 Apr;9(4):1566-72 [12684433.001]
  • [Cites] Anticancer Drugs. 2003 Aug;14 (7):515-22 [12960735.001]
  • [Cites] J Clin Oncol. 1999 Sep;17 (9):2762-71 [10561351.001]
  • [Cites] Pathol Res Pract. 2000;196(5):277-84 [10834383.001]
  • [Cites] Hum Pathol. 2002 Feb;33(2):213-9 [11957147.001]
  • [Cites] Clin Cancer Res. 2000 May;6(5):2006-11 [10815926.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23 ):6938-43 [12460910.001]
  • [Cites] Cancer Res. 1998 Oct 1 ;58(19):4363-7 [9766665.001]
  • [Cites] Biochem Biophys Res Commun. 1986 Nov 14;140(3):901-7 [2430572.001]
  • [Cites] J Exp Med. 2001 Mar 5;193(5):607-20 [11238591.001]
  • [Cites] Cancer Res. 1999 Jul 15;59(14):3374-8 [10416597.001]
  • [Cites] J Clin Oncol. 2001 Feb 15;19(4):1195-206 [11181686.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;44(5):411-6 [10501915.001]
  • [Cites] Ann Med. 2003;35(7):476-87 [14649330.001]
  • [Cites] Invest New Drugs. 1997;15(1):39-48 [9195288.001]
  • [Cites] Cancer Res. 2002 May 15;62(10):2731-5 [12019144.001]
  • [Cites] Cancer. 1996 Jan 15;77(2):362-72 [8625246.001]
  • [Cites] Ann Oncol. 2002 Jan;13(1):12-5 [11863092.001]
  • [Cites] Br J Cancer. 2000 Sep;83(5):588-93 [10944597.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):1878-86 [10766175.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1306-11 [10728691.001]
  • [Cites] FASEB J. 2002 May;16(7):681-90 [11978732.001]
  • [Cites] Neoplasia. 1999 Apr;1(1):31-41 [10935468.001]
  • [Cites] Cancer J. 2001 Sep-Oct;7(5):427-36 [11693902.001]
  • [Cites] J Neurooncol. 1999;45(3):247-55 [10845396.001]
  • (PMID = 15565458.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents, Alkylating; 0 / Cyclooxygenase 2 Inhibitors; 0 / Cyclooxygenase Inhibitors; 0 / Isoenzymes; 0 / Lactones; 0 / Membrane Proteins; 0 / Sulfones; 0QTW8Z7MCR / rofecoxib; 7GR28W0FJI / Dacarbazine; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases; YF1K15M17Y / temozolomide
  •  go-up   go-down


50. Bink A, Gaa J, Franz K, Weidauer S, Yan B, Lanfermann H, Seifert V, Zanella FE: Importance of diffusion-weighted imaging in the diagnosis of cystic brain tumors and intracerebral abscesses. Zentralbl Neurochir; 2005 Aug;66(3):119-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Importance of diffusion-weighted imaging in the diagnosis of cystic brain tumors and intracerebral abscesses.
  • OBJECTIVE: It is often difficult to decide whether a cystic brain lesion is a tumor or an abscess by means of conventional MRI techniques.
  • The immediate diagnosis of a brain abscess is important for the patient's outcome.
  • PATIENTS AND METHODS: Ten patients (five men, five women) with cystic brain lesions were examined with MRI.
  • Histology revealed glioblastoma multiforme in six patients and abscess in four patients.
  • RESULTS: All brain abscesses showed markedly hyperintense signal changes on diffusion-weighted imaging, whereas the appearance of glioblastoma varied from slightly hyperintense to hypointense signal conversion.
  • The mean ADC value calculated in the six patients with cystic brain tumor was: 2.05 x 10 (-3) mm(2)/s (1.38-2.88 x 10 (-3) mm(2)/s).
  • The mean ADC value of the four patients with brain abscess was: 0.57 x 10 (-3) mm(2)/s (0.38-0.77 x 10 (-3) mm(2)/s).
  • CONCLUSION: Diffusion-weighted imaging and calculation of ADC maps constitute a helpful tool to differentiate between cystic brain tumors and brain abscesses.
  • [MeSH-major] Brain Abscess / diagnosis. Brain Neoplasms / diagnosis. Diffusion Magnetic Resonance Imaging
  • [MeSH-minor] Adult. Aged. Brain / microbiology. Brain / pathology. Child. Diagnosis, Differential. Echo-Planar Imaging. Female. Glioblastoma / diagnosis. Glioblastoma / pathology. Gram-Positive Bacterial Infections / diagnosis. Gram-Positive Bacterial Infections / microbiology. Gram-Positive Bacterial Infections / pathology. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Nervous System Diseases / etiology. Peptococcus

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16116554.001).
  • [ISSN] 0044-4251
  • [Journal-full-title] Zentralblatt für Neurochirurgie
  • [ISO-abbreviation] Zentralbl. Neurochir.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


51. Mamelak AN, Rosenfeld S, Bucholz R, Raubitschek A, Nabors LB, Fiveash JB, Shen S, Khazaeli MB, Colcher D, Liu A, Osman M, Guthrie B, Schade-Bijur S, Hablitz DM, Alvarez VL, Gonda MA: Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma. J Clin Oncol; 2006 Aug 1;24(22):3644-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma.
  • PURPOSE: TM-601 binds to malignant brain tumor cells with high affinity and does not seem to bind to normal brain tissue.
  • PATIENTS AND METHODS: Eighteen adult patients (17 with glioblastoma multiforme and one with anaplastic astrocytoma) with histologically documented recurrent glioma and a Karnofsky performance status of > or = 60% who were eligible for cytoreductive craniotomy were enrolled.
  • An intracavitary catheter with subcutaneous reservoir was placed in the tumor cavity during surgery.
  • 131I-TM-601 bound to the tumor periphery and demonstrated long-term retention at the tumor with minimal uptake in any other organ system.
  • [MeSH-major] Brachytherapy. Brain Neoplasms / radiotherapy. Glioma / radiography. Iodine Radioisotopes / administration & dosage. Iodine Radioisotopes / adverse effects. Scorpion Venoms / administration & dosage. Scorpion Venoms / adverse effects
  • [MeSH-minor] Adult. Aged. Female. Humans. Karnofsky Performance Status. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local / radiotherapy. Radiometry. Radiopharmaceuticals / administration & dosage. Radiopharmaceuticals / adverse effects. Radiotherapy Dosage. Survival Analysis. Time Factors. Tomography, Emission-Computed, Single-Photon. Treatment Outcome

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16877732.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chlorotoxin; 0 / Iodine Radioisotopes; 0 / Radiopharmaceuticals; 0 / Scorpion Venoms
  •  go-up   go-down


52. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW: An integrated genomic analysis of human glioblastoma multiforme. Science; 2008 Sep 26;321(5897):1807-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An integrated genomic analysis of human glioblastoma multiforme.
  • Glioblastoma multiforme (GBM) is the most common and lethal type of brain cancer.
  • To identify the genetic alterations in GBMs, we sequenced 20,661 protein coding genes, determined the presence of amplifications and deletions using high-density oligonucleotide arrays, and performed gene expression analyses using next-generation sequencing technologies in 22 human tumor samples.
  • These studies demonstrate the value of unbiased genomic analyses in the characterization of human brain cancer and identify a potentially useful genetic alteration for the classification and targeted therapy of GBMs.

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827854877 for PMID:18772396 [PharmGKB] .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • SciCrunch. OMIM: Data: Gene Annotation .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 2003 Jul 1;31(13):3812-4 [12824425.001]
  • [Cites] Science. 2008 Aug 15;321(5891):956-60 [18599741.001]
  • [Cites] J Comput Chem. 2004 Oct;25(13):1605-12 [15264254.001]
  • [Cites] J Biol Chem. 2004 Aug 6;279(32):33946-57 [15173171.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5048-50 [15289301.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6892-9 [15466178.001]
  • [Cites] J Comp Neurol. 1973 Mar 15;148(2):211-6 [4700508.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1801-6 [18772397.001]
  • [Cites] Biotechniques. 2008 Jul;45(1):81-94 [18611170.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1383-7 [10728703.001]
  • [Cites] Neuro Oncol. 1999 Jan;1(1):44-51 [11550301.001]
  • [Cites] Nat Biotechnol. 2002 May;20(5):508-12 [11981567.001]
  • [Cites] Free Radic Biol Med. 2002 Jun 1;32(11):1185-96 [12031902.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Oct;84(19):6899-903 [3477813.001]
  • [Cites] Nature. 1989 Dec 7;342(6250):705-8 [2531845.001]
  • [Cites] Cell. 1992 Apr 17;69(2):275-81 [1568247.001]
  • [Cites] Nat Genet. 1995 Oct;11(2):210-2 [7550353.001]
  • [Cites] Science. 1995 Oct 20;270(5235):484-7 [7570003.001]
  • [Cites] Cancer Res. 1996 Jan 1;56(1):150-3 [8548755.001]
  • [Cites] Anticancer Res. 1995 Nov-Dec;15(6B):2495-9 [8669813.001]
  • [Cites] Science. 1997 Mar 28;275(5308):1943-7 [9072974.001]
  • [Cites] Biochemistry. 1997 Nov 4;36(44):13743-7 [9354646.001]
  • [Cites] Mol Biol Evol. 1998 Dec;15(12):1674-84 [9866202.001]
  • [Cites] J Biol Chem. 1999 Oct 22;274(43):30527-33 [10521434.001]
  • [Cites] Brain Pathol. 2004 Oct;14(4):372-7 [15605984.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] N Engl J Med. 2005 Nov 10;353(19):2012-24 [16282176.001]
  • [Cites] Nat Methods. 2006 Jan;3(1):31-3 [16369550.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):159-67 [16397228.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):3987-91 [16618716.001]
  • [Cites] Cancer Biol Ther. 2006 Apr;5(4):360-70 [16575211.001]
  • [Cites] Methods Mol Biol. 2007;356:319-50 [16988414.001]
  • [Cites] Science. 2006 Oct 13;314(5797):268-74 [16959974.001]
  • [Cites] Mol Cancer Res. 2006 Oct;4(10):709-14 [17050665.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11502-13 [17114236.001]
  • [Cites] Clin Cancer Res. 2007 Apr 1;13(7):2038-45 [17404084.001]
  • [Cites] Am J Pathol. 2007 May;170(5):1445-53 [17456751.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Mol Cell Biochem. 2007 Aug;302(1-2):27-34 [17646934.001]
  • [Cites] Genome Res. 2007 Sep;17(9):1304-18 [17693572.001]
  • [Cites] Free Radic Biol Med. 2007 Oct 15;43(8):1197-207 [17854715.001]
  • [Cites] Science. 2007 Nov 16;318(5853):1108-13 [17932254.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Mar 18;105(11):4283-8 [18337506.001]
  • [Cites] Cell. 2008 May 2;133(3):523-36 [18423832.001]
  • [Cites] Nat Methods. 2008 Jul;5(7):621-8 [18516045.001]
  • [Cites] Science. 2004 Apr 23;304(5670):554 [15016963.001]
  • (PMID = 18772396.001).
  • [ISSN] 1095-9203
  • [Journal-full-title] Science (New York, N.Y.)
  • [ISO-abbreviation] Science
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA043460-27; United States / NCI NIH HHS / CA / CA57345; United States / NCI NIH HHS / CA / R37 CA043460; United States / NCI NIH HHS / CA / R37 CA043460-27; United States / NINDS NIH HHS / NS / NS052507; United States / NCI NIH HHS / CA / CA121113; United States / NCI NIH HHS / CA / P50 CA062924; United States / NCI NIH HHS / CA / R37 CA057345-13; United States / NCI NIH HHS / CA / CA62924; United States / NCI NIH HHS / CA / R37 CA057345-18; United States / NCI NIH HHS / CA / CA09547; United States / NCI NIH HHS / CA / R01 CA121113; United States / NCI NIH HHS / CA / R01 CA140316; United States / NCI NIH HHS / CA / CA108786; United States / NCI NIH HHS / CA / CA43460; United States / NCI NIH HHS / CA / CA062924-160017; United States / NCI NIH HHS / CA / R01 CA121113-04; United States / NCI NIH HHS / CA / CA057345-13; United States / NCI NIH HHS / CA / P50 CA062924-160017; United States / NCI NIH HHS / CA / CA057345-17; United States / NCI NIH HHS / CA / CA11898; United States / Howard Hughes Medical Institute / / ; United States / NCI NIH HHS / CA / CA057345-18; United States / NCI NIH HHS / CA / R37 CA057345-17; United States / NCI NIH HHS / CA / R37 CA057345; United States / NINDS NIH HHS / NS / 5P50-NS-20023
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.1.1.41 / Isocitrate Dehydrogenase
  • [Other-IDs] NLM/ NIHMS105586; NLM/ PMC2820389
  •  go-up   go-down


53. Joensuu H, Puputti M, Sihto H, Tynninen O, Nupponen NN: Amplification of genes encoding KIT, PDGFRalpha and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme. J Pathol; 2005 Oct;207(2):224-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amplification of genes encoding KIT, PDGFRalpha and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme.
  • The four secondary glioblastomas arising from pre-existing lower grade astrocytic tumours investigated had KIT amplification but none had EGFR amplification.
  • We conclude that KIT, PDGFRA and VEGFR2 are commonly amplified in primary glioblastoma and that they may also be amplified in secondary glioblastoma.
  • [MeSH-major] Brain Neoplasms / genetics. Glioblastoma / genetics. Protein-Tyrosine Kinases / antagonists & inhibitors. Proto-Oncogene Proteins c-kit / genetics. Receptor, Platelet-Derived Growth Factor alpha / genetics. Vascular Endothelial Growth Factor Receptor-2 / genetics
  • [MeSH-minor] Adult. Aged. Endothelial Cells / pathology. Exons / genetics. Female. Gene Amplification / genetics. Genes, erbB-1 / genetics. Humans. Immunohistochemistry / methods. In Situ Hybridization, Fluorescence / methods. Male. Middle Aged. Mutation. Phosphorylation. Survival Analysis

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
  • (PMID = 16021678.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


54. Floeth FW, Pauleit D, Sabel M, Reifenberger G, Stoffels G, Stummer W, Rommel F, Hamacher K, Langen KJ: 18F-FET PET differentiation of ring-enhancing brain lesions. J Nucl Med; 2006 May;47(5):776-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18F-FET PET differentiation of ring-enhancing brain lesions.
  • In all patients, the main differential diagnosis after MRI was a malignant lesion, in particular glioblastoma multiforme, versus a benign lesion, in particular brain abscess.
  • A malignant tumor was suspected for lesions showing increased (18)F-FET uptake on PET images with a mean lesion-to-brain ratio of at least 1.6 ((18)F-FET PET positive).
  • A nonneoplastic lesion was suspected in cases of minimal or absent (18)F-FET uptake, with a mean lesion-to-brain ratio of less than 1.6 ((18)F-FET PET negative).
  • RESULTS: Histology and clinical follow-up showed high-grade malignant gliomas in 5 patients and nonneoplastic lesions in 9 patients.
  • The findings of (18)F-FET PET were positive in all 5 glioma patients and in 3 of 9 patients with nonneoplastic lesions, including 2 patients with brain abscesses and 1 patient with a demyelinating lesion.
  • CONCLUSION: Although (18)F-FET PET has been shown to be valuable for the diagnostic evaluation of brain tumors, our data indicate that, like (18)F-FDG PET, (18)F-FET PET has limited specificity in distinguishing between neoplastic and nonneoplastic ring-enhancing intracerebral lesions.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18 / pharmacology. Positron-Emission Tomography / methods
  • [MeSH-minor] Adult. Aged. Biopsy. Female. Glioma / radionuclide imaging. Humans. Magnetic Resonance Imaging / methods. Male. Middle Aged. Radiopharmaceuticals / pharmacology. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16644747.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


55. Jung CS, Foerch C, Schänzer A, Heck A, Plate KH, Seifert V, Steinmetz H, Raabe A, Sitzer M: Serum GFAP is a diagnostic marker for glioblastoma multiforme. Brain; 2007 Dec;130(Pt 12):3336-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum GFAP is a diagnostic marker for glioblastoma multiforme.
  • A serum marker for malignant cerebral astrocytomas could improve both differential diagnosis and clinical management of brain tumour patients.
  • To evaluate whether the serum concentration of glial fibrillary acidic protein (GFAP) may indicate glioblastoma multiforme (GBM) in patients with single supratentorial space-occupying lesions, we prospectively examined 50 consecutive patients with histologically proven GBM, World Health Organization (WHO) grade IV, 14 patients with anaplastic astrocytoma (WHO grade III), 4 patients with anaplastic oligodendroglioma, 13 patients with diffuse astrocytoma (WHO grade II), 17 patients with a single cerebral metastasis and 50 healthy controls.
  • [MeSH-major] Biomarkers, Tumor / blood. Brain Neoplasms / diagnosis. Glial Fibrillary Acidic Protein / blood. Glioblastoma / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Necrosis. Neoplasm Proteins / blood. Prospective Studies. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17998256.001).
  • [ISSN] 1460-2156
  • [Journal-full-title] Brain : a journal of neurology
  • [ISO-abbreviation] Brain
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glial Fibrillary Acidic Protein; 0 / Neoplasm Proteins
  •  go-up   go-down


56. Martinez R, Rohde V, Schackert G: Different molecular patterns in glioblastoma multiforme subtypes upon recurrence. J Neurooncol; 2010 Feb;96(3):321-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Different molecular patterns in glioblastoma multiforme subtypes upon recurrence.
  • One of the hallmarks of glioblastoma is its inherent tendency to recur.
  • In all tumor samples, we have analyzed p53 and PTEN status by sequencing analysis, EGFR amplification by semiquantitative PCR and a wide-genome fingerprinting was performed by microsatellite analysis.
  • Upon recurrence, we have detected two molecular patterns of tumor progression: GBM initially showing either type 1 or type 2 profiles conserved them at the time of relapse.
  • Taken together, our results strongly suggest that recurrences of GBM may display two distinct pattern of accumulation of molecular alterations depending on the profile of the original tumor.
  • [MeSH-major] Central Nervous System Neoplasms / genetics. Glioblastoma / genetics. Mutation / genetics. PTEN Phosphohydrolase / genetics. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Adult. Aged. DNA Mutational Analysis. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Glioblastoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain Pathol. 1999 Jul;9(3):469-79 [10416987.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):793-7 [10029064.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89 [15977639.001]
  • [Cites] Am J Hum Genet. 2006 Nov;79(5):923-34 [17033968.001]
  • [Cites] Br J Cancer. 2007 Mar 26;96(6):960-9 [17342095.001]
  • [Cites] Am J Pathol. 2007 May;170(5):1445-53 [17456751.001]
  • [Cites] Carcinogenesis. 2007 Jun;28(6):1264-8 [17272309.001]
  • [Cites] Int J Cancer. 2007 Dec 1;121(11):2458-64 [17691113.001]
  • [Cites] Lancet Oncol. 2008 Jan;9(1):29-38 [18082451.001]
  • [Cites] J Neurooncol. 2008 Mar;87(1):71-8 [18004504.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1061-8 [18772890.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):159-67 [16397228.001]
  • [Cites] Jpn J Cancer Res. 1999 Sep;90(9):934-41 [10551321.001]
  • [Cites] Cancer Res. 2000 May 1;60(9):2368-71 [10811111.001]
  • [Cites] Hum Mutat. 2000;16(2):109-22 [10923032.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Oct;9(10):1037-42 [11045785.001]
  • [Cites] Mol Carcinog. 2000 Nov;29(3):143-50 [11108659.001]
  • [Cites] Ann Oncol. 2001 Feb;12(2):255-7 [11300334.001]
  • [Cites] Carcinogenesis. 2001 Oct;22(10):1715-9 [11577014.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Jan 1;132(1):20-4 [11801303.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1375-82 [11870182.001]
  • [Cites] J Natl Cancer Inst. 2002 May 1;94(9):681-90 [11983757.001]
  • [Cites] Nat Genet. 2003 Mar;33(3):357-65 [12567188.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2003 Jun;74(6):779-83 [12754350.001]
  • [Cites] Cancer J. 2003 Mar-Apr;9(2):82-90 [12784873.001]
  • [Cites] Oncogene. 2004 Mar 11;23(10):1954-6 [14647431.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2004 May;75(5):723-6 [15090567.001]
  • [Cites] Oncogene. 2004 Sep 2;23(40):6806-14 [15286718.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6892-9 [15466178.001]
  • [Cites] N Engl J Med. 1980 Dec 4;303(23):1323-9 [7001230.001]
  • [Cites] J Neurosurg. 1992 Sep;77(3):432-7 [1324297.001]
  • [Cites] Hum Genet. 1994 May;93(5):607-8 [8168846.001]
  • [Cites] J Neurosurg. 1994 Sep;81(3):427-36 [8057151.001]
  • [Cites] Cancer Res. 1994 Sep 15;54(18):4855-78 [8069852.001]
  • [Cites] Br J Cancer. 1994 Nov;70(5):813-8 [7947085.001]
  • [Cites] J Neuropathol Exp Neurol. 1995 Jan;54(1):57-64 [7815080.001]
  • [Cites] J Neurooncol. 1994;21(2):151-7 [7861191.001]
  • [Cites] Oncogene. 1996 Aug 1;13(3):661-4 [8760309.001]
  • [Cites] Nat Genet. 1997 May;16(1):64-7 [9140396.001]
  • [Cites] Oncogene. 1999 Feb 11;18(6):1385-90 [10022821.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • (PMID = 19644652.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  • [Other-IDs] NLM/ PMC2811648
  •  go-up   go-down


57. Prados MD, Lamborn K, Yung WK, Jaeckle K, Robins HI, Mehta M, Fine HA, Wen PY, Cloughesy T, Chang S, Nicholas MK, Schiff D, Greenberg H, Junck L, Fink K, Hess K, Kuhn J, North American Brain Tumor Consortium: A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol; 2006 Apr;8(2):189-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.
  • Adult patients age 18 or older with a KPS of 60 or higher who had measurable recurrent grade III anaplastic glioma (AG) or grade IV glioblastoma multiforme (GBM) were eligible.
  • Patients with stable or responding disease could be treated until tumor progression or a total of 12 months of therapy.
  • The primary end point of the study was to determine whether CPT-11 could significantly delay tumor progression, using the rate of six-month progression-free survival (PFS-6).

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuro Oncol. 1999 Oct;1(4):282-8 [11550320.001]
  • [Cites] J Neurooncol. 2002 Jan;56(2):183-8 [11995820.001]
  • [Cites] Ann Oncol. 2003 Apr;14(4):603-14 [12649109.001]
  • [Cites] Cancer. 2003 May 1;97(9 Suppl):2352-8 [12712456.001]
  • [Cites] Cancer. 2003 May 1;97(9 Suppl):2381-6 [12712460.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1516-25 [10334539.001]
  • [Cites] Neuro Oncol. 2004 Jan;6(1):44-54 [14769140.001]
  • [Cites] Cancer Chemother Pharmacol. 1997;39(3):187-91 [8996518.001]
  • [Cites] Cancer Chemother Pharmacol. 1997;39(5):440-4 [9054958.001]
  • [Cites] Drug Metab Dispos. 1998 Aug;26(8):769-74 [9698291.001]
  • [Cites] Neuro Oncol. 2004 Jan;6(1):21-7 [14769136.001]
  • (PMID = 16533878.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA062399; United States / NCI NIH HHS / CA / CA 62399
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Antineoplastic Agents, Phytogenic; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  • [Other-IDs] NLM/ PMC1871932
  •  go-up   go-down


58. Galanis E, Jaeckle KA, Maurer MJ, Reid JM, Ames MM, Hardwick JS, Reilly JF, Loboda A, Nebozhyn M, Fantin VR, Richon VM, Scheithauer B, Giannini C, Flynn PJ, Moore DF Jr, Zwiebel J, Buckner JC: Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol; 2009 Apr 20;27(12):2052-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study.
  • PURPOSE: Vorinostat, a histone deacetylase inhibitor, represents a rational therapeutic target in glioblastoma multiforme (GBM).
  • Grade 3 or worse nonhematologic toxicity occurred in 26% of patients and consisted mainly of fatigue (17%), dehydration (6%), and hypernatremia (5%); grade 3 or worse hematologic toxicity occurred in 26% of patients and consisted mainly of thrombocytopenia (22%).


59. Ances BM, Danish SF, Kolson DL, Judy KD, Liebeskind DS: Cerebral gumma mimicking glioblastoma multiforme. Neurocrit Care; 2005;2(3):300-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebral gumma mimicking glioblastoma multiforme.
  • This article reports an unusual case of a syphilitic gumma with a clinical and radiographical presentation initially suggestive of glioblastoma multiforme.
  • [MeSH-major] Brain Neoplasms / diagnostic imaging. Brain Neoplasms / pathology. Glioblastoma / diagnostic imaging. Glioblastoma / pathology. Neurosyphilis / diagnostic imaging. Neurosyphilis / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Male. Radiography

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJNR Am J Neuroradiol. 2001 Feb;22(2):314-6 [11156776.001]
  • [Cites] Neurosci Lett. 2003 Feb 27;338(2):119-22 [12566167.001]
  • [Cites] Neurol Med Chir (Tokyo). 1995 Jul;35(7):462-6 [7477692.001]
  • [Cites] AJNR Am J Neuroradiol. 1995 Apr;16(4):703-11 [7611026.001]
  • (PMID = 16159080.001).
  • [ISSN] 1541-6933
  • [Journal-full-title] Neurocritical care
  • [ISO-abbreviation] Neurocrit Care
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Hilverda K, Bosma I, Heimans JJ, Postma TJ, Peter Vandertop W, Slotman BJ, Buter J, Reijneveld JC, Klein M: Cognitive functioning in glioblastoma patients during radiotherapy and temozolomide treatment: initial findings. J Neurooncol; 2010 Mar;97(1):89-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cognitive functioning in glioblastoma patients during radiotherapy and temozolomide treatment: initial findings.
  • The aim of this study was to evaluate cognitive functioning in newly-diagnosed glioblastoma multiforme (GBM) patients during treatment with radiotherapy (RT) plus concomitant and adjuvant temozolomide (TMZ).
  • [MeSH-minor] Adolescent. Adult. Aged. Attention / drug effects. Attention / radiation effects. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Female. Follow-Up Studies. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Humans. Magnetic Resonance Imaging. Male. Memory / drug effects. Memory / physiology. Memory / radiation effects. Mental Processes / drug effects. Mental Processes / radiation effects. Middle Aged. Neuropsychological Tests. Psychomotor Performance / drug effects. Psychomotor Performance / radiation effects. Verbal Learning / drug effects. Verbal Learning / radiation effects

  • Genetic Alliance. consumer health - Glioblastoma.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 2000 Aug;47(2):324-33; discussion 333-4 [10942005.001]
  • [Cites] J Clin Oncol. 2001 Oct 15;19(20):4037-47 [11600605.001]
  • [Cites] J Neurooncol. 2003 May;63(1):55-61 [12814255.001]
  • [Cites] Lancet Neurol. 2004 Mar;3(3):159-68 [14980531.001]
  • [Cites] Ann Oncol. 2007 Jul;18(7):1145-51 [17284616.001]
  • [Cites] Lancet Oncol. 2005 Dec;6(12):937-44 [16321761.001]
  • [Cites] J Clin Oncol. 2006 Dec 1;24(34):5427-33 [17135644.001]
  • [Cites] Neuro Oncol. 2007 Jan;9(1):53-62 [17018697.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • (PMID = 19718545.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  • [Other-IDs] NLM/ PMC2814037
  •  go-up   go-down


61. Terasaki M, Ogo E, Fukushima S, Sakata K, Miyagi N, Abe T, Shigemori M: Impact of combination therapy with repeat surgery and temozolomide for recurrent or progressive glioblastoma multiforme: a prospective trial. Surg Neurol; 2007 Sep;68(3):250-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of combination therapy with repeat surgery and temozolomide for recurrent or progressive glioblastoma multiforme: a prospective trial.
  • We examined the case histories of these 7 patients and determined the location of tumor and extent of their surgical procedures.
  • Survival time did not depend on removing the entire tumor at initial and second surgery.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Dacarbazine / analogs & derivatives. Glioblastoma / drug therapy. Glioblastoma / surgery. Supratentorial Neoplasms / drug therapy. Supratentorial Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Cohort Studies. Feasibility Studies. Female. Humans. Male. Middle Aged. Reoperation. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17719957.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


62. Srivastava NK, Pradhan S, Gowda GA, Kumar R: In vitro, high-resolution 1H and 31P NMR based analysis of the lipid components in the tissue, serum, and CSF of the patients with primary brain tumors: one possible diagnostic view. NMR Biomed; 2010 Feb;23(2):113-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro, high-resolution 1H and 31P NMR based analysis of the lipid components in the tissue, serum, and CSF of the patients with primary brain tumors: one possible diagnostic view.
  • In vitro, high-resolution (1)H and (31)P NMR based qualitative and quantitative analyses of the lipid components of the tissue, serum, and CSF of patients with primary brain tumors were performed.
  • Proton NMR spectra of the lipid extract of serum (blood specimen collected before the surgical procedure) and surgically discarded tissue showed that the total cholesterol (T.CHOL) and choline containing phospholipids (PL) were significantly higher in quantity in medulloblastoma and glioblastoma multiforme as compared to normal subjects.
  • Serum lipid extracts of grade II/ III gliomas showed a higher quantity of PL than normal subjects.
  • There was a reduction in the quantity of CHOLest in the serum lipid extract of the tumor patients as compared to normal subjects.
  • Ratio of CHOL to CHOLest distinguishes the different grades of tumors versus normal subjects as well as between different grades of tumors (except medulloblastoma versus glioblastoma).
  • Medulloblastoma could be differentiated from glioblastoma as well as from normal subjects in serum lipid extract by the ratio of the Ph to PC.
  • PL and T.CHOL provided discrimination between different grades of tumors (except glioblastoma versus medulloblastoma) in the lipid extract of the CSF.
  • This study suggests the role of lipid estimation in CSF and serum as a complementary diagnostic tool for the evaluation of brain tumors preoperatively.
  • NMR-based lipid estimation of post-surgical tumor tissue may also contribute to differentiating the tumor types.
  • [MeSH-major] Brain Neoplasms / blood. Brain Neoplasms / cerebrospinal fluid. Lipids / analysis. Magnetic Resonance Spectroscopy / methods
  • [MeSH-minor] Adult. Cholesterol / analysis. Cholesterol / blood. Cholesterol / cerebrospinal fluid. Female. Humans. Male. Phospholipids / analysis. Phospholipids / blood. Phospholipids / cerebrospinal fluid. Tissue Extracts

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 John Wiley & Sons, Ltd.
  • (PMID = 19774696.001).
  • [ISSN] 1099-1492
  • [Journal-full-title] NMR in biomedicine
  • [ISO-abbreviation] NMR Biomed
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Lipids; 0 / Phospholipids; 0 / Tissue Extracts; 97C5T2UQ7J / Cholesterol
  •  go-up   go-down


63. Dall'oglio S, D'Amico A, Pioli F, Gabbani M, Pasini F, Passarin MG, Talacchi A, Turazzi S, Maluta S: Dose-intensity temozolomide after concurrent chemoradiotherapy in operated high-grade gliomas. J Neurooncol; 2008 Dec;90(3):315-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-intensity temozolomide after concurrent chemoradiotherapy in operated high-grade gliomas.
  • PURPOSE: We performed a new phase II trial enrolling patients with newly diagnosed high-grade glioma (HGG) to test the efficacy of a weekly alternating temozolomide (TMZ) schedule after surgery and concomitant chemoradiotherapy.
  • There were 32 glioblastoma multiforme and two anaplastic astrocytoma.
  • Hematological toxicity was seen in six patients (18%): grade 1 neutropenia in four, grade 2 thrombocytopenia in one, and grade 4 thrombocytopenia plus grade 1 neutropenia in one.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Glioma / drug therapy
  • [MeSH-minor] Adult. Aged. Dose-Response Relationship, Drug. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Magnetic Resonance Imaging. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2008 Sep;89(2):179-85 [18431544.001]
  • [Cites] Br J Cancer. 2003 Apr 7;88(7):1004-11 [12671695.001]
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12 ):1470-5 [17442989.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23 (18):4235-6; author reply 4236 [15961774.001]
  • [Cites] Br J Cancer. 2006 Nov 6;95(9):1155-60 [17024124.001]
  • [Cites] Lancet Neurol. 2008 Jan;7(1):14-6 [18093552.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jan 1;40(1):51-5 [9422557.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3357-61 [17664483.001]
  • [Cites] Eur J Cancer. 2006 Sep;42(14 ):2335-42 [16899365.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] Br J Cancer. 1999 Nov;81(6):1022-30 [10576660.001]
  • [Cites] Clin Cancer Res. 2007 Apr 1;13(7):2038-45 [17404084.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • (PMID = 18688571.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; YF1K15M17Y / temozolomide
  •  go-up   go-down


64. Micallef J, Taccone M, Mukherjee J, Croul S, Busby J, Moran MF, Guha A: Epidermal growth factor receptor variant III-induced glioma invasion is mediated through myristoylated alanine-rich protein kinase C substrate overexpression. Cancer Res; 2009 Oct 1;69(19):7548-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glioblastoma multiforme (GBM) is the most common and most malignant adult brain tumor.
  • [MeSH-major] Brain Neoplasms / enzymology. Glioblastoma / enzymology. Membrane Proteins / biosynthesis. Receptor, Epidermal Growth Factor / metabolism
  • [MeSH-minor] Animals. Cell Line, Tumor. Epidermal Growth Factor / pharmacology. Humans. Intracellular Signaling Peptides and Proteins / genetics. Intracellular Signaling Peptides and Proteins / metabolism. Mice. Neoplasm Invasiveness. Protein Kinase C-alpha / metabolism. RNA, Small Interfering / genetics. Signal Transduction. Transfection

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19773446.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / Membrane Proteins; 0 / RNA, Small Interfering; 0 / epidermal growth factor receptor VIII; 125267-21-2 / myristoylated alanine-rich C kinase substrate; 62229-50-9 / Epidermal Growth Factor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.13 / Protein Kinase C-alpha
  •  go-up   go-down


65. Metro G, Fabi A, Mirri MA, Vidiri A, Pace A, Carosi M, Russillo M, Maschio M, Giannarelli D, Pellegrini D, Pompili A, Cognetti F, Carapella CM: Phase II study of fixed dose rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme. Cancer Chemother Pharmacol; 2010 Jan;65(2):391-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of fixed dose rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme.
  • PURPOSE: In order to evaluate the activity of gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme (GBM), a prospective single-center phase II study was conducted.
  • After chemo-radiotherapy, irrespective of tumor response, patients went on to receive oral temozolomide at 150-200 mg/m(2) for 5 days every 28 days.
  • Seventeen patients had received subtotal resection of the tumor, while six patients had biopsied-only tumors.
  • The concomitant radiotherapy-gemcitabine combination was well tolerated and severe adverse events were rare, consisting of grade 3 neutropenia and hypertransaminasemia in two cases each.
  • CONCLUSIONS: Concomitant radiotherapy-gemcitabine is active and well tolerated in newly diagnosed glioblastoma multiforme.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Deoxycytidine / analogs & derivatives. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Radiation-Sensitizing Agents / therapeutic use
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. DNA Modification Methylases / genetics. DNA Modification Methylases / metabolism. DNA Repair Enzymes / genetics. DNA Repair Enzymes / metabolism. Female. Humans. Magnetic Resonance Imaging. Male. Methylation. Middle Aged. Promoter Regions, Genetic. Tumor Suppressor Proteins / genetics. Tumor Suppressor Proteins / metabolism

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19847425.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiation-Sensitizing Agents; 0 / Tumor Suppressor Proteins; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


66. Drappatz J, Wong ET, Schiff D, Kesari S, Batchelor TT, Doherty L, Lafrankie DC, Ramakrishna N, Weiss S, Smith ST, Ciampa A, Zimmerman J, Ostrowsky L, David K, Norden A, Barron L, Sceppa C, Black PM, Wen PY: A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys; 2009 Jan 1;73(1):222-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme.
  • PURPOSE: To define the maximum tolerated dose (MTD) of lenalidomide, an analogue of thalidomide with enhanced immunomodulatory and antiangiogenic properties and a more favorable toxicity profile, in patients with newly diagnosed glioblastoma multiforme (GBM) when given concurrently with radiotherapy.
  • PATIENTS AND METHODS: Patients with newly diagnosed GBM received radiotherapy concurrently with lenalidomide given for 3 weeks followed by a 1-week rest period and continued lenalidomide until tumor progression or unacceptable toxicity.
  • RESULTS: Twenty-three patients were enrolled, of whom 20 were treated and evaluable for both toxicity and tumor response and 2 were evaluable for toxicity only.
  • [MeSH-major] Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Thalidomide / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / administration & dosage. Combined Modality Therapy. Dose-Response Relationship, Drug. Female. Humans. Male. Middle Aged. Pilot Projects. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18513880.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 4Z8R6ORS6L / Thalidomide; F0P408N6V4 / lenalidomide
  •  go-up   go-down


67. Ram Z, Cohen ZR, Harnof S, Tal S, Faibel M, Nass D, Maier SE, Hadani M, Mardor Y: Magnetic resonance imaging-guided, high-intensity focused ultrasound for brain tumor therapy. Neurosurgery; 2006 Nov;59(5):949-55; discussion 955-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging-guided, high-intensity focused ultrasound for brain tumor therapy.
  • The system delivers small volumetric sonications from an ultrasound phased array transmitter that focuses energy selectively to destroy the target with verification by magnetic resonance imaging-generated thermal maps.
  • METHODS: To date, three patients with histologically verified recurrent glioblastoma multiforme have been treated with MRIgFUS.
  • Sonications were applied to induce thermocoagulation of the enhancing tumor mass.
  • In one patient, heating of brain tissue in the sonication path resulted in a secondary focus outside the target causing neurological deficit.
  • CONCLUSION: In this first clinical report, MRIgFUS was demonstrated to be a potentially effective means of destroying tumor tissue by thermocoagulation, although with an associated morbidity and the inherent invasive nature of the procedure requiring creation of a bone window.
  • [MeSH-major] Brain Neoplasms / therapy. Image Interpretation, Computer-Assisted / methods. Magnetic Resonance Imaging / methods. Ultrasonic Therapy / methods
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17143231.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Lottaz C, Beier D, Meyer K, Kumar P, Hermann A, Schwarz J, Junker M, Oefner PJ, Bogdahn U, Wischhusen J, Spang R, Storch A, Beier CP: Transcriptional profiles of CD133+ and CD133- glioblastoma-derived cancer stem cell lines suggest different cells of origin. Cancer Res; 2010 Mar 1;70(5):2030-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcriptional profiles of CD133+ and CD133- glioblastoma-derived cancer stem cell lines suggest different cells of origin.
  • Glioblastoma multiforme (GBM) is paradigmatic for the investigation of cancer stem cells (CSC) in solid tumors.
  • Using a newly derived 24-gene signature, we can now distinguish two subgroups of GBM: Type I CSC lines display "proneural" signature genes and resemble fetal neural stem cell (fNSC) lines, whereas type II CSC lines show "mesenchymal" transcriptional profiles similar to adult NSC (aNSC) lines.
  • Thus, our data suggest that the heterogeneous tumor entity GBM may derive from cells that have preserved or acquired properties of either fNSC or aNSC but lost the corresponding differentiation potential.
  • [MeSH-major] Antigens, CD / biosynthesis. Glioblastoma / genetics. Glioblastoma / pathology. Glycoproteins / biosynthesis. Neoplastic Stem Cells / physiology
  • [MeSH-minor] Cell Growth Processes / genetics. Cell Line, Tumor. Gene Expression Profiling. Humans. Mesoderm / pathology. Peptides. Transcription, Genetic

  • Genetic Alliance. consumer health - Glioblastoma.
  • COS Scholar Universe. author profiles.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20145155.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Glycoproteins; 0 / Peptides
  •  go-up   go-down


69. Martinez R, Setien F, Voelter C, Casado S, Quesada MP, Schackert G, Esteller M: CpG island promoter hypermethylation of the pro-apoptotic gene caspase-8 is a common hallmark of relapsed glioblastoma multiforme. Carcinogenesis; 2007 Jun;28(6):1264-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CpG island promoter hypermethylation of the pro-apoptotic gene caspase-8 is a common hallmark of relapsed glioblastoma multiforme.
  • Glioblastoma multiforme (GBM) is an incurable malignancy with inherent tendency to recur.
  • In this study, we have comparatively analyzed the epigenetic profile of 32 paired tumor samples of relapsed GBM and their corresponding primary neoplasms with special attention to genes involved in the mitochondria-independent apoptotic pathway.
  • Thirteen genes were analyzed for DNA methylation: the pro-apoptotic CASP8, CASP3, CASP9, DcR1, DR4, DR5 and TMS1; the cell adherence CDH1 and CDH13; the candidate tumor suppressor RASSF1A and BLU; the cell cycle regulator CHFR and the DNA repair MGMT.
  • This finding was also linked to the observation that an unmethylated CASP8 CpG island together with methylated BLU promoter in the primary GBM was associated with prolonged time to tumor progression (P = 0.0035).
  • [MeSH-major] Apoptosis / genetics. Apoptosis Regulatory Proteins / genetics. Caspase 8 / genetics. Caspase 8 / metabolism. CpG Islands / genetics. DNA Methylation. Glioblastoma / enzymology. Promoter Regions, Genetic
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Glioblastoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17272309.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Biomarkers, Tumor; EC 3.4.22.- / Caspase 8
  •  go-up   go-down


70. Kioi M, Husain SR, Croteau D, Kunwar S, Puri RK: Convection-enhanced delivery of interleukin-13 receptor-directed cytotoxin for malignant glioma therapy. Technol Cancer Res Treat; 2006 Jun;5(3):239-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The treatment of patients with malignant brain tumors, in particular glioblastoma multiforme (GBM) is very challenging because of their diffuse infiltrative nature and the cytological heterogeneity.
  • Novel approaches for brain tumor therapy are needed.
  • We have discovered that high affinity plasma membrane receptor for interleukin-13 (IL-13), an immune regulatory cytokine, is over-expressed in 60-80% of malignant brain tumors.
  • In contrast, normal cells including brain, immune, and endothelial cells were generally not affected by this cytotoxin due to no or low expression of IL-13R.
  • IL-13 cytotoxin was found to mediate remarkable efficacy in animal models of human brain tumors.
  • Encouraged by these pre-clinical studies, four Phase 1/2 clinical trials in adult patients with recurrent malignant glioma have been completed.
  • These clinical trials involved convection-enhanced delivery (CED) of IL-13 cytotoxin either intratumoral or intraparenchymal after resection of tumor.
  • [MeSH-major] Brain Neoplasms / drug therapy. Convection. Drug Delivery Systems. Exotoxins / administration & dosage. Glioma / drug therapy. Interleukin-13 / administration & dosage

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16700620.001).
  • [ISSN] 1533-0346
  • [Journal-full-title] Technology in cancer research & treatment
  • [ISO-abbreviation] Technol. Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Exotoxins; 0 / IL13-PE38QQR; 0 / IL13RA1 protein, human; 0 / Interleukin-13; 0 / Interleukin-13 Receptor alpha1 Subunit; 0 / Receptors, Interleukin; 0 / Receptors, Interleukin-13
  • [Number-of-references] 104
  •  go-up   go-down


71. Singh D, Banerji AK, Dwarakanath BS, Tripathi RP, Gupta JP, Mathew TL, Ravindranath T, Jain V: Optimizing cancer radiotherapy with 2-deoxy-d-glucose dose escalation studies in patients with glioblastoma multiforme. Strahlenther Onkol; 2005 Aug;181(8):507-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optimizing cancer radiotherapy with 2-deoxy-d-glucose dose escalation studies in patients with glioblastoma multiforme.
  • Since higher 2-DG doses are expected to improve the therapeutic gain, present studies were undertaken to examine the tolerance and safety of escalating 2-DG dose during combined treatment (2-DG + radiotherapy) in glioblastoma multiforme patients.
  • PATIENTS AND METHODS: Untreated patients with histologically proven glioblastoma multiforme (WHO criteria) were included in the study.
  • Seven weekly fractions of (60)Co gamma-rays (5 Gy/fraction) were delivered to the tumor volume (presurgical CT/MRI evaluation) plus 3 cm margin.
  • No significant damage to the normal brain tissue was observed during follow-up in seven out of ten patients who received complete treatment and survived between 11 and 46 months after treatment.
  • CONCLUSION: Oral administration of 2-DG combined with large fractions of radiation (5 Gy/fraction/week) is safe and could be tolerated in glioblastoma patients without any acute toxicity and late radiation damage to the normal brain.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Deoxyglucose / administration & dosage. Glioblastoma / radiotherapy. Radiopharmaceuticals / administration & dosage
  • [MeSH-minor] Administration, Oral. Adult. Aged. Clinical Trials, Phase I as Topic. Clinical Trials, Phase II as Topic. Cobalt Radioisotopes / therapeutic use. Dose Fractionation. Female. Follow-Up Studies. Humans. Karnofsky Performance Status. Male. Middle Aged. Radiotherapy Dosage. Time Factors

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. 2-DEOXY-D-GLUCOSE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16044218.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cobalt Radioisotopes; 0 / Radiopharmaceuticals; 9G2MP84A8W / Deoxyglucose
  •  go-up   go-down


72. Bokstein F, Kovner F, Blumenthal DT, Ram Z, Templehoff H, Kanner AA, Corn BW: A common sense approach to radiotherapy planning of glioblastoma multiforme situated in the temporal lobe. Int J Radiat Oncol Biol Phys; 2008 Nov 1;72(3):900-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A common sense approach to radiotherapy planning of glioblastoma multiforme situated in the temporal lobe.
  • PURPOSE: Irradiation remains the cornerstone of management for glioblastoma multiforme.
  • The Radiation Therapy Oncology Group and European Organization for Research and Treatment of Cancer advocate encompassing the primary tumor plus a 2-cm margin in the high-dose volume.
  • We investigated whether the temporal bone (rather than the aforementioned 2-cm radius) would serve as a barrier to tumor spread when regarded as the anterior margin for temporal lobe lesions.
  • We hypothesized that by using the temporal bone as the radiation field margin, toxicity could be reduced without compromising tumor control.
  • METHODS AND MATERIALS: Between 2003 and 2007, 342 patients with newly diagnosed glioblastoma multiforme were treated with surgery and primary irradiation at our institution.
  • At a median follow-up of 12.95 months, 8 patients had not yet shown signs of tumor progression, 24 had local failure, 7 had distant or mixed (local plus distant) failure, and only 1 patient had failure in the infratemporal fossa.
  • The strategy we have proposed achieves tumor control and respects optic tolerance without resorting to complex, expensive approaches such as intensity-modulated radiotherapy.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Glioblastoma / radiotherapy. Radiotherapy / adverse effects. Radiotherapy Planning, Computer-Assisted / methods. Radiotherapy, Intensity-Modulated / methods. Temporal Lobe / radiation effects
  • [MeSH-minor] Adult. Aged. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Middle Aged. Patient Care Team. Radiotherapy Dosage. Retrospective Studies. Time Factors. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18407432.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. MacDonald TJ, Stewart CF, Kocak M, Goldman S, Ellenbogen RG, Phillips P, Lafond D, Poussaint TY, Kieran MW, Boyett JM, Kun LE: Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012. J Clin Oncol; 2008 Feb 20;26(6):919-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012.
  • PURPOSE: A phase I trial of the antiangiogenesis agent cilengitide (EMD 121974), an alpha v beta 3,5 integrin antagonist, was performed to estimate the maximum-tolerated dose (MTD) and describe dose-limiting toxicities (DLTs) and the incidence and severity of other toxicities when administered to children with refractory brain tumors.
  • Three of 13 patients at the dosage level of 2,400 mg/m(2) experienced grade 3 or 4 intratumoral hemorrhage (ITH) possibly related to the study drug; however, two of the ITH events were asymptomatic and, by the current toxicity criteria, would be classified as grade 1.
  • Three patients completed 1 year of protocol therapy; one patient with glioblastoma multiforme demonstrated complete response, and two patients had stable disease (SD).
  • CONCLUSION: The phase II dosage of intravenous cilengitide in children with refractory brain tumors is 1,800 mg/m(2).
  • A phase II trial to assess the efficacy of cilengitide therapy for children with refractory brain tumors is being developed by the Children's Oncology Group.
  • [MeSH-major] Angiogenesis Inhibitors / administration & dosage. Angiogenesis Inhibitors / adverse effects. Brain Neoplasms / drug therapy. Snake Venoms / administration & dosage. Snake Venoms / adverse effects
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Drug Administration Schedule. Female. Genotype. Humans. Infant. Infusions, Intravenous. Magnetic Resonance Imaging. Male. P-Glycoprotein / genetics. P-Glycoproteins. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18281665.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01 CA81457
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABCB1 protein, human; 0 / Angiogenesis Inhibitors; 0 / P-Glycoprotein; 0 / P-Glycoproteins; 0 / Snake Venoms; 4EDF46E4GI / Cilengitide
  •  go-up   go-down


74. Stylli SS, Kaye AH, MacGregor L, Howes M, Rajendra P: Photodynamic therapy of high grade glioma - long term survival. J Clin Neurosci; 2005 May;12(4):389-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy of high grade glioma - long term survival.
  • For primary (newly diagnosed) tumours, median survival from initial diagnosis was 76.5 months for anaplastic astrocytoma (AA) and 14.3 months for glioblastoma multiforme (GBM).
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Combined Modality Therapy / methods. Confidence Intervals. Female. Humans. Longitudinal Studies. Male. Middle Aged. Proportional Hazards Models. Radiosurgery / methods. Retrospective Studies. Survival Rate. Time Factors

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15925768.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Hematoporphyrins
  •  go-up   go-down


75. Barajas RF Jr, Hodgson JG, Chang JS, Vandenberg SR, Yeh RF, Parsa AT, McDermott MW, Berger MS, Dillon WP, Cha S: Glioblastoma multiforme regional genetic and cellular expression patterns: influence on anatomic and physiologic MR imaging. Radiology; 2010 Feb;254(2):564-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glioblastoma multiforme regional genetic and cellular expression patterns: influence on anatomic and physiologic MR imaging.
  • PURPOSE: To determine whether magnetic resonance (MR) imaging is influenced by genetic and cellular features of glioblastoma multiforme (GBM) aggressiveness.
  • By using monoclonal antibodies, tissue specimens were examined for microvascular expression, hypoxia, tumor and overall cellular density, and histopathologic features of GBM aggressiveness.
  • RESULTS: Tumor biopsy of 13 adult patients yielded 16 enhancing and 14 peritumoral nonenhancing specimens.
  • RNA expression patterns between tumor regions were found to be significantly different (FDR < 0.05), with hierarchical clustering by biopsy region only.
  • CONCLUSION: These findings suggest MR imaging is significantly influenced by GBM genetic and cellular biologic features of aggressiveness and imply physiologic MR imaging may be useful in pinpointing regions of highest malignancy within heterogeneous tissues, thus facilitating histologic grading of primary glial brain tumors.

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurol Sci. 2000 Apr 1;175(1):33-9 [10785254.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 May;21(5):881-90 [10815664.001]
  • [Cites] J Neurooncol. 2000 Dec;50(3):215-26 [11263501.001]
  • [Cites] AJNR Am J Neuroradiol. 2001 May;22(5):969-76 [11337344.001]
  • [Cites] AJNR Am J Neuroradiol. 2001 Jun-Jul;22(6):1109-16 [11415906.001]
  • [Cites] AJNR Am J Neuroradiol. 2002 Jan;23(1):7-14 [11827869.001]
  • [Cites] Radiology. 2002 Jul;224(1):177-83 [12091680.001]
  • [Cites] Bioinformatics. 2003 Jan 22;19(2):185-93 [12538238.001]
  • [Cites] Oncogene. 2003 Apr 17;22(15):2361-73 [12700671.001]
  • [Cites] Magn Reson Med. 2003 May;49(5):848-55 [12704767.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 Nov-Dec;24(10):1989-98 [14625221.001]
  • [Cites] Australas Radiol. 2004 Sep;48(3):324-32 [15344981.001]
  • [Cites] Nat Rev Neurosci. 2004 Oct;5(10):782-92 [15378038.001]
  • [Cites] Genome Biol. 2004;5(10):R80 [15461798.001]
  • [Cites] J Natl Cancer Inst. 1972 Feb;48(2):347-56 [4347034.001]
  • [Cites] J Neurol Sci. 1981 Jan;49(1):55-66 [7205320.001]
  • [Cites] J Neurol Sci. 1981 Jan;49(1):67-77 [7205321.001]
  • [Cites] Cancer. 1985 Mar 1;55(5):928-31 [3967200.001]
  • [Cites] Am J Surg Pathol. 1986 Sep;10(9):611-7 [2428262.001]
  • [Cites] Radiology. 1986 Nov;161(2):401-7 [3763909.001]
  • [Cites] AJR Am J Roentgenol. 1992 Sep;159(3):591-9 [1503032.001]
  • [Cites] Radiology. 1994 Apr;191(1):41-51 [8134596.001]
  • [Cites] Acta Neuropathol. 1994;87(1):47-54 [7511316.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jan 31;92(3):768-72 [7531342.001]
  • [Cites] J Cutan Pathol. 1995 Jun;22(3):215-22 [7593814.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 Feb;21(2):357-66 [10696024.001]
  • [Cites] J Magn Reson Imaging. 2000 Feb;11(2):114-9 [10713942.001]
  • [Cites] Cancer. 2000 Mar 15;88(6):1477-83 [10717633.001]
  • [Cites] Glia. 1995 Nov;15(3):211-21 [8586458.001]
  • [Cites] Cancer Res. 1996 May 1;56(9):2185-90 [8616870.001]
  • [Cites] Radiology. 1996 May;199(2):391-401 [8668784.001]
  • [Cites] Cancer. 1997 Apr 1;79(7):1381-93 [9083161.001]
  • [Cites] Surg Neurol. 1998 Apr;49(4):436-40 [9537664.001]
  • [Cites] Microvasc Res. 1998 Nov;56(3):145-53 [9828152.001]
  • [Cites] AJR Am J Roentgenol. 1998 Dec;171(6):1479-86 [9843274.001]
  • [Cites] J Magn Reson Imaging. 1999 Jan;9(1):53-60 [10030650.001]
  • [Cites] Neuroimaging Clin N Am. 1999 May;9(2):309-31 [10318717.001]
  • [Cites] Neuroimaging Clin N Am. 1999 May;9(2):343-61 [10318719.001]
  • [Cites] Radiology. 1999 Jun;211(3):791-8 [10352608.001]
  • [Cites] Pediatr Radiol. 1999 Jul;29(7):524-6 [10398789.001]
  • [Cites] J Neurooncol. 1999 May;43(1):19-25 [10448867.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 Apr;26(4):777-83 [15814920.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 Jun-Jul;26(6):1446-54 [15956514.001]
  • [Cites] Eur J Radiol. 2005 Sep;55(3):393-400 [16129247.001]
  • [Cites] Med Mol Morphol. 2005 Mar;38(1):36-42 [16158178.001]
  • [Cites] Brain Pathol. 2005 Oct;15(4):297-310 [16389942.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):157-73 [16530701.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Mar;27(3):475-87 [16551981.001]
  • [Cites] Neurosurgery. 2006 Jun;58(6):1099-107; discussion 1099-107 [16723889.001]
  • [Cites] Diagn Mol Pathol. 2006 Dec;15(4):195-205 [17122647.001]
  • [Cites] AJNR Am J Neuroradiol. 2007 Jun-Jul;28(6):1078-84 [17569962.001]
  • [Cites] Neuro Oncol. 2007 Oct;9(4):424-9 [17622647.001]
  • [Cites] AJNR Am J Neuroradiol. 2008 Mar;29(3):476-82 [18079184.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Apr 1;105(13):5213-8 [18362333.001]
  • [Cites] Radiology. 2008 Oct;249(1):268-77 [18796682.001]
  • [Cites] Nat Protoc. 2009;4(1):44-57 [19131956.001]
  • [Cites] AJNR Am J Neuroradiol. 2009 Feb;30(2):367-72 [19022867.001]
  • [Cites] Radiology. 2009 Nov;253(2):486-96 [19789240.001]
  • (PMID = 20093527.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / K23 NS045013; United States / NCRR NIH HHS / RR / UL1 RR024131; United States / NCRR NIH HHS / RR / TL1 RR024129-01; United States / NINDS NIH HHS / NS / NS045013; United States / NCRR NIH HHS / RR / UL1RR024131; United States / NCRR NIH HHS / RR / TL1 RR024129
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 63231-63-0 / RNA
  • [Other-IDs] NLM/ PMC2809924
  •  go-up   go-down


76. Kunwar S, Chang S, Westphal M, Vogelbaum M, Sampson J, Barnett G, Shaffrey M, Ram Z, Piepmeier J, Prados M, Croteau D, Pedain C, Leland P, Husain SR, Joshi BH, Puri RK, PRECISE Study Group: Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro Oncol; 2010 Aug;12(8):871-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma.
  • Convection-enhanced delivery (CED) of cintredekin besudotox (CB) was compared with Gliadel wafers (GW) in adult patients with glioblastoma multiforme (GBM) at first recurrence.
  • CB (0.5 microg/mL; total flow rate 0.75 mL/h) was administered over 96 hours via 2-4 intraparenchymal catheters placed after tumor resection.
  • GW (3.85%/7.7 mg carmustine per wafer; maximum 8 wafers) were placed immediately after tumor resection.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Brain Neoplasms / drug therapy. Exotoxins / administration & dosage. Glioblastoma / drug therapy. Interleukin-13 / administration & dosage. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Carmustine. Catheters, Indwelling. Convection. Decanoic Acids / administration & dosage. Decanoic Acids / adverse effects. Drug Administration Routes. Female. Humans. Kaplan-Meier Estimate. Magnetic Resonance Imaging. Male. Middle Aged. Polyesters / administration & dosage. Polyesters / adverse effects. Young Adult

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Carmustine .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):2076-80 [8134351.001]
  • [Cites] Lancet. 1995 Apr 22;345(8956):1008-12 [7723496.001]
  • [Cites] J Neurosurg. 1995 Jun;82(6):1021-9 [7539062.001]
  • [Cites] J Biol Chem. 1996 Sep 13;271(37):22428-33 [8798406.001]
  • [Cites] J Neurosurg. 1997 Oct;87(4):586-94 [9322847.001]
  • [Cites] Neurosurgery. 1998 May;42(5):1044-55; discussion 1055-6 [9588549.001]
  • [Cites] Clin Cancer Res. 1995 Nov;1(11):1253-8 [9815919.001]
  • [Cites] J Neurosurg. 1999 Feb;90(2):315-20 [9950503.001]
  • [Cites] Clin Cancer Res. 1999 May;5(5):985-90 [10353730.001]
  • [Cites] Am J Physiol. 1999 Oct;277(4 Pt 2):R1218-29 [10516265.001]
  • [Cites] J Neurosurg. 2004 Dec;101(6):1004-11 [15597761.001]
  • [Cites] Protein Expr Purif. 2005 Feb;39(2):189-98 [15642470.001]
  • [Cites] J Neurosurg. 2005 Feb;102(2):267-75 [15739554.001]
  • [Cites] Pharm Res. 2006 Nov;23(11):2493-504 [16972184.001]
  • [Cites] J Neurooncol. 2007 Jan;81(2):139-48 [17004103.001]
  • [Cites] Neurology. 2007 Jan 23;68(4):254-61 [17065591.001]
  • [Cites] Neurosurgery. 2007 Feb;60(2 Suppl 1):ONS89-98; discussion ONS98-9 [17297371.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):837-44 [17327604.001]
  • [Cites] J Neurooncol. 2007 May;83(1):97-109 [17203397.001]
  • [Cites] Neuro Oncol. 2007 Jul;9(3):343-53 [17435179.001]
  • [Cites] Cancer Res. 2007 Sep 1;67(17):7983-6 [17804706.001]
  • [Cites] Neurotherapeutics. 2008 Jan;5(1):123-7 [18164491.001]
  • [Cites] Neuro Oncol. 2008 Apr;10(2):153-61 [18316474.001]
  • [Cites] Neuroimage. 2011 Jan;54 Suppl 1:S196-203 [19761848.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1168-72 [10728667.001]
  • [Cites] Cancer Immunol Immunother. 2000 Aug;49(6):319-24 [10946814.001]
  • [Cites] Int J Cancer. 2001 Apr 15;92(2):168-75 [11291041.001]
  • [Cites] Int J Cancer. 2003 Jan 1;103(1):45-52 [12455052.001]
  • [Cites] Mol Cancer Ther. 2002 Oct;1(12):999-1007 [12481422.001]
  • [Cites] J Neurooncol. 2003 Aug-Sep;64(1-2):125-37 [12952293.001]
  • [Cites] Ann Neurol. 2003 Oct;54(4):479-87 [14520660.001]
  • [Cites] Acta Neurochir Suppl. 2003;88:105-11 [14531568.001]
  • [Cites] J Neurooncol. 2003 Oct;65(1):3-13 [14649881.001]
  • [Cites] J Neurooncol. 2003 Oct;65(1):27-35 [14649883.001]
  • [Cites] J Neurosurg. 2004 Mar;100(3):472-9 [15035283.001]
  • [Cites] Neurology. 1988 Sep;38(9):1374-9 [3412585.001]
  • [Cites] Am J Surg. 1993 Mar;165(3):358-61 [8447543.001]
  • [Cites] Am J Physiol. 1994 Jan;266(1 Pt 2):R292-305 [8304553.001]
  • (PMID = 20511192.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Decanoic Acids; 0 / Exotoxins; 0 / IL13-PE38QQR; 0 / Interleukin-13; 0 / Polyesters; 90409-78-2 / decanedioic acid-4,4'-(1,3-propanediylbis(oxy))bis(benzoic acid) copolymer; U68WG3173Y / Carmustine
  • [Other-IDs] NLM/ PMC2940677
  •  go-up   go-down


77. Thon N, Damianoff K, Hegermann J, Grau S, Krebs B, Schnell O, Tonn JC, Goldbrunner R: Presence of pluripotent CD133+ cells correlates with malignancy of gliomas. Mol Cell Neurosci; 2010 Jan;43(1):51-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Presence of CD133(+) cancer stem cells has been demonstrated within glioblastoma multiforme (GBM), the most malignant phenotype of gliomas (WHO grade IV).
  • Since GBM frequently develops from low grade gliomas (WHO grade II) we assessed a possible qualitative or quantitative correlation of CD133(+) cells and glioma grade to get new insights in gliomagenesis.
  • RESULTS: The amount of CD133(+) cells within the bulk tumor mass, analyzed by immunostaining and Western blotting, showed a clear quantitative correlation with glioma grade (WHO degrees II, III and IV).
  • Most of CD133(+) cells were arranged in clusters frequently associated to tumor vessels.
  • CONCLUSIONS: These findings indicate a solely quantitative correlation of glioma grade with the presence of neural CD133(+) cells within tumors supporting the concept of a CD133(+) stem cell dependent gliomagenesis.
  • [MeSH-major] Antigens, CD / metabolism. Glioblastoma. Glioma. Glycoproteins / metabolism. Neoplastic Stem Cells / metabolism. Peptides / metabolism. Pluripotent Stem Cells / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Animals. Biomarkers, Tumor / metabolism. Cell Culture Techniques. Cell Differentiation / physiology. Cell Lineage. Female. Humans. Male. Middle Aged. Nerve Tissue Proteins / metabolism. RNA-Binding Proteins / metabolism. Tumor Cells, Cultured. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008. Published by Elsevier Inc.
  • (PMID = 18761091.001).
  • [ISSN] 1095-9327
  • [Journal-full-title] Molecular and cellular neurosciences
  • [ISO-abbreviation] Mol. Cell. Neurosci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / MSI1 protein, human; 0 / Nerve Tissue Proteins; 0 / Peptides; 0 / RNA-Binding Proteins
  •  go-up   go-down


78. Cloughesy TF, Wen PY, Robins HI, Chang SM, Groves MD, Fink KL, Junck L, Schiff D, Abrey L, Gilbert MR, Lieberman F, Kuhn J, DeAngelis LM, Mehta M, Raizer JJ, Yung WK, Aldape K, Wright J, Lamborn KR, Prados MD: Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol; 2006 Aug 1;24(22):3651-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.
  • The population included 67 patients with glioblastoma multiforme (GBM) and an exploratory group of 22 patients with anaplastic glioma (AG).
  • [MeSH-major] Anticonvulsants / administration & dosage. Anticonvulsants / pharmacology. Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Enzyme Induction / drug effects. Glioblastoma / drug therapy. Glioma / drug therapy. Quinolones / therapeutic use
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Drug Administration Schedule. Epilepsy / etiology. Epilepsy / prevention & control. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. North America. Treatment Outcome

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16877733.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5-U01CA62399-09; United States / NCI NIH HHS / CA / CA16672; United States / NCI NIH HHS / CA / CA62412; United States / NCI NIH HHS / CA / CA6242; United States / NCI NIH HHS / CA / CA62426; United States / NCI NIH HHS / CA / CA62455-08; United States / NCRR NIH HHS / RR / M01 RR03186; United States / NCRR NIH HHS / RR / M01-RR00042; United States / NCRR NIH HHS / RR / M01-RR00056; United States / NCRR NIH HHS / RR / M01-RR00079; United States / NCRR NIH HHS / RR / M01-RR00633; United States / NCRR NIH HHS / RR / M01-RR0865; United States / NCI NIH HHS / CA / U01CA62399; United States / NCI NIH HHS / CA / U01CA62405; United States / NCI NIH HHS / CA / U01CA62407-08; United States / NCI NIH HHS / CA / U01CA62421-08; United States / NCI NIH HHS / CA / U01CA62422
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Antineoplastic Agents; 0 / Quinolones; 192185-72-1 / tipifarnib
  •  go-up   go-down


79. Jalali R, Basu A, Gupta T, Munshi A, Menon H, Sarin R, Goel A: Encouraging experience of concomitant Temozolomide with radiotherapy followed by adjuvant Temozolomide in newly diagnosed glioblastoma multiforme: single institution experience. Br J Neurosurg; 2007 Dec;21(6):583-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Encouraging experience of concomitant Temozolomide with radiotherapy followed by adjuvant Temozolomide in newly diagnosed glioblastoma multiforme: single institution experience.
  • The purpose of this study was to report our experience with concomitant and adjuvant temozolomide (TMZ) with radiotherapy in patients with newly diagnosed glioblastoma multiforme (GBM).
  • Treatment was generally well tolerated with 9% of patients developing grade 3 anaemia, 2% grade 3 leucopoenia, and 7% patients grade 3 or 4 thrombocytopenia respectively during the treatment.
  • Concomitant radiotherapy and TMZ followed by adjuvant TMZ prolongs survival in patients with glioblastoma multiforme and is well tolerated in our patient population.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Dacarbazine / analogs & derivatives. Glioblastoma / drug therapy. Glioblastoma / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Karnofsky Performance Status. Male. Middle Aged. Survival Analysis

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18071985.001).
  • [ISSN] 0268-8697
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


80. Mahzouni P, Mohammadizadeh F, Mougouei K, Moghaddam NA, Chehrei A, Mesbah A: Determining the relationship between "microvessel density" and different grades of astrocytoma based on immunohistochemistry for "factor VIII-related antigen" (von Willebrand factor) expression in tumor microvessels. Indian J Pathol Microbiol; 2010 Oct-Dec;53(4):605-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Determining the relationship between "microvessel density" and different grades of astrocytoma based on immunohistochemistry for "factor VIII-related antigen" (von Willebrand factor) expression in tumor microvessels.
  • BACKGROUND: Astrocytic brain tumors are the most common primary central nervous system tumors, which are classified into four grades.
  • One of the most important pathologic criteria for the diagnosis of higher-grade astrocytomas (especially glioblastoma multiforme) is microvessel proliferation, particularly in the form of glomeruloid complex.
  • Because tumor angiogenesis is a necessary factor for growth and invasiveness of malignancies, microvessel density (MVD) and intensity of angiogenesis may be used to determine the grade of astrocytomas and plan therapy accordingly.
  • We have planned this study to evaluate the relationship between vwf expression in microvessels and different grades of astrocytoma.
  • MATERIALS AND METHODS: Sixty-four formalin-fixed and paraffin-embedded blocks of surgical specimens with diagnosis of astrocytoma (grades I to IV, each of them 16 blocks) were selected in a simple-nonrandom sampling.
  • Scores 0 and 1 of microvessel staining intensity were not observed in any grades studied, but severe staining intensity (score 3) was observed in 18.8%, 37.5%, 56.3%, and 87.5% of grades I, II, III, and IV astrocytomas, respectively.
  • "Vwf vessel index" (MVD staining intensity of microvessels) was 23.84, 25.62, 31.62, and 62.43 in grades I, II, III, and IV astrocytomas, respectively.
  • The intensity of microvessel stain increases in parallel with increasing tumor grade.
  • Regarding "microvessel density" and "vwf vessel index," the difference is predominantly between grade IV and all other grades.
  • [MeSH-major] Astrocytoma / pathology. Microvessels / pathology. Neovascularization, Pathologic. Severity of Illness Index. von Willebrand Factor / analysis
  • [MeSH-minor] Adult. Child. Female. Formaldehyde. Humans. Immunohistochemistry / methods. Male. Microscopy. Middle Aged. Paraffin Embedding. Pathology / methods. Statistics as Topic. Tissue Fixation

  • Hazardous Substances Data Bank. FORMALDEHYDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21045378.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / von Willebrand Factor; 1HG84L3525 / Formaldehyde
  •  go-up   go-down


81. Yamamoto T, Nakai K, Tsurubuchi T, Matsuda M, Shirakawa M, Zaboronok A, Endo K, Matsumura A: Boron neutron capture therapy for newly diagnosed glioblastoma: a pilot study in Tsukuba. Appl Radiat Isot; 2009 Jul;67(7-8 Suppl):S25-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Boron neutron capture therapy for newly diagnosed glioblastoma: a pilot study in Tsukuba.
  • Neutron capture therapy (NCT) theoretically allows an unique tumor-cell-selective high-LET particle radiotherapy.
  • The survival benefits and safety of NCT were evaluated in 15 patients with newly diagnosed glioblastoma multiforme (GBM).
  • [MeSH-major] Boron Neutron Capture Therapy / methods. Brain Neoplasms / radiotherapy. Glioblastoma / radiotherapy
  • [MeSH-minor] Adult. Aged. Clinical Protocols. Combined Modality Therapy. Humans. Japan / epidemiology. Kaplan-Meier Estimate. Middle Aged. Pilot Projects. Radiotherapy Dosage

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19375927.001).
  • [ISSN] 1872-9800
  • [Journal-full-title] Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine
  • [ISO-abbreviation] Appl Radiat Isot
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


82. Medhkour A, Chan M: Extremely rare glioblastoma multiforme of the conus medullaris with holocord and brain stem metastases, leading to cranial nerve deficit and respiratory failure: a case report and review of the literature. Surg Neurol; 2005 Jun;63(6):576-82; discussion 582-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extremely rare glioblastoma multiforme of the conus medullaris with holocord and brain stem metastases, leading to cranial nerve deficit and respiratory failure: a case report and review of the literature.
  • BACKGROUND: Spinal glioblastoma multiforme (GBM) is an uncommon entity and metastases are extremely rare.
  • Glioblastoma multiforme of the conus medullaris is a rare and highly aggressive entity that can quickly progress to a dismal state.
  • Proper diagnosis via histopathologic and immunochemical staining with close clinical and radiological follow-up is important for the management of this very aggressive tumor.
  • CASE DESCRIPTION: The authors report the clinical features, histopathologic and immunochemical staining characteristics, as well as the radiographic evidence of a case of primary GBM of the conus medullaris with metastases to the whole spinal cord and brain in a 20-year-old man who presented with low back pain and bilateral lower extremity weakness and numbness.
  • Serial magnetic resonance scans, performed after the initial surgery, demonstrated enlargement of the primary GBM in the conus medullaris with metastases to the thoracic and cervical spinal cord as well as to the brain.
  • CONCLUSIONS: Glioblastoma multiforme of the conus medullaris with such clinical findings is extremely rare.
  • [MeSH-major] Brain Stem Neoplasms / secondary. Glioblastoma / secondary. Spinal Cord Compression / pathology. Spinal Cord Neoplasms / pathology. Spinal Cord Neoplasms / secondary
  • [MeSH-minor] Adult. Brain Stem / pathology. Brain Stem / physiopathology. Cranial Nerve Diseases / etiology. Cranial Nerve Diseases / pathology. Cranial Nerve Diseases / physiopathology. Disease Progression. Fatal Outcome. Glial Fibrillary Acidic Protein / metabolism. Humans. Low Back Pain / etiology. Low Back Pain / pathology. Low Back Pain / physiopathology. Magnetic Resonance Imaging. Male. Neoplasm Metastasis. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / physiopathology. Paresis / etiology. Paresis / pathology. Paresis / physiopathology. Rare Diseases. Respiratory Insufficiency / etiology. Respiratory Insufficiency / pathology. Respiratory Insufficiency / physiopathology. Spinal Cord / pathology. Spinal Cord / physiopathology

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15936395.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein
  • [Number-of-references] 13
  •  go-up   go-down


83. Das S, Srikanth M, Kessler JA: Cancer stem cells and glioma. Nat Clin Pract Neurol; 2008 Aug;4(8):427-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite continued advances in surgical and medical therapies, the outcomes for patients diagnosed with glioblastoma multiforme remain dismal.
  • Recent data suggest that progression of these brain tumors is driven by a small subpopulation of tumor cells, which are termed cancer stem cells (CSCs) because of their capability to self-renew, proliferate and give rise to progeny of multiple neuroepithelial lineages.
  • According to the CSC hypothesis, current therapies that are extremely cytotoxic to the bulk of highly proliferative tumor cells fail to obliterate the relatively quiescent and resistant CSC compartment, thereby allowing these cells to survive and drive tumor recurrence.
  • This Review summarizes current knowledge regarding neural stem cells in the normal adult brain and CSCs in glial tumors and discusses the implications of the CSC hypothesis for the development of future therapies for brain tumors.
  • [MeSH-minor] Animals. Glioblastoma / pathology. Glioblastoma / therapy. Humans. Signal Transduction / physiology

  • Genetic Alliance. consumer health - Glioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18628751.001).
  • [ISSN] 1745-8358
  • [Journal-full-title] Nature clinical practice. Neurology
  • [ISO-abbreviation] Nat Clin Pract Neurol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 91
  •  go-up   go-down


84. Spence AM, Muzi M, Swanson KR, O'Sullivan F, Rockhill JK, Rajendran JG, Adamsen TC, Link JM, Swanson PE, Yagle KJ, Rostomily RC, Silbergeld DL, Krohn KA: Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival. Clin Cancer Res; 2008 May 1;14(9):2623-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival.
  • We measured the volume of hypoxic tumor and the maximum level of hypoxia in glioblastoma multiforme before radiotherapy with [(18)F]fluoromisonidazole positron emission tomography to assess their impact on time to progression (TTP) or survival.
  • The volume of tumor with T/B values above 1.2 defined the hypoxic volume (HV).
  • RESULTS: Kaplan-Meier plots showed shorter TTP and survival in patients whose tumors contained HVs or tumor T/B(max) ratios greater than the median (P < or = 0.001).
  • In univariate analyses, greater HV or tumor T/B(max) were associated with shorter TTP or survival (P < 0.002).
  • CONCLUSIONS: The volume and intensity of hypoxia in glioblastoma multiforme before radiotherapy are strongly associated with poorer TTP and survival.
  • This type of imaging could be integrated into new treatment strategies to target hypoxia more aggressively in glioblastoma multiforme and could be applied to assess the treatment outcomes.

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18451225.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA042045; United States / NCI NIH HHS / CA / P01CA42045; United States / NCRR NIH HHS / RR / S10 RR17229
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 13551-89-8 / fluoromisonidazole; 8FE7LTN8XE / Misonidazole
  • [Other-IDs] NLM/ NIHMS679394; NLM/ PMC4415875
  •  go-up   go-down


86. Loh KC, Willert J, Meltzer H, Roberts W, Kerlin B, Kadota R, Levy M, White G, Geddis A, Schiff D, Martin L, Yu A, Kung F, Spear MA: Temozolomide and radiation for aggressive pediatric central nervous system malignancies. J Pediatr Hematol Oncol; 2005 May;27(5):254-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temozolomide and radiation for aggressive pediatric central nervous system malignancies.
  • This study describes the outcomes of children treated with combinations of temozolomide and radiation therapy for various aggressive central nervous system malignancies.
  • Toxicities observed included low-grade neutropenia, thrombocytopenia, and lymphopenia.
  • The combination of temozolomide and radiotherapy appears to be well tolerated in a variety of treatment schemas for aggressive pediatric central nervous system malignancies.
  • This information is of particular use in designing future studies, given the recent positive results in a randomized study examining the use of temozolomide concomitant with radiation in the treatment of adult glioblastoma.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Central Nervous System Neoplasms / drug therapy. Central Nervous System Neoplasms / radiotherapy. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15891559.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


87. Piroth MD, Pinkawa M, Holy R, Stoffels G, Demirel C, Attieh C, Kaiser HJ, Langen KJ, Eble MJ: Integrated-boost IMRT or 3-D-CRT using FET-PET based auto-contoured target volume delineation for glioblastoma multiforme--a dosimetric comparison. Radiat Oncol; 2009;4:57
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Integrated-boost IMRT or 3-D-CRT using FET-PET based auto-contoured target volume delineation for glioblastoma multiforme--a dosimetric comparison.
  • BACKGROUND: Biological brain tumor imaging using O-(2-[18F]fluoroethyl)-L-tyrosine (FET)-PET combined with inverse treatment planning for locally restricted dose escalation in patients with glioblastoma multiforme seems to be a promising approach.The aim of this study was to compare inverse with forward treatment planning for an integrated boost dose application in patients suffering from a glioblastoma multiforme, while biological target volumes are based on FET-PET and MRI data sets.
  • METHODS: In 16 glioblastoma patients an intensity-modulated radiotherapy technique comprising an integrated boost (IB-IMRT) and a 3-dimensional conventional radiotherapy (3D-CRT) technique were generated for dosimetric comparison.
  • The integrated boost volume (PTV1) was auto-contoured using a cut-off tumor-to-brain ratio (TBR) of > or = 1.6 from FET-PET.
  • The EUD for the brain was equal with both planning techniques.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Glioblastoma / radiotherapy. Positron-Emission Tomography. Radiopharmaceuticals. Radiotherapy Planning, Computer-Assisted / methods. Tyrosine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Radiotherapy, Conformal. Radiotherapy, Intensity-Modulated

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. L-TYROSINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet Oncol. 2005 Dec;6(12):953-60 [16321763.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):511-9 [16168843.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Apr 1;64(5):1570-80 [16580506.001]
  • [Cites] Nucl Med Biol. 2006 Apr;33(3):287-94 [16631076.001]
  • [Cites] Neurosurg Focus. 2006;20(4):E16 [16709021.001]
  • [Cites] Strahlenther Onkol. 2007 Jan;183(1):23-9 [17225942.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):1135-44 [17208388.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):144-50 [17306935.001]
  • [Cites] J Appl Clin Med Phys. 2007;8(2):47-60 [17592465.001]
  • [Cites] Med Dosim. 2007 Winter;32(4):299-304 [17980832.001]
  • [Cites] Phys Med Biol. 2008 Jan 7;53(1):23-36 [18182685.001]
  • [Cites] Strahlenther Onkol. 2008 Oct;184(10):536-42 [19016044.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):479-85 [18834673.001]
  • [Cites] Radiat Oncol. 2008;3:44 [19108742.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2009 Feb;36(2):182-93 [18818918.001]
  • [Cites] Med Phys. 2008 Dec;35(12):5851-60 [19175141.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Mar 1;73(3):699-708 [18723297.001]
  • [Cites] Lancet Oncol. 2009 May;10(5):459-66 [19269895.001]
  • [Cites] Radiother Oncol. 2009 Nov;93(2):213-9 [19717197.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jul 1;47(4):1137-43 [10863087.001]
  • [Cites] Radiother Oncol. 2000 Aug;56(2):151-6 [10927133.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Dec 1;48(5):1371-80 [11121636.001]
  • [Cites] J Neurosurg. 2000 Dec;93 Suppl 3:219-22 [11143252.001]
  • [Cites] Radiother Oncol. 2001 Jul;60(1):49-59 [11410304.001]
  • [Cites] Int J Cancer. 2001 Dec 20;96(6):341-9 [11745504.001]
  • [Cites] Med Phys. 2002 Jul;29(7):1590-8 [12148742.001]
  • [Cites] Neurosurgery. 2002 Aug;51(2):343-55; discussion 355-7 [12182772.001]
  • [Cites] Med Phys. 2003 Sep;30(9):2332-9 [14528955.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):875-90 [14529795.001]
  • [Cites] Med Dosim. 2003 Winter;28(4):261-5 [14684191.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Feb 1;58(2):617-24 [14751535.001]
  • [Cites] Technol Cancer Res Treat. 2004 Feb;3(1):59-67 [14750894.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Nov 1;60(3):853-60 [15465203.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1979 Oct;5(10):1725-31 [231022.001]
  • [Cites] Neurology. 1980 Sep;30(9):907-11 [6252514.001]
  • [Cites] Ann Neurol. 1989 Oct;26(4):531-4 [2684003.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22 [2032882.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):123-35 [2032883.001]
  • [Cites] Br J Cancer. 1991 Oct;64(4):769-74 [1654987.001]
  • [Cites] J Clin Oncol. 1992 Sep;10(9):1379-85 [1325539.001]
  • [Cites] Radiology. 1993 Jan;186(1):45-53 [8380108.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Jan 15;25(2):243-9 [8380568.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Apr 30;32(1):99-104 [7721644.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jul 15;32(4):931-41 [7607967.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Jul 15;35(5):1124-5 [8751425.001]
  • [Cites] Med Phys. 1997 Jan;24(1):103-10 [9029544.001]
  • [Cites] Can J Neurol Sci. 1997 Nov;24(4):307-12 [9398977.001]
  • [Cites] Eur J Nucl Med. 1998 Feb;25(2):150-6 [9473263.001]
  • [Cites] Tumori. 1998 Mar-Apr;84(2):140-3 [9620236.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jul 15;41(5):1005-11 [9719109.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Sep 1;42(2):464 [9788430.001]
  • [Cites] J Neurosurg. 1999 Jan;90(1):72-7 [10413158.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Nov;31(11):1464-70 [15248032.001]
  • [Cites] Brain. 2005 Mar;128(Pt 3):678-87 [15689365.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2005 Apr;32(4):422-9 [15650870.001]
  • [Cites] Neurosurgery. 2005 Sep;57(3):505-11; discussion 505-11 [16145529.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Mar 1;64(3):892-7 [16458777.001]
  • (PMID = 19930657.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / O-(2-((18)F)fluoroethyl)-L-tyrosine; 0 / Radiopharmaceuticals; 42HK56048U / Tyrosine
  • [Other-IDs] NLM/ PMC2787527
  •  go-up   go-down


88. Laprie A, Catalaa I, Cassol E, McKnight TR, Berchery D, Marre D, Bachaud JM, Berry I, Moyal EC: Proton magnetic resonance spectroscopic imaging in newly diagnosed glioblastoma: predictive value for the site of postradiotherapy relapse in a prospective longitudinal study. Int J Radiat Oncol Biol Phys; 2008 Mar 1;70(3):773-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proton magnetic resonance spectroscopic imaging in newly diagnosed glioblastoma: predictive value for the site of postradiotherapy relapse in a prospective longitudinal study.
  • PURPOSE: To investigate the association between magnetic resonance spectroscopic imaging (MRSI)-defined, metabolically abnormal tumor regions and subsequent sites of relapse in data from patients treated with radiotherapy (RT) in a prospective clinical trial.
  • METHODS AND MATERIALS: Twenty-three examinations were performed prospectively for 9 patients with newly diagnosed glioblastoma multiforme studied in a Phase I trial combining Tipifarnib and RT.
  • [MeSH-major] Brain Neoplasms / metabolism. Glioblastoma / metabolism. Magnetic Resonance Spectroscopy. Neoplasm Recurrence, Local / metabolism
  • [MeSH-minor] Adult. Aspartic Acid / analogs & derivatives. Aspartic Acid / metabolism. Choline / metabolism. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Predictive Value of Tests. Prospective Studies. Protons

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-ASPARTIC ACID .
  • Hazardous Substances Data Bank. CHOLINE CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18262090.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protons; 30KYC7MIAI / Aspartic Acid; 997-55-7 / N-acetylaspartate; N91BDP6H0X / Choline
  •  go-up   go-down


89. Rosati A, Marconi S, Pollo B, Tomassini A, Lovato L, Maderna E, Maier K, Schwartz A, Rizzuto N, Padovani A, Bonetti B: Epilepsy in glioblastoma multiforme: correlation with glutamine synthetase levels. J Neurooncol; 2009 Jul;93(3):319-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epilepsy in glioblastoma multiforme: correlation with glutamine synthetase levels.
  • PURPOSE: The hypothesis addressed by this study is that a glutamine synthetase (GS) deficiency in neoplastic astrocytes is a possible molecular basis associated with seizure generation in glioblastoma multiforme (GBM).
  • [MeSH-major] Brain Neoplasms / enzymology. Epilepsy / enzymology. Epilepsy / etiology. Glioblastoma / complications. Glioblastoma / enzymology. Glutamate-Ammonia Ligase / metabolism
  • [MeSH-minor] Adult. Aged. Blotting, Western. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Epilepsy.
  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Epilepsy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Experientia. 1982 Oct 15;38(10):1199-202 [6128246.001]
  • [Cites] Glia. 2000 Oct;32(1):15-24 [10975907.001]
  • [Cites] Acta Psychiatr Neurol Scand Suppl. 1952;81:1-149 [14933179.001]
  • [Cites] Epilepsy Res. 1998 Sep;32(1-2):286-303 [9761328.001]
  • [Cites] Comp Biochem Physiol C. 1989;94(2):399-404 [2576778.001]
  • [Cites] Epilepsy Res Suppl. 1996;11:9-16 [9294725.001]
  • [Cites] Science. 1977 Mar 25;195(4284):1356-8 [14400.001]
  • [Cites] Neuropathol Appl Neurobiol. 1982 May-Jun;8(3):227-36 [6126838.001]
  • [Cites] Lancet. 2004 Jan 3;363(9402):28-37 [14723991.001]
  • [Cites] Neuro Oncol. 2002 Oct;4(4):278-99 [12356358.001]
  • [Cites] Neurology. 2000 May 23;54(10):1886-93 [10822423.001]
  • [Cites] Brain Res Mol Brain Res. 1989 Dec;6(4):223-32 [2574402.001]
  • [Cites] J Neurocytol. 2002 Sep-Nov;31(8-9):681-92 [14501207.001]
  • [Cites] Epilepsy Res. 1996 Dec;26(1):163-75 [8985698.001]
  • [Cites] J Neurosci Res. 1999 Aug 15;57(4):417-28 [10440891.001]
  • [Cites] Epilepsia. 2003 Sep;44(9):1223-32 [12919395.001]
  • [Cites] Neurol Clin. 2001 May;19(2):237-50 [11358743.001]
  • [Cites] Neurology. 1996 Apr;46(4):985-91 [8780077.001]
  • [Cites] Eur J Pharmacol. 2002 Jul 5;447(2-3):227-37 [12151014.001]
  • [Cites] Lancet. 1993 Jun 26;341(8861):1607-10 [8099987.001]
  • [Cites] Dev Neurosci. 1988;10(1):47-56 [2897279.001]
  • [Cites] Epilepsia. 2002 Jul;43(7):703-10 [12102672.001]
  • [Cites] Brain Res. 2005 May 24;1044(2):190-6 [15885217.001]
  • [Cites] No To Shinkei. 1993 Apr;45(4):362-8 [8101449.001]
  • [Cites] Brain Res. 1982 May;256(1):3-11 [6124308.001]
  • [Cites] Semin Oncol. 2003 Dec;30(6 Suppl 19):49-52 [14765386.001]
  • [Cites] Neurochem Int. 2002 Aug-Sep;41(2-3):123-42 [12020613.001]
  • [Cites] Neuropathol Appl Neurobiol. 1990 Jun;16(3):205-11 [1976235.001]
  • (PMID = 19183851.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 6.3.1.2 / Glutamate-Ammonia Ligase
  •  go-up   go-down


90. Stark AM, Nabavi A, Mehdorn HM, Blömer U: Glioblastoma multiforme-report of 267 cases treated at a single institution. Surg Neurol; 2005 Feb;63(2):162-9; discussion 169
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glioblastoma multiforme-report of 267 cases treated at a single institution.
  • OBJECTIVE: Glioblastoma multiforme (GBM) is the most common and most malignant primary brain tumor in adults.
  • In 35 cases (13.1%) the tumor was multicentric.
  • (5) total tumor resection, P = .014;.
  • CONCLUSIONS: Glioblastoma multiforme remains an important cause of morbidity and mortality from intracranial tumors.
  • [MeSH-major] Brain Neoplasms / surgery. Glioblastoma / surgery
  • [MeSH-minor] Adult. Age Factors. Aged. Combined Modality Therapy. Craniotomy. Female. Humans. Karnofsky Performance Status / statistics & numerical data. Male. Middle Aged. Neoplasm Recurrence, Local / surgery. Prognosis. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15680662.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Colavolpe C, Guedj E, Metellus P, Barrie M, Figarella-Branger D, Mundler O, Chinot O: FDG-PET to predict different patterns of progression in multicentric glioblastoma: a case report. J Neurooncol; 2008 Oct;90(1):47-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG-PET to predict different patterns of progression in multicentric glioblastoma: a case report.
  • True multicentric glioblastoma multiforme (GBM) is rare and consists of separate distinct tumors in different cerebral lobes or hemispheres without any apparent route of dissemination.
  • In this paper, we report on the case of a man with bifocal tumor in the right frontal and temporal lobes who underwent FDG-PET imaging.
  • The diagnosis of glioblastoma was confirmed by neuropathological examination in both cases but with much higher immunohistochemical expression of O(6)-methylguanine-DNA-methyltransferase (MGMT) in the temporal lesion.
  • [MeSH-major] Brain Neoplasms / diagnostic imaging. Brain Neoplasms / pathology. Fluorodeoxyglucose F18. Glioblastoma / diagnostic imaging. Glioblastoma / pathology. Positron-Emission Tomography
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Disease Progression. Humans. Magnetic Resonance Imaging. Male. Neurosurgical Procedures

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurg Rev. 2003 Oct;26(4):275-9 [12898393.001]
  • [Cites] Surg Neurol. 1994 Jul;42(1):14-8 [7940089.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):890-900 [17283119.001]
  • [Cites] Nat Rev Cancer. 2006 Jun;6(6):425-36 [16723989.001]
  • [Cites] Clin Cancer Res. 2008 Jan 1;14 (1):123-9 [18172261.001]
  • [Cites] N Engl J Med. 2000 Nov 9;343(19):1350-4 [11070098.001]
  • [Cites] Neurosurgery. 1983 Aug;13(2):170-5 [6310436.001]
  • [Cites] Clin Neurol Neurosurg. 2003 Dec;106(1):38-40 [14643915.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] J Comput Assist Tomogr. 1993 Jul-Aug;17 (4):509-61 [8392523.001]
  • [Cites] Cancer Cell. 2005 Oct;8(4):323-35 [16226707.001]
  • [Cites] Neurol Med Chir (Tokyo). 1990 Aug;30(8):604-9 [1703639.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] J Neurooncol. 2000 Sep;49(2):157-63 [11206011.001]
  • [Cites] Am J Pathol. 2002 Apr;160(4):1279-92 [11943713.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 1995;51:167-223 [7659775.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):997-1003 [15758010.001]
  • [Cites] J Neurooncol. 2003 Sep;64(3):227-37 [14558598.001]
  • [Cites] J Neurosurg. 1963 Feb;20:122-36 [14192080.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • (PMID = 18568292.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


92. Klase D, Gottschalk S, Reusche E, Hagel C, Goebel E, Tronnier V, Giese A: Lumbosacral glioblastoma and leptomeningeal gliomatosis complicating the course of a cervicothoracic astrocytoma WHO grade II. Childs Nerv Syst; 2007 Aug;23(8):907-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lumbosacral glioblastoma and leptomeningeal gliomatosis complicating the course of a cervicothoracic astrocytoma WHO grade II.
  • CASE REPORT: The reported female patient underwent sub-total resection of an intra-medullary cervicothoracic astrocytoma classified as WHO grade II in 1984 at the age of 18 months and received local irradiation.
  • After an extended biopsy, the invasive lumbosacral tumour was classified as glioblastoma multiforme.
  • [MeSH-major] Astrocytoma / complications. Glioblastoma / complications. Meningeal Neoplasms / complications. Spinal Cord Neoplasms / complications
  • [MeSH-minor] Adult. Back Pain / etiology. Blindness / complications. Blindness / pathology. Cerebrospinal Fluid Shunts. Eye / pathology. Fatal Outcome. Female. Humans. Lordosis / etiology. Magnetic Resonance Imaging. Peripheral Nervous System Diseases / complications. Pituitary Gland / pathology. Pseudotumor Cerebri / pathology. Pseudotumor Cerebri / physiopathology

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Childs Nerv Syst. 1987;3(2):89-92 [3040249.001]
  • [Cites] Pediatr Blood Cancer. 2004 Nov;43(6):629-32 [15390309.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2001 Feb;70(2):256-8 [11160482.001]
  • [Cites] Neurosurg Clin N Am. 2001 Oct;12(4):775-97, ix [11524298.001]
  • [Cites] J Neurosurg. 2000 Oct;93(2 Suppl):183-93 [11012047.001]
  • [Cites] Neurosurgery. 1989 Dec;25(6):855-9 [2601814.001]
  • [Cites] Neurosurgery. 1994 Jan;34(1):68-78 [8121571.001]
  • [Cites] J Neurosurg. 1995 Apr;82(4):536-47 [7897512.001]
  • [Cites] Childs Nerv Syst. 1997 Jul;13(7):375-82 [9298273.001]
  • [Cites] J Neurooncol. 2003 Jul;63(3):305-12 [12892238.001]
  • [Cites] J Neurooncol. 2000 May;47(3):219-24 [11016738.001]
  • [Cites] Acta Neurochir (Wien). 1993;120(1-2):59-65 [7679540.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1060-71 [16373081.001]
  • [Cites] J Neurosurg. 1990 Apr;72 (4):523-32 [2319309.001]
  • [Cites] J Neurosurg. 1996 Dec;85(6):1036-43 [8929492.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Nov 1;51(3):704-10 [11597812.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1624-36 [12697889.001]
  • [Cites] J Neurooncol. 2003 Feb;61(3):227-35 [12675316.001]
  • (PMID = 17440736.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


93. Ruano Y, Ribalta T, de Lope AR, Campos-Martín Y, Fiaño C, Pérez-Magán E, Hernández-Moneo JL, Mollejo M, Meléndez B: Worse outcome in primary glioblastoma multiforme with concurrent epidermal growth factor receptor and p53 alteration. Am J Clin Pathol; 2009 Feb;131(2):257-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Worse outcome in primary glioblastoma multiforme with concurrent epidermal growth factor receptor and p53 alteration.
  • Primary glioblastoma multiforme (GBM), in contrast with secondary GBM, has been associated with the presence of EGFR amplification and absence of p53 mutation.
  • [MeSH-major] Brain Neoplasms / genetics. Cyclin-Dependent Kinase 4 / genetics. Gene Expression Regulation, Neoplastic. Glioblastoma / genetics. Receptor, Epidermal Growth Factor / genetics. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Combined Modality Therapy. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged. Prognosis. Survival Rate. Tissue Array Analysis. Young Adult

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19141386.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.22 / CDK4 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 4
  •  go-up   go-down


94. Silvani A, Gaviani P, Fiumani A, Scaioli V, Lamperti E, Eoli M, Botturi A, Salmaggi A: Systemic sagopilone (ZK-EPO) treatment of patients with recurrent malignant gliomas. J Neurooncol; 2009 Oct;95(1):61-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ZK-EPO (16 mg/m(2)) was administered iv for 3 h every 21 days.
  • PFS-6 was achieved in five patients (33%), three with glioblastoma multiforme and two with anaplastic astrocytoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzothiazoles / therapeutic use. Brain Neoplasms / drug therapy. Epothilones / therapeutic use. Glioma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Drug Administration Schedule. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Severity of Illness Index. Survival Analysis. Young Adult